Pathology In Depth

Library › Liver, gallbladder and extrahepatic bile duct pathology: hepatitis, steatotic and metabolic liver disease, cholestatic, vascular and transplant pathology, liver tumors and gallbladder disease

Liver, gallbladder and extrahepatic bile duct pathology: hepatitis, steatotic and metabolic liver disease, cholestatic, vascular and transplant pathology, liver tumors and gallbladder disease

Last reviewed 2026-11-17 by a board-certified pathologist. 218 references.

Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections

Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (steatohepatitis, cirrhosis, iron, copper and alpha-1-antitrypsin deficiency) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (biliary and cholestatic patterns, ductopenia) Related page: Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy (vascular patterns, allograft rejection) Related page: Liver, Kidney and Gastrointestinal Function Tests (liver test patterns and the R ratio as a laboratory calculation) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (ANA, ASMA, anti-LKM1 and anti-SLA in autoimmune hepatitis) Related page: Normal Liver, FNA Indications and Reactive Changes on Liver FNA (normal and reactive liver on FNA) Related page: Benign Liver Lesions on FNA (Abscess, Hydatid Cyst, Focal Nodular Hyperplasia, Hepatocellular Adenoma and Hemangioma) (abscess and hydatid cyst on FNA)

Normal liver histology and acinar zonation

  • Lobule and acinus. The classic lobule is hexagonal with a central vein at its center and portal tracts at its vertices. The acinus is the functional unit defined by blood supply. Zone 1 is periportal, zone 3 is pericentral and zone 2 lies between them. Zones are assigned by distance from the portal tract and decreasing oxygen tension (Choi 2025; Boyd et al. 2020).
  • Portal tract. A portal tract contains a branch of the portal vein, a branch of the hepatic artery and a bile duct (Boyd et al. 2020).
  • Plates, sinusoids and canaliculi. Hepatocytes form one-cell-thick plates separated by sinusoids lined by fenestrated endothelium. The space of Disse contains vitamin A-storing stellate cells. Bile canaliculi measure 1–2 µm and drain into the canals of Hering, which harbor stem/progenitor cells (Choi 2025).
  • Glutamine synthetase. Glutamine synthetase immunostaining marks the hepatocytes around the central vein and shows normal metabolic zonation (Choi 2025).
  • Subcapsular fibrosis. The subcapsular 2-mm zone may contain fibrotic portal tracts with bridging bands that mimic cirrhosis in superficial samples (Choi 2025).
  • Age-related findings. Pediatric livers show two-cell-thick plates, glycogenated nuclei, occasional extramedullary hematopoiesis and higher iron and copper stores. Normal portal tracts contain few lymphocytes and virtually no neutrophils or plasma cells (Choi 2025).
Acinar zone Location Injury patterns concentrated in the zone Source
Zone 1 Periportal, adjacent to the portal tract Interface hepatitis at the limiting plate; alpha-1-antitrypsin globules; periportal copper in chronic cholestasis; fibrosis of chronic biliary disease begins here Choi 2025; Boyd et al. 2020
Zone 3 Pericentral, closest to the hepatic venule Acetaminophen coagulative necrosis; hypoxic (ischemic) necrosis; confluent necrosis of severe lobular hepatitis; sinusoidal dilatation of outflow obstruction; pericellular fibrosis of steatotic liver disease; accentuation of microvesicular steatosis Fontana et al. 2023; Fernández et al. 2024; Choi 2025

Handling and adequacy of the medical liver biopsy

  • Needle and size. A 16-gauge or wider cutting needle is recommended. Biopsy length correlates with portal tract number, and a length of 20–25 mm is preferred (Boyd et al. 2020).
  • Portal tract count. Ten to 12 portal tracts are considered sufficient for reliable analysis (Boyd et al. 2020). The International AIH Pathology Group specifies an 18- or 16-gauge needle, a length of 1.5 cm and at least 6–8, preferably 10, portal tracts (Sakhuja and Goyal 2024).
  • Fixation and sectioning. Cores are placed immediately in 10% neutral-buffered formalin. Specimen length above 1.5 cm reduces sampling error. Step sections are cut at several levels, and unstained slides are kept for immunohistochemistry and molecular tests (Choi 2025).
  • Tissue for special studies. Fresh tissue is needed for microbiology and copper quantification (Boyd et al. 2020). In jaundiced infants, a snap-frozen fragment is kept for molecular studies and a glutaraldehyde-fixed fragment for electron microscopy (Choi 2025).
  • Gross color of the core. Yellow indicates marked steatosis, green indicates cholestasis, brown indicates iron overload, and firm white tissue usually indicates neoplasm. Fragmented cores frequently accompany cirrhosis (Choi 2025).
  • Transjugular route. The transjugular approach avoids puncture of the liver capsule in coagulopathy, thrombocytopenia or ascites. The cores may be smaller and need more passes (Boyd et al. 2020).
  • Complications. In a UK audit, clinically significant bleeding occurred in 0.4% and mortality was 0.11%. Targeted biopsy carried more major complications than nontargeted biopsy (Boyd et al. 2020).

Routine and special stains in the medical liver biopsy

  • Core panel. Most laboratories cut two H&E levels with an iron stain and a trichrome stain. At minimum, every biopsy receives H&E and a fibrosis stain (Choi 2025).
  • Elastic fibers. Orcein and elastic stains show mature elastic fibers in longstanding fibrosis. Recent collapse after necrosis lacks them (Boyd et al. 2020).
Stain Target Use in the medical liver biopsy Source
Masson trichrome Type I collagen (blue); Mallory–Denk bodies and megamitochondria (red) Fibrosis stage Choi 2025
Sirius red Type I and III collagen (red) Fibrosis stage; more sensitive than trichrome Choi 2025
Reticulin (Gordon and Sweet) Type III collagen (black) Plate thickness, collapse after necrosis, nodular regenerative hyperplasia, benign versus malignant hepatocellular nodules Choi 2025; Boyd et al. 2020
Perls Prussian blue Ferric iron (blue) Hemochromatosis and secondary iron overload Choi 2025
PAS Glycogen, basement membrane, fungi Glycogen storage; zones of hepatocyte loss in confluent necrosis Choi 2025; Boyd et al. 2020
PAS after diastase (PAS-D) Alpha-1-antitrypsin globules, ceroid-laden macrophages Alpha-1-antitrypsin deficiency; prior hepatocyte injury Choi 2025
Rhodanine Copper (reddish orange) Wilson disease; chronic cholestasis Choi 2025
Shikata orcein HBsAg (dark brown), copper-associated protein, elastic fibers Chronic hepatitis B; chronic cholestasis; fibrosis age Choi 2025; Boyd et al. 2020
Victoria blue HBsAg (blue) Chronic hepatitis B Choi 2025
Phosphotungstic acid hematoxylin Fibrin (blue-purple) Fibrin-ring granuloma Choi 2025
Oil red O Lipid; needs frozen tissue Microvesicular steatosis (acute fatty liver of pregnancy, Reye syndrome) Choi 2025
Congo red Amyloid; apple-green birefringence Vascular, portal and perisinusoidal amyloid Choi 2025
Ziehl–Neelsen, Grocott, Warthin–Starry Acid-fast bacilli, fungi, spirochetes Granulomatous and infectious hepatitis Choi 2025
CK7 and CK19 Biliary epithelium Ductopenia, ductular reaction; periportal CK7 hepatocytes in chronic cholestasis Choi 2025

Pattern-based approach to the medical liver biopsy

  • Patterns. The principal patterns are hepatitic, necrotic, steatotic, biliary/cholestatic, vascular, depositional/storage, granulomatous, infiltrative and neoplastic (Choi 2025). The DILI Network classified biopsies into 18 patterns, including minimal nonspecific change and normal liver (Kleiner et al. 2014).
  • Hepatitic pattern. The hepatitic pattern is lymphocyte-predominant inflammation of lobules, portal tracts or both (Choi 2025).
  • Acute versus chronic. Chronicity is defined by aminotransferase elevation for longer than 6 months. Moderate to severe diffuse lobular inflammation favors an acute process. Established fibrosis indicates chronic hepatitis (Choi 2025).
  • Lobular disarray. Severe acute hepatitis causes widespread necrosis with loss of plate architecture (lobular disarray) or collapse (Boyd et al. 2020).
  • Apoptotic hepatocytes. An apoptotic (Councilman or acidophil) body is a hepatocyte undergoing programmed death and stains pink on H&E (Boyd et al. 2020).
  • Interface hepatitis. Interface activity, formerly piecemeal necrosis, is inflammation of periportal hepatocytes abutting portal collagen. It is graded by the circumferential extent of involvement and has no etiologic specificity (Choi 2025).
  • Necrosis terms. Confluent necrosis involves clusters of 3 or more hepatocytes and usually centers on zone 3. Bridging necrosis links portal-to-portal, portal-to-central or central-to-central regions. Submassive necrosis involves 25%–75% of the parenchyma and massive necrosis more than 75% (Choi 2025).
  • Resolving hepatitis. Small clusters of pigmented macrophages with minimal inflammation follow a mild self-limited acute hepatitis (Choi 2025).
  • Lobular neutrophils. "Surgical hepatitis" in resections shows zone 3 sinusoidal neutrophils without hepatocyte injury. In transplant biopsies, numerous lobular microabscesses are frequently associated with cytomegalovirus (Choi 2025).
  • Pseudo-ground-glass change. Ground-glass inclusions occur in chronic hepatitis B. Pseudo-ground-glass inclusions occur in drug injury (Choi 2025). Induction hepatocytes with ground-glass-like cytoplasm follow polypharmacy and chronic phenytoin or barbiturate use (Fontana et al. 2023).
  • Etiology in the report. Chronic hepatitis is signed out by etiology, grade and stage, for example "autoimmune hepatitis, severe, stage 3" (Batts and Ludwig 1995). The terms chronic active, chronic persistent and chronic lobular hepatitis are obsolete (Batts and Ludwig 1995).

Grading and staging of chronic hepatitis

  • Separate grade and stage. Grade measures necroinflammatory activity. Stage measures fibrosis and progression toward cirrhosis (Chowdhury and Mehta 2023).
  • Mixed disease. Chronic hepatitis schemes do not apply to mixed disease such as coexisting steatohepatitis (Theise 2007).
  • Practice versus trials. Ishak staging is less reproducible than METAVIR and Batts–Ludwig. AASLD considers complex systems appropriate for clinical trials and the simpler systems appropriate for individual patients (Chowdhury and Mehta 2023).
  • METAVIR thresholds. METAVIR F2 or higher is significant fibrosis, and F3 or higher is advanced fibrosis (Chowdhury and Mehta 2023).
  • METAVIR algorithm. METAVIR activity was derived from piecemeal (interface) necrosis and lobular necrosis, with 84% concordance with expert grading (Bedossa and Poynard 1996).
Feature Batts–Ludwig (modified Scheuer) METAVIR Ishak (modified HAI) Source
Grade scale 0–4 A0–A3 0–18 Chowdhury and Mehta 2023
Grade components Portal/periportal activity or lobular activity; the more severe one sets the grade Piecemeal necrosis (0–3) and lobular necrosis (0–2) combined by algorithm Interface hepatitis 0–4, confluent necrosis 0–6, focal lobular necrosis 0–4, portal inflammation 0–4 Chowdhury and Mehta 2023; Bedossa and Poynard 1996
Stage scale 0–4 F0–F4 0–6 Chowdhury and Mehta 2023
Septal fibrosis without nodules Stage 3 F3 (advanced fibrosis) Several Ishak stages correspond to each METAVIR or Batts–Ludwig stage Batts and Ludwig 1995; Chowdhury and Mehta 2023
Cirrhosis Stage 4 F4 Stage 5 (incomplete) and stage 6 (definite) Chowdhury and Mehta 2023

Acute viral hepatitis A, B, D and E

  • Shared histology. Acute viral hepatitis is a lobular hepatitis with spotty necrosis, apoptotic bodies, lobular disarray and variable cholestasis (Boyd et al. 2020; Choi 2025). Fulminant hepatotropic viral infection shows massive or submassive necrosis with lymphocytic infiltrates (Fernández et al. 2024).
  • Serologic assignment of etiology. Etiology is assigned by anti-HAV IgM, anti-HBc IgM with HBsAg and HBV DNA, anti-HCV with HCV RNA, and anti-HEV IgM with HEV RNA (Fernández et al. 2024).
  • Hepatitis A. In 17 adults with serologically proven hepatitis A, biopsies showed centrilobular lesions with a striking plasma cell-rich portal and periportal infiltrate resembling chronic active hepatitis. Centrilobular cholestasis was common. All patients recovered without chronic disease (Teixeira et al. 1982).
  • Hepatitis B in adults and children. Most infections acquired in childhood persist. Most infections acquired in adulthood clear (Chua et al. 2021).
  • Hepatitis E genotypes. Genotypes 1–4 infect humans. Genotypes 1 and 2 spread by the fecal-oral route through contaminated water. Genotypes 3 and 4 infect pigs, deer and wild boar and reach humans through undercooked meat (Orosz et al. 2024).
  • Hepatitis E in pregnancy. Hepatitis E in pregnancy can cause fulminant liver failure with mortality up to 25% (Orosz et al. 2024). Genotype 1 infection in pregnancy is associated with fulminant hepatic failure, fetal loss and preterm birth (Tian et al. 2025).
  • Chronic hepatitis E. Immunosuppressed patients can develop chronic hepatitis E that progresses to cirrhosis. Acute hepatitis E superimposed on cirrhosis can cause acute-on-chronic liver failure (Orosz et al. 2024).
  • Acute hepatitis E histology. In 11 patients with sporadic acute hepatitis E, the characteristic findings were severe intralobular necrosis, polymorph inflammation and acute cholangitis with numerous neutrophils. Cholestasis was present in 8 and cholangitis in 9, and a pseudoglandular pattern in only 1 (Peron et al. 2007). Autochthonous acute hepatitis E showed portal tracts expanded by a severe mixed neutrophilic and lymphocytic infiltrate, moderate to severe interface hepatitis and cholangiolitis, cholestatic rosettes and zone 3 canalicular and cytoplasmic bilirubinostasis (Malcolm et al. 2007).
  • Chronic hepatitis E histology. Chronic hepatitis E developed in 8 organ-transplant recipients, with persistent aminotransferase elevation, serum HEV RNA and histologic chronic hepatitis (Kamar et al. 2008). Its lesions resemble chronic hepatitis C, with a dense lymphocytic portal infiltrate, constant piecemeal necrosis and fibrosis (Selves et al. 2010).

Chronic hepatitis B and hepatitis D

  • Portal infiltrate. Chronic hepatitis B shows a predominantly lymphocytic portal infiltrate with interface activity (Boyd et al. 2020).
  • Ground-glass hepatocytes. Accumulated HBsAg gives hepatocyte cytoplasm a ground-glass appearance. It stains with Shikata orcein and Victoria blue (Chua et al. 2021).
  • HBsAg and HBcAg immunohistochemistry. HBcAg positivity indicates active viral replication (Choi 2025). Nuclear HBcAg was independently associated with high serum HBV DNA and low histologic activity (Serinoz et al. 2003). Subjects with HBeAg-positive, high-replicative infection showed discrete cytoplasmic HBsAg, and nuclear core antigen in 4 of 5 (Mukhopadhya et al. 2006).
  • Genotypes. HBV genotypes C and D are associated with a higher risk of progression to cirrhosis (Chua et al. 2021).
  • Hepatitis D. HDV immunohistochemistry detects coinfection or superinfection in HBV-infected patients (Choi 2025). Fibrosis advances quickly in chronic HDV infection, and cirrhosis, hepatocellular carcinoma and decompensation develop more often than with other hepatitis viruses (Mermutluoğlu et al. 2026).

Chronic hepatitis C

  • Diagnostic triad. Hepatitis C is associated with a triad of bile duct injury, lymphoid follicles with germinal centers, and small- and large-droplet steatosis (Chua et al. 2021).
  • Chronicity. HCV persists as chronic infection in about 80% of infected hosts (Chua et al. 2021).
  • Autoantibody overlap. ASMA occurs in up to 66% and ANA in up to 41% of chronic hepatitis C. Interface activity with lymphoid follicles in HCV can therefore lead to misdiagnosis as AIH (Sakhuja and Goyal 2024).

Herpesvirus and adenovirus hepatitis

  • Immunocompromised hosts. Non-hepatotropic viruses cause hepatitis mainly in immunocompromised and transplant patients. Immunostains for cytomegalovirus, herpes simplex virus, EBV and adenovirus confirm the agent (Choi 2025).
  • Herpes simplex hepatitis. HSV causes about 1% of acute liver failure. Pregnancy, corticosteroids, HIV infection and autoimmune disease predispose. Fewer than half of patients have mucocutaneous lesions, and many cases are anicteric. Rapidly progressive liver failure occurs in 74%, with mortality up to 90% (Then et al. 2019).
  • Adenovirus hepatitis. About 65% of adenovirus hepatitis occurs in children, and prior liver transplantation is the most common predisposing factor. Under the Wisconsin criteria, definite infection requires adenovirus nuclear inclusions, positive tissue culture or PCR from a sterile site (Khalifa et al. 2022).
Virus Characteristic liver histology Confirmatory test Source
Herpes simplex virus Coagulative necrosis with ballooned cells, multinucleated cells, ground-glass nuclei and Cowdry type A intranuclear inclusions at its margin HSV immunostain; HSV DNA PCR Tashiro et al. 1989; Then et al. 2019
Cytomegalovirus Viral cytopathic inclusions; microgranulomas; neutrophilic microabscesses; bile duct injury less frequent and milder than in T-cell-mediated rejection CMV immunostain; plasma CMV DNA Koga et al. 2026; Choi 2025
Epstein–Barr virus Diffuse lymphocytic sinusoidal infiltrate in a "string of beads" pattern; portal expansion by lymphocytes; intact lobular architecture EBV-encoded RNA (EBER) in situ hybridization Schechter and Lamps 2018
Adenovirus Nuclear inclusions Adenovirus immunostain; PCR Khalifa et al. 2022; Choi 2025
Hepatotropic viruses A, B, C, D, E Massive or submassive necrosis in fulminant disease Serology and nucleic acid testing Fernández et al. 2024
  • CMV versus rejection. In allograft biopsies, microgranulomas occurred in 7 of 11 CMV hepatitis cases and 1 of 12 T-cell-mediated rejection controls. Neutrophilic microabscesses occurred in 4 of 11 versus 0 of 12 (Koga et al. 2026).

Autoimmune hepatitis

  • Presentation. AIH affects young women more often but occurs from infancy to old age. About one-third of patients have cirrhosis at presentation, usually macronodular (Sakhuja and Goyal 2024).
  • Serologic types. Type 1 and type 2 AIH are defined by autoantibody profile, covered with assay methods in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (Sakhuja and Goyal 2024).
  • Autoantibody-negative AIH. Autoantibody-negative AIH accounts for 10%–20% of cases, resembles type 1 AIH and responds to steroids. Biopsy is mandatory for its diagnosis (Sakhuja and Goyal 2024).
  • Plasma cells. Plasma cells are prominent in about two-thirds of AIH biopsies. A plasma cell cluster is 5 or more plasma cells in one focus (Sakhuja and Goyal 2024; Moral et al. 2024). AIH plasma cells are typically IgG-dominant. PBC contains relatively more IgM-positive plasma cells (Choi 2025).
  • Emperipolesis and rosettes. Emperipolesis is a lymphocyte, rarely a plasma cell, within hepatocyte cytoplasm and was reported in 65%–78% of AIH biopsies. Rosettes are regenerating hepatocytes arranged around a small lumen. Both also occur in drug injury, PBC and chronic viral hepatitis (Sakhuja and Goyal 2024).
  • Lobular and centrilobular injury. Centrilobular inflammation and necrosis are prominent in about one-third of AIH biopsies and may predominate in acute AIH (Sakhuja and Goyal 2024). Acute AIH in liver failure shows centrilobular and confluent necrosis with lymphoplasmacytic infiltration and interface hepatitis. Autoantibodies are negative in up to half of AIH-related acute liver failure (Fernández et al. 2024).
  • Kupffer cell hyaline globules. These are round, glassy, sharply circumscribed Kupffer cell inclusions best seen on PAS-D. Criteria including them had a positive predictive value of 70%–88% for AIH (Sakhuja and Goyal 2024).
  • Grading. The International AIH Pathology Group prefers the Ishak modified histological activity index for AIH because it assesses centrilobular necroinflammation (Sakhuja and Goyal 2024).

Histologic criteria for autoimmune hepatitis: International AIH Pathology Group 2022 and the 2008 simplified criteria

  • Current rule (2022). The biopsy is first classed as portal (chronic) or lobular (acute) hepatitis, then as likely, possible or unlikely AIH. Emperipolesis and rosettes are not regarded as specific for AIH (Lohse et al. 2022).
  • Previous rule (2008). The simplified criteria scored histology as typical (2 points), compatible (1 point) or atypical (0 points) within a score that also included autoantibodies, IgG and exclusion of viral hepatitis (Moral et al. 2024; Hennes et al. 2008). Probable AIH was a total of 6 points and definite AIH 7 or more (Hennes et al. 2008).
  • Reclassification under the 2022 criteria. Applied to 78 AIH biopsies, the 2022 recommendations moved 16 (20.5%) to a higher category and none to a lower category (Moral et al. 2024).
Category International AIH Pathology Group 2022 2008 simplified criteria (previous rule) Source
Highest category Likely AIH: predominantly portal lymphoplasmacytic hepatitis with more than mild interface or lobular activity; or predominantly lobular hepatitis, with or without centrilobular necroinflammation, plus portal lymphoplasmacytic hepatitis, interface hepatitis or portal-based fibrosis; no features of another liver disease Typical (2 points): interface hepatitis with portal lymphocytic or lymphoplasmacytic infiltrate, emperipolesis and hepatocellular rosettes Lohse et al. 2022; Moral et al. 2024
Middle category Possible AIH, which includes AIH-type hepatitis with features of PBC, PSC or steatotic liver disease Compatible (1 point): chronic hepatitis pattern Sakhuja and Goyal 2024; Moral et al. 2024
Lowest category Unlikely AIH Atypical (0 points) Moral et al. 2024

Overlap features and AIH differential diagnosis

  • Biliary changes in AIH. Focal lymphocytic cholangitis and bile duct injury occur in 12%–20% of AIH and do not exclude it (Sakhuja and Goyal 2024).
  • PBC or PSC with AIH features. Bile duct loss or chronic cholestasis (periportal copper or copper-associated protein, periportal CK7-positive intermediate hepatocytes) in a suspected AIH biopsy raises the possibility of PBC or PSC with AIH-like features (Sakhuja and Goyal 2024). PSC overlap also requires cholangiographic strictures (Sakhuja and Goyal 2024).
  • Steatohepatitis. Steatotic liver disease coexists in 15%–30% of AIH. Ballooning, Mallory–Denk bodies and centrilobular chicken-wire fibrosis indicate concurrent steatohepatitis (Sakhuja and Goyal 2024).
  • Drug injury. Severe Ishak activity favors AIH. Portal neutrophils and hepatocellular cholestasis are more frequent in drug injury (Sakhuja and Goyal 2024). Drug-induced AIH shows more prominent portal neutrophils than plasma cells with cholestasis on a background of portal inflammation, interface hepatitis and rosettes (Fontana et al. 2023).

Drug-induced liver injury

  • Mechanisms. Direct hepatotoxins such as acetaminophen injure nearly all exposed individuals above a threshold dose. Idiosyncratic injury is largely dose-independent and occurs in 1 in 1000 to 1 in a million exposed persons. Indirect injury results from the drug's effect on host immunity, for example immune checkpoint inhibitor hepatitis and HBV reactivation after rituximab (Fontana et al. 2023).
  • Biochemical pattern. AASLD 2023 classifies idiosyncratic DILI at presentation as hepatocellular, mixed or cholestatic by the R value (Fontana et al. 2023). The formula and thresholds are covered in Liver, Kidney and Gastrointestinal Function Tests.
  • Correlation with histology. Hepatocellular presentations showed more inflammation, necrosis, apoptosis, lobular disarray and rosettes. Cholestatic presentations more often showed bile plugs and duct paucity (Kleiner et al. 2014).
  • Common histologic patterns. Among 249 DILI biopsies, the commonest patterns were cholestatic hepatitis (29%), acute hepatitis (21%), chronic hepatitis (14%), chronic cholestasis (10%) and acute cholestasis (9%) (Kleiner et al. 2014).
  • Common agents. Amoxicillin-clavulanate is the most frequently implicated single agent in many Western countries. Antituberculosis agents dominate in Asia, and herbal and dietary supplements account for 27%–62% of DILI in China, Korea and Singapore (Fontana et al. 2023).
  • Latency. Most DILI appears within 6 months of starting a drug. Nitrofurantoin and methotrexate have longer latency, and amoxicillin-clavulanate injury can present after the drug is stopped (Fontana et al. 2023).
  • Role of biopsy. Biopsy is not required for diagnosis. It helps in diagnostic uncertainty, a severe or protracted course, or failure to improve after dechallenge (Fontana et al. 2023).
  • Prognostic findings. Eosinophils and granulomas are associated with milder injury. Necrosis, fibrosis, microvesicular steatosis and ductular reaction are associated with severe or fatal injury (Kleiner et al. 2014; Fontana et al. 2023).
  • Vanishing bile duct syndrome. Bile duct loss exceeding 50% in chronic cholestatic DILI is termed vanishing bile duct syndrome (Fontana et al. 2023).
  • Vascular patterns. Sinusoidal obstruction syndrome, nodular regenerative hyperplasia and obliterative portal venopathy, with their causative drugs, are covered in Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy.
  • Adaptive changes. Induction hepatocytes follow phenytoin or barbiturate use. Phospholipidosis, with foamy granular hepatocyte cytoplasm, follows cationic amphiphilic drugs such as amiodarone (Fontana et al. 2023).
Histologic pattern Characteristic histology Prototype agents Source
Acute hepatitis Spotty necrosis, apoptosis, lobular inflammation with or without portal inflammation and interface hepatitis Phenytoin, dapsone, isoniazid, sulfonamides Fontana et al. 2023
Panlobular hepatitis Acidophil bodies throughout the lobule, lytic necrosis, lymphocytic infiltrate Ipilimumab, nivolumab Fontana et al. 2023
Zonal or confluent necrosis Zone 3 coagulative necrosis or submassive to massive necrosis Acetaminophen, halothane, carbon tetrachloride, cocaine, ferrous sulfate Fontana et al. 2023
Granulomatous hepatitis Noncaseating granulomas with inflammation; fibrin-ring granulomas Sulfonamides, phenytoin, carbamazepine, quinidine, hydralazine, interferon-α, ipilimumab Fontana et al. 2023
Chronic hepatitis Portal inflammation, interface hepatitis, fibrosis or cirrhosis Atorvastatin, methotrexate, herbal and dietary supplements Fontana et al. 2023
Drug-induced AIH AIH-type hepatitis with portal neutrophils and cholestasis Nitrofurantoin, minocycline, α-methyldopa, hydralazine, diclofenac, statins, TNF inhibitors Fontana et al. 2023
Bland (acute) cholestasis Bile in hepatocytes and canaliculi with little or no inflammation Anabolic steroids, oral contraceptives Fontana et al. 2023
Cholestatic hepatitis Cholestasis with prominent lobular inflammation and hepatocyte injury Amoxicillin-clavulanate, erythromycin, ACE inhibitors, phenothiazines Fontana et al. 2023
Chronic cholestasis Cholestasis, cholate stasis, bile duct loss Amoxicillin-clavulanate, flucloxacillin, terbinafine, enalapril Fontana et al. 2023
Sclerosing cholangitis Intraepithelial lymphocytes in bile ducts and periductal fibrosis Nivolumab Fontana et al. 2023
Microvesicular steatosis Numerous small droplets with central nuclei Aspirin (Reye syndrome), valproic acid, tetracycline, nucleoside reverse transcriptase inhibitors Fontana et al. 2023
Macrovesicular steatosis and steatohepatitis Large droplets displacing nuclei; ballooning and Mallory–Denk bodies Methotrexate, glucocorticoids, tamoxifen, irinotecan, amiodarone Fontana et al. 2023

Acetaminophen and immune checkpoint inhibitor hepatotoxicity

  • Acetaminophen. Overdose, usually more than 4 g at a single time point, causes hepatocellular injury with aminotransferases often above 1000 U/L within 24 h (Fontana et al. 2023). Histology shows coagulative confluent necrosis in centrilobular areas (Fernández et al. 2024).
  • Acetaminophen and acute liver failure. Acetaminophen overdose is the most common cause of acute liver failure in developed countries, accounting for 60% of cases in the UK and 46% in the US (Fernández et al. 2024).
  • Checkpoint inhibitor hepatitis. About 70% of biopsies show panlobular hepatitis and about 20% show centrilobular coagulative necrosis. Plasma cells are not predominant, and CD8-positive T cells outnumber CD4-positive cells. Sclerosing cholangitis is uncommon (Fontana et al. 2023).
  • Fibrin-ring granulomas. Fibrin-ring granulomas occurred in two patients with hepatitis on combined ipilimumab and nivolumab (Everett et al. 2017).

Causality assessment in drug-induced liver injury

  • RUCAM. The Roussel Uclaf Causality Assessment Method was published in 1993. The 2016 update scores −9 to +14 points in five likelihood categories (Fontana et al. 2023).
  • RECAM. The Revised Electronic Causality Assessment Method is a computerized platform scoring −6 to +20 points. It was developed for single-drug cases and has not been tested in herbal and dietary supplement injury (Fontana et al. 2023).

Acute liver failure

  • Causes. Drug-induced injury is the main cause of acute liver failure in Europe and the US. Non-acetaminophen DILI accounts for 5%–20% of cases (Fernández et al. 2024).
  • Biopsy. Transjugular biopsy is safe in acute liver failure. It diagnoses causes that only histology identifies, such as malignant infiltration and granulomatous hepatitis (Fernández et al. 2024).
  • Submassive necrosis. Submassive necrosis may show regenerative nodules among collapsed tissue (Choi 2025).
Cause of acute liver failure Liver histology Source
Hepatitis viruses A, B, C, E Massive or submassive necrosis with lymphocytic infiltrates; fibrosis in HBV reactivation Fernández et al. 2024
Herpes simplex, varicella-zoster, cytomegalovirus, EBV, adenovirus Massive or submassive necrosis with viral inclusions Fernández et al. 2024
Acetaminophen Centrilobular coagulative confluent necrosis Fernández et al. 2024
Autoimmune hepatitis Centrilobular and confluent necrosis, lymphoplasmacytic infiltrate, interface hepatitis, variable fibrosis Fernández et al. 2024
Wilson disease Microvesicular steatosis, glycogenated nuclei, variable fibrosis Fernández et al. 2024
Hypoxic hepatitis and heatstroke Predominantly centrilobular necrosis Fernández et al. 2024
Amatoxin mushroom poisoning Massive coagulative necrosis Fernández et al. 2024
Malignant infiltration Atypical cells in sinusoids Fernández et al. 2024

Granulomatous hepatitis

  • Definition. A granuloma consists of epithelioid histiocytes rimmed by lymphocytes, often with multinucleated giant cells, in portal tracts or lobules (Choi 2025).
  • Causes in practice. Leading Western causes are PBC, idiopathic disease, sarcoidosis, infection and drug injury (Choi 2025). In a US series of 251 cases, 31% were idiopathic, 20% autoimmune (84% of these PBC), 19% steatohepatitis-associated, 10% sarcoidosis, 8% infectious and 4% drug-induced (Wang et al. 2026).
  • Regional variation. Sarcoidosis accounts for about 22% of hepatic granulomas in the United States, autoimmune disease for 15.0%–48.6% in Europe and tuberculosis for up to 88.9% worldwide (Wang et al. 2026).
  • Morphologic clues. Sarcoid granulomas are lobular, well formed, epithelioid and noncaseating. PBC granulomas are portal-based, duct-centric, poorly formed and lymphoplasmacytic (the florid duct lesion). Necrotizing granulomas suggest mycobacterial or fungal infection (Wang et al. 2026).
  • Stains. Unexplained granulomas are stained with Ziehl–Neelsen or another acid-fast stain and Grocott methenamine silver. Send-out broad-range pathogen molecular testing detected an organism in 12 of 37 (32%) and 4 of 8 (50%) histologically suspicious cases at two institutions (Wang et al. 2026).
  • Drug-induced granulomas. Ipilimumab was the most frequent possible agent among drug-induced granulomas (3 of 10) (Wang et al. 2026).
Granuloma type Typical causes Source
Lipogranuloma Steatotic liver disease Choi 2025
Fibrin-ring (doughnut) granuloma: central fat vacuole, fibrin ring, macrophages and lymphocytes Q fever (Coxiella burnetii); also tuberculosis, CMV, EBV, toxoplasmosis, leishmaniasis, Hodgkin lymphoma, sarcoidosis, drugs and checkpoint inhibitors Lee et al. 2012; Everett et al. 2017
Noncaseating epithelioid granuloma Sarcoidosis, PBC, drugs Choi 2025; Wang et al. 2026
Caseating granuloma Tuberculosis Choi 2025
Necrotizing granuloma Bacterial, fungal and parasitic infection; drugs Choi 2025
Egg granuloma in portal tracts Schistosoma species Da Silva and Carrilho 1992
Foreign-body granuloma Injection sites, surgery Choi 2025
  • Q fever. In acute Q fever hepatitis, typical fibrin-ring granulomas were found in liver biopsies, and epithelioid granulomas with eosinophils and giant cells also occurred (Lee et al. 2012). Phosphotungstic acid hematoxylin and trichrome stains highlight the fibrin ring (Choi 2025; Lee et al. 2012).

Hepatic abscess and echinococcosis

  • Routes of infection. Hepatic abscess arises through the bile ducts, the hepatic artery or portal vein, or by contiguity (Lardière-Deguelte et al. 2015).
  • Pyogenic abscess. Pyogenic abscess is the most prevalent type in Western countries and amebic abscess in South-East Asia and Africa (Lardière-Deguelte et al. 2015). In a Danish population cohort, biliary tract disease was the most frequent source (35%), 31% were cryptogenic, and Escherichia coli and the Streptococcus anginosus group were the most frequent isolates (Dudina et al. 2026). Klebsiella pneumoniae abscess is increasing and can seed distant sites (Lardière-Deguelte et al. 2015).
  • Amebic abscess. Entamoeba histolytica trophozoites invade the cecum and reach the liver through the portal vein. Amebic abscess favors the right lobe, which receives portal blood mainly from the superior mesenteric vein draining the cecum. Males are 4–9 times more often affected, and heavy alcohol use is reported in up to 85% (Kumar et al. 2024).
  • Amebic serology. Anti-amebic antibodies are found in about 95% of amebic liver abscess. Only 10%–40% of patients have concurrent intestinal amebiasis (Kumar et al. 2024).
  • Amebic abscess contents. The aspirate is thick, brown, acellular, odorless and almost always sterile debris of dead hepatocytes, the so-called anchovy sauce. The absence of neutrophils is attributed mainly to their lysis by the protozoan (Kumar et al. 2024). The abscess has a connective tissue rim and contains a few trophozoites and inflammatory cells (Cooney et al. 2025). Trophozoites are found in only 7.2%–25% of aspirates and only when the cyst wall is sampled (Kumar et al. 2024).
  • Echinococcosis. Echinococcus granulosus causes cystic echinococcosis, with solitary or multiple grape-like cysts. Echinococcus multilocularis causes alveolar echinococcosis, with multiple small cysts and a bread-like cut surface that resembles cancer (Frey and Barth 2025; Kim et al. 2011).
  • Laminated layer. The PAS-positive laminated layer is the microscopic hallmark. It is broad and striated in cystic echinococcosis and thin and fragmented in alveolar echinococcosis (Frey and Barth 2025). Monoclonal antibodies Em2G11 and EmG3 separate the two species when only small particles are present (Frey and Barth 2025). Protoscolices and hooklets in aspirated cyst fluid are covered in Benign Liver Lesions on FNA (Abscess, Hydatid Cyst, Focal Nodular Hyperplasia, Hepatocellular Adenoma and Hemangioma).
Feature Pyogenic abscess Amebic abscess Cystic echinococcosis Alveolar echinococcosis Source
Agent E. coli, Streptococcus anginosus group, Klebsiella pneumoniae Entamoeba histolytica Echinococcus granulosus Echinococcus multilocularis Dudina et al. 2026; Lardière-Deguelte et al. 2015; Frey and Barth 2025
Route or source Biliary tract disease most often; portal or arterial seeding Portal vein from the cecum Larval stage Larval stage Dudina et al. 2026; Kumar et al. 2024; Frey and Barth 2025
Gross findings Abscess cavity Usually right lobe Solitary or multiple grape-like cysts Multiple small cysts, bread-like, infiltrative mass Kumar et al. 2024; Frey and Barth 2025
Microscopy or microbiology Organism identified in 69% Inflammation and necrosis caused by trophozoites Broad, striated PAS-positive laminated layer Thin, fragmented PAS-positive laminated layer with granulomatous inflammation and necrosis Dudina et al. 2026; Kumar et al. 2024; Frey and Barth 2025; Kim et al. 2011

Schistosomiasis, leishmaniasis and other hepatic infections

  • Hepatosplenic schistosomiasis. Eggs carried in the portal circulation produce portal and periportal granulomas and amputation of intrahepatic portal veins. A coarse periportal ("pipestem", Symmers) fibrosis follows in a minority with a high worm load (Da Silva and Carrilho 1992).
  • Portal hypertension without liver failure. The portal block is presinusoidal and the parenchyma is preserved. Variceal bleeding is the most frequent cause of death, and advanced liver failure does not occur without a second liver disease (Da Silva and Carrilho 1992).
  • Visceral leishmaniasis. The liver shows hypertrophy and hyperplasia of Kupffer cells parasitized by amastigotes, with diffuse fibrosis of the space of Disse in some cases. Fibrosis and parasitism regressed after treatment in a reported patient (Corbett et al. 1993).
  • Syphilis. In 55 biopsied adults with syphilitic hepatitis, biopsies showed portal or lobular inflammation (87%), cholestasis (49%), hepatocellular necrosis (45%), granulomas with multinucleated giant cells (20%) and fibrosis (18%). Spirochetes were shown in 19 of 28 stained cases, 15 by immunostain and 4 by Warthin–Starry stain. ALP and GGT rise more than aminotransferases (Huang et al. 2018).
  • Liver flukes. Opisthorchis viverrini and Clonorchis sinensis inhabit the bile ducts, cause periductal inflammation and fibrosis, and are associated with cholangiocarcinoma (Chua et al. 2021).
  • Fungi and mycobacteria. Grocott methenamine silver detects fungi and Ziehl–Neelsen detects acid-fast bacilli (Choi 2025). Histoplasma capsulatum and nontuberculous mycobacteria were among the agents identified in hepatic granulomas (Wang et al. 2026).

Differential diagnosis of lobular and portal hepatitis on biopsy

Feature Acute viral hepatitis Autoimmune hepatitis Drug-induced hepatitis Checkpoint inhibitor hepatitis EBV hepatitis Source
Dominant inflammation Lobular with spotty necrosis; plasma cell-rich periportal infiltrate in hepatitis A Portal lymphoplasmacytic with interface activity, or lobular with centrilobular necrosis in acute AIH Acute or chronic hepatitis, cholestatic hepatitis Panlobular hepatitis or centrilobular necrosis Sinusoidal "string of beads" lymphocytes with portal lymphocytes Teixeira et al. 1982; Lohse et al. 2022; Kleiner et al. 2014; Fontana et al. 2023; Schechter and Lamps 2018
Plasma cells Prominent in hepatitis A Prominent in two-thirds; clusters of 5 or more Present in 23% Not predominant Infiltrate predominantly lymphocytic Teixeira et al. 1982; Sakhuja and Goyal 2024; Kleiner et al. 2014; Fontana et al. 2023; Schechter and Lamps 2018
Other clues Centrilobular cholestasis in hepatitis A IgG-dominant plasma cells; Kupffer cell hyaline globules Eosinophils in 38%; portal neutrophils; cholestasis CD8-positive T cells exceed CD4-positive; fibrin-ring granulomas Intact architecture Teixeira et al. 1982; Choi 2025; Sakhuja and Goyal 2024; Kleiner et al. 2014; Fontana et al. 2023; Everett et al. 2017
Confirmation Serology and nucleic acid tests Autoantibodies, IgG, biopsy category Drug history, dechallenge, RUCAM or RECAM Drug exposure EBER in situ hybridization Fernández et al. 2024; Lohse et al. 2022; Fontana et al. 2023; Schechter and Lamps 2018

Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease

Related page: Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections (biopsy adequacy, special stain table, zonal anatomy and chronic hepatitis grading) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (neonatal cholestasis and biliary cirrhosis) Related page: Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy (outflow obstruction and donor steatosis) Related page: Microcytic Anemias and Iron Studies (iron studies, HFE genotypes and hepcidin) Related page: Toxic Metals and Trace Elements: Lead, Arsenic, Mercury, Implant Metals, Copper and Wilson Disease (ceruloplasmin, urine and exchangeable copper) Related page: Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders (tyrosinemia, urea cycle, galactosemia, glycogen storage and fatty acid oxidation biochemistry) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (the alpha-1-antitrypsin band) Related page: Renal Biopsy Evaluation and Nephrotic Glomerular Diseases: Minimal Change Disease, FSGS, Membranous and Diabetic Nephropathy, Amyloidosis and Monoclonal Immunoglobulin Deposition (amyloid typing by mass spectrometry) Related page: Porphyrias and Vitamin Testing (protoporphyria biochemistry)

Hepatic steatosis: definition, grade and droplet type

  • Threshold. Steatosis in more than 5% of hepatocytes is the working definition of fatty liver (Boyd et al. 2020; Cataldo et al. 2021).
  • Grade. Steatosis is graded as mild (5%–33%), moderate (34%–66%) or severe (>66%) at low to medium magnification (Cataldo et al. 2021).
  • Macrovesicular steatosis. One large droplet displaces the nucleus to the periphery. More than 90% of cases occur with metabolic syndrome or chronic alcohol use (Choi 2025).
  • Microvesicular steatosis. Numerous small droplets leave the nucleus central. It reflects mitochondrial injury in drug and toxic injury, acute fatty liver of pregnancy and fatty acid oxidation or urea cycle disorders (Choi 2025).
  • Distribution. Steatosis of MASLD begins in zone 3. A zone 1-predominant distribution occurs in about 1% of adults and about 12% of children and teenagers (Leow et al. 2023).

Steatotic liver disease nomenclature: MASLD, MASH, MetALD and ALD

  • Current rule (2023). Steatotic liver disease is the umbrella term. Metabolic dysfunction-associated steatotic liver disease (MASLD) is hepatic steatosis with at least 1 of 5 cardiometabolic risk factors and no other discernible cause (Rinella et al. 2023).
  • Previous terms. MASLD replaces nonalcoholic fatty liver disease (NAFLD), and metabolic dysfunction-associated steatohepatitis (MASH) replaces nonalcoholic steatohepatitis (NASH) (Rinella et al. 2023).
  • Previous alcohol rule. The NAFLD definition excluded alcohol intake above 20 g/day in women and 30 g/day in men (Rinella et al. 2023).
  • MetALD. MetALD is MASLD with alcohol intake of 140–350 g/week in women and 210–420 g/week in men (Rinella et al. 2023).
  • Cryptogenic steatotic liver disease. Steatosis without metabolic risk factors or a known cause is cryptogenic steatotic liver disease (Rinella et al. 2023).
  • Coexisting disease. Because MASLD is an affirmative diagnosis, it can coexist with autoimmune or viral hepatitis (Rinella et al. 2023).
  • Steatohepatitis retained. Steatohepatitis was retained as a distinct concept because 95% of respondents considered it prognostically important (Rinella et al. 2023).
Category (2023) Definition Previous term Source
Steatotic liver disease Hepatic steatosis of any cause, diagnosed histologically or by imaging Fatty liver disease Rinella et al. 2023
MASLD Steatosis with at least 1 cardiometabolic risk factor and no other cause NAFLD Rinella et al. 2023
MASH MASLD with steatohepatitis NASH Rinella et al. 2023
MetALD MASLD with 140–350 g/week (women) or 210–420 g/week (men) of alcohol No equivalent category Rinella et al. 2023
Alcohol-related liver disease (ALD) Steatotic liver disease caused by alcohol Alcoholic liver disease Rinella et al. 2023
Cryptogenic steatotic liver disease No metabolic risk factor and no identifiable cause No equivalent category Rinella et al. 2023

Diagnostic histology of MASH

  • Required features. Steatohepatitis requires steatosis above 5% with both lobular inflammation and hepatocyte ballooning, mainly in zone 3. Portal inflammation, Mallory–Denk bodies, glycogenated nuclei, apoptosis, megamitochondria and iron are neither necessary nor sufficient (Cataldo et al. 2021).
  • Ballooning. A ballooned hepatocyte is 1.5–2 times normal size (diameter above about 30 µm), round and with rarefied cytoplasm (Cataldo et al. 2021). Loss of keratin 8/18 reflects cytoskeletal injury, and clumped keratin fragments form Mallory–Denk bodies (Leow et al. 2023).
  • Ballooning versus glycogenosis. Glycogen-filled hepatocytes have homogeneously clear cytoplasm but keep a polygonal contour (Cataldo et al. 2021).
  • Lobular inflammation. Lobular inflammation is mild and mainly lymphocytic with macrophages. Severe lobular inflammation suggests alcohol or drugs (Cataldo et al. 2021).
  • Lipogranulomas. Lipogranulomas are frequent in steatohepatitis and are not counted as lobular inflammation (Cataldo et al. 2021).
  • Portal inflammation. Diffuse moderate to severe portal inflammation disproportionate to lobular inflammation suggests concurrent viral or autoimmune hepatitis (Leow et al. 2023). More than mild portal inflammation in MASH correlates with advanced fibrosis (Cataldo et al. 2021).
  • Glycogenated nuclei. Glycogenated nuclei are normal in children, are common in steatotic liver disease and are associated with diabetes (Cataldo et al. 2021).
  • Fibrosis pattern. Fibrosis begins as zone 3 pericellular "chicken-wire" fibrosis and later involves portal tracts, bridges and cirrhosis (Leow et al. 2023). The NASH Clinical Research Network scores pericellular fibrosis as mild when seen only on trichrome and moderate when also visible on H&E (Choi 2025).
  • Adverse histologic features. Portal inflammation and Mallory–Denk bodies are associated with fibrosis and adverse outcomes (Leow et al. 2023).

NAFLD activity score and NASH Clinical Research Network fibrosis stage

  • Design. The NASH Clinical Research Network system was validated on 50 cases (32 adult and 18 pediatric). The NAFLD activity score (NAS) is the unweighted sum of steatosis, lobular inflammation and ballooning (Kleiner et al. 2005).
  • NAS is an activity score. NAS ≥5 correlated with a diagnosis of NASH, and scores below 3 were "not NASH" (Kleiner et al. 2005). NAS was designed to grade activity and is not a numerical diagnostic criterion. In one study, 7% of biopsies judged not NASH had NAS ≥5 (Chowdhury and Mehta 2023; Leow et al. 2023).
  • Trial use. NAS of 4 or more is an inclusion criterion in many NASH trials (Leow et al. 2023).
  • Brunt system. The 1999 Brunt system grades NASH activity in 3 tiers, stages fibrosis 0–4 and requires a diagnosis of steatohepatitis first (Cataldo et al. 2021).
  • SAF score and FLIP algorithm. The SAF score combines steatosis (S0–S3), activity (A0–A4; ballooning 0–2 plus lobular inflammation 0–2) and fibrosis (F0–F4). The FLIP algorithm classifies a biopsy as steatosis or steatohepatitis and raised interobserver agreement among general pathologists from κ 0.35 to κ 0.61 (Leow et al. 2023).
Component Score Definition Source
Steatosis 0–3 <5%, 5%–33%, 34%–66% or >66% of hepatocytes Cataldo et al. 2021
Lobular inflammation 0–3 None, <2, 2–4 or >4 foci per 200× field (20× objective) Cataldo et al. 2021
Ballooning 0–2 None; few (mild); many (moderate to marked) Cataldo et al. 2021
NAS total 0–8 Sum of the three components; activity grade Kleiner et al. 2005; Leow et al. 2023
Fibrosis stage 1a 1 Delicate zone 3 pericellular fibrosis seen only on a connective tissue stain Leow et al. 2023
Fibrosis stage 1b 1 Dense zone 3 pericellular fibrosis visible on H&E Leow et al. 2023
Fibrosis stage 1c 1 Portal/periportal fibrosis only (pediatric pattern) Leow et al. 2023
Fibrosis stage 2 2 Zone 3 pericellular plus portal/periportal fibrosis Cataldo et al. 2021
Fibrosis stage 3 3 Bridging fibrosis Cataldo et al. 2021
Fibrosis stage 4 4 Cirrhosis Cataldo et al. 2021

Pediatric steatohepatitis

  • Type 2 pattern. About half of pediatric NASH shows the "type 2" pattern: moderate to severe panacinar steatosis, portal inflammation and portal fibrosis, with less ballooning and fewer Mallory–Denk bodies (Leow et al. 2023).
  • Zone 1 fibrosis. Pediatric steatohepatitis more often shows periportal fibrosis without perisinusoidal fibrosis because fat is deposited first in zone 1 (Leow et al. 2023; Sergi 2024).
  • Young adults. The type 2 pattern also occurs in a subset of young adults (Leow et al. 2023).
  • Steatosis. Steatosis develops in 90% of people drinking more than 60 g/day over decades, or 120–150 g/day for 2–3 weeks (Philips 2024). It is usually macrovesicular and centrilobular and involves the whole lobule in severe disease (Schroeder et al. 2021).
  • Alcohol-associated hepatitis. Alcohol-associated hepatitis is the clinical syndrome of abrupt jaundice after heavy recent drinking. Alcoholic steatohepatitis is its histologic counterpart and can occur without the syndrome. Mortality at 28 days is 25%–40% (Philips 2024).
  • Histology of alcoholic steatohepatitis. Classical features are neutrophil-rich lobular inflammation, ballooning, satellitosis (neutrophils surrounding ballooned hepatocytes), numerous Mallory–Denk bodies, glycogenated nuclei, megamitochondria and zone 3 perivenular and pericellular fibrosis (Philips 2024). Mallory–Denk bodies can persist up to 6 months after abstinence (Philips 2024).
  • Separation from MASH. Marked cholestasis with strong hepatocyte keratin 7 staining and sclerosing hyaline necrosis with central vein obliteration favor alcohol-associated hepatitis (Philips 2024). Alcoholic foamy degeneration and sclerosing hyaline necrosis are not features of MASLD (Leow et al. 2023). The two cannot usually be separated on histology alone (Boyd et al. 2020).
  • Megamitochondria. Megamitochondria are round eosinophilic cytoplasmic inclusions of 2–10 µm. They also occur in Wilson disease and MASLD (Schroeder et al. 2021).
  • Mallory–Denk bodies outside steatohepatitis. Mallory–Denk bodies occur in chronic cholestasis (especially PBC), amiodarone injury, alpha-1-antitrypsin deficiency, focal nodular hyperplasia and up to 50% of Wilson disease (Schroeder et al. 2021).
  • Alcoholic hepatitis histology score. The AHHS scores fibrosis, bilirubinostasis, neutrophil infiltration and megamitochondria from 0 to 9. Scores of 0–3, 4–5 and 6–9 indicate mild, intermediate and severe categories and predict mortality (Chowdhury and Mehta 2023).
  • Severity. Severe alcohol-associated hepatitis is defined by MELD above 20, Maddrey discriminant function ≥32 or overt encephalopathy (Philips 2024).
Feature Alcoholic steatohepatitis MASH Source
Lobular inflammation Neutrophil-rich with satellitosis Mild, mainly lymphocytic Philips 2024; Cataldo et al. 2021
Mallory–Denk bodies and ballooning Numerous Fewer Leow et al. 2023
Cholestasis Marked in decompensation; keratin 7-positive hepatocytes Marked cholestasis absent Philips 2024
Sclerosing hyaline necrosis and foamy degeneration Present Absent Leow et al. 2023
Glycogenated nuclei Less common More common; associated with diabetes Leow et al. 2023
Fibrosis Zone 3 perivenular and pericellular Zone 3 pericellular Philips 2024; Leow et al. 2023

Cirrhosis: morphology, etiologic clues, Laennec substage and regression

  • Definition. Cirrhosis is diffuse replacement of the parenchyma by fibrous bands and regenerative nodules (Choi 2025).
  • Nodule size. Classification by nodule size into micronodular and macronodular cirrhosis is no longer clinically relevant (Choi 2025).
  • Biopsy criteria for cirrhosis. Advanced diffuse fibrosis in active alcoholic steatohepatitis is considered cirrhosis even without discrete nodules. Fragmentation alone is not a criterion for cirrhosis (Choi 2025).
  • Reversibility. Cirrhosis is now regarded as a potentially reversible stage of a bidirectional process (Choi 2025).
Etiology Pattern of fibrosis and clues Source
Chronic viral hepatitis Portal expansion, then periportal and septal fibrosis Lo and Kim 2017
Alcohol-related and adult MASLD Centrilobular perivenular and sinusoidal fibrosis Lo and Kim 2017
Pediatric MASLD Periportal pattern without perisinusoidal fibrosis Lo and Kim 2017
Biliary disease Irregular "jigsaw" micronodules with periseptal halos of feathery degeneration Lo and Kim 2017
Venous outflow obstruction Central-to-central linkage ("reversed lobulation") or veno-portal cirrhosis Lo and Kim 2017
Hemochromatosis Iron in hepatocytes, Kupffer cells, macrophages, biliary epithelium and endothelium with a periportal-to-centrilobular gradient Li et al. 2019
Alpha-1-antitrypsin deficiency PAS-D-positive globules in zone 1 hepatocytes Choi 2025
Wilson disease Glycogenated nuclei, steatosis, Mallory–Denk bodies, copper in hepatocytes and macrophages Schroeder et al. 2021; Menon et al. 2021

Laennec substaging of cirrhosis

  • Stage 4A. Mild cirrhosis with mostly thin septa (Lo and Kim 2017).
  • Stage 4B. Moderate cirrhosis with at least two broad septa and no very broad septa (Lo and Kim 2017).
  • Stage 4C. Severe cirrhosis with at least one very broad septum or many micronodules (Lo and Kim 2017).
  • Clinical correlation. Laennec substage correlates with clinical stage, portal hypertension and recurrence of hepatocellular carcinoma after resection (Lo and Kim 2017).

Histologic features of fibrosis regression

  • Hepatic repair complex. Wanless described delicate perforated septa, isolated thick collagen fibers, delicate periportal fibrous spikes, portal tract remnants, hepatic vein remnants with prolapsed hepatocytes, hepatocytes within portal tracts or splitting septa, minute regenerative nodules and aberrant parenchymal veins (Khan and Saxena 2021).
  • Incomplete septal cirrhosis. Incomplete septal cirrhosis has a vaguely macronodular pattern with delicate incomplete septa and is proposed to represent regressed cirrhosis (Khan and Saxena 2021).
  • Beijing classification. Fibrosis in treated chronic hepatitis B is classed as predominantly progressive (broad, pale, cellular septa with ductular reaction), indeterminate or predominantly regressive (Lo and Kim 2017).
  • Limits of regression. Large regions of parenchymal extinction persist, so complete regression of cirrhosis is almost never seen (Khan and Saxena 2021).
  • Collapse versus fibrosis. Fibrosis is new collagen deposition. Parenchymal collapse is approximation of the pre-existing reticulin network after hepatocyte loss (Khan and Saxena 2021).

Hereditary hemochromatosis and hepatic iron overload

  • Definition (EASL). Hemochromatosis is a genetic disorder of iron homeostasis with increased intestinal iron absorption, elevated transferrin saturation and iron loading mainly in the liver, without anemia or reticulocytosis (Srinivasamurthy and Mehta 2026).
  • Genetics. HFE-related hemochromatosis is autosomal recessive. C282Y homozygosity accounts for most cases and occurs almost exclusively in people of northern European descent (Srinivasamurthy and Mehta 2026). Genotype interpretation is covered in Microcytic Anemias and Iron Studies.
  • Mechanism. Loss of function of HFE, HJV (HFE2), HAMP or TFR2 impairs hepcidin induction (Srinivasamurthy and Mehta 2026).
  • Penetrance. C282Y homozygosity alone does not cause disease. Many homozygotes show biochemical iron overload, fewer have symptoms and fewer still develop cirrhosis or hepatocellular carcinoma (Srinivasamurthy and Mehta 2026).
  • Diagnosis without biopsy. Biochemical diagnostic thresholds in C282Y homozygotes are covered in Microcytic Anemias and Iron Studies. Other HFE genotypes need hepatic iron overload shown by MRI or biopsy (EASL 2022).
  • Role of biopsy. Biopsy is no longer needed to diagnose hemochromatosis. It stages fibrosis and assesses iron distribution and coexisting disease (Chowdhury and Mehta 2023). Patients with advanced fibrosis enter hepatocellular carcinoma surveillance (EASL 2022).
  • Iron distribution in hepcidin-deficient hemochromatosis. Iron accumulates in parenchymal cells with little Kupffer cell iron until late-stage disease (Srinivasamurthy and Mehta 2026). In heavy loading, iron decreases in a gradient from periportal to centrilobular hepatocytes and also involves Kupffer cells, biliary epithelium and endothelium (Li et al. 2019; Boyd et al. 2020).
  • Iron grading. The Batts–Ludwig method grades hepatocyte iron from 1 to 4 by the proportion of staining hepatocytes, and grade 4 is panlobular (Chowdhury and Mehta 2023).
  • Hepatic iron concentration and index. The hepatic iron index is the hepatic iron concentration (µmol/g dry weight) divided by age in years. In the original series, no homozygote had an index below 1.9 and no heterozygote an index above 1.5, and a concentration above 75 µmol/g clearly indicated homozygous hemochromatosis (Summers et al. 1990). Normal hepatic iron concentration is below 35.5 µmol/g (Adams et al. 1997).
  • Limits of the hepatic iron index. The index exceeded 1.9 in 51 of 55 (93%) American patients with hemochromatosis (Kowdley et al. 1997). In another series, 4 of 55 homozygotes (7%) had an index of 1.9 or less, so the index is not an absolute diagnostic criterion (Adams et al. 1997). It also lacks specificity for hemochromatosis in end-stage liver disease (Cotler et al. 1998).
  • Iron and fibrosis. Fibrosis or cirrhosis in hemochromatosis occurred only above a hepatic iron concentration of about 400 µmol/g (22.3 mg/g) dry weight (Bassett et al. 1986).
  • Phlebotomy targets. Phlebotomy aims for a ferritin <50 µg/L during induction and <100 µg/L during maintenance (EASL 2022).
Condition Main iron-bearing cells Transferrin saturation Source
HFE, HJV, HAMP and TFR2 hemochromatosis Hepatocytes (periportal first); Kupffer cells only late Elevated Srinivasamurthy and Mehta 2026; Li et al. 2019
Ferroportin disease (loss-of-function SLC40A1) Kupffer cells and spleen Normal to low Srinivasamurthy and Mehta 2026
Transfusional (secondary) iron overload Predominantly Kupffer cells Variable Choi 2025
Cirrhosis and chronic liver disease Parenchymal iron from reduced hepcidin, especially with advanced fibrosis Variable Choi 2025
MASLD Mesenchymal, parenchymal or mixed iron in about one-third of patients Variable Cataldo et al. 2021
Sickle cell disease Kupffer cell erythrophagocytosis and hemosiderosis Variable Saeed et al. 2022

Wilson disease

  • Genetics. Wilson disease is autosomal recessive and caused by ATP7B variants on chromosome 13. ATP7B exports copper from hepatocytes and incorporates it into ceruloplasmin (Schroeder et al. 2021).
  • Early histology. Early disease shows mild nonspecific lobular changes, apoptosis, spotty necrosis, mild macrovesicular steatosis, occasional ballooning and glycogenated nuclei in periportal hepatocytes (Schroeder et al. 2021).
  • Progression. Portal inflammation, interface activity and ballooning increase, then bridging fibrosis and cirrhosis develop. Anisonucleosis is prominent late (Schroeder et al. 2021).
  • Fulminant presentation. Acute liver failure shows marked hepatocyte degeneration, apoptosis and parenchymal collapse, typically on a background of cirrhosis (Schroeder et al. 2021). Coombs-negative hemolysis and an alkaline phosphatase/bilirubin ratio below 2 support the diagnosis (Fernández et al. 2024).
  • Steatosis pattern. Steatosis in Wilson disease is mainly large-droplet and evenly distributed across the lobule. MASH more often shows zone 3 predominance (Schroeder et al. 2021).
  • Copper stains. Rhodanine and rubeanic acid stains may show hepatocyte copper. A negative stain does not exclude Wilson disease because accumulation is patchy, and mild copper is common in cholestatic disease (Schroeder et al. 2021). Some regenerative nodules contain no copper, so sampling at least two cores is recommended (Choi 2025).
  • Hepatic copper: current rule (AASLD 2022). A summary of the AASLD 2022 guidance lists hepatic copper >250 µg/g as increased in Wilson disease presenting with hepatitis, steatosis, cirrhosis or acute liver failure, and hepatic copper >75 µg/g in asymptomatic patients without organ damage (Alkhouri et al. 2023).
  • Hepatic copper: previous rule (EASL 2012). The EASL 2012 cutoff was 250 µg/g dry weight (>4 µmol/g). Its sensitivity and specificity were 83.3% and 98.6% in one study, and a cutoff of 209 µg/g gave 99.4% sensitivity and 96.1% specificity in another. About half of PBC and PSC livers exceeded 250 µg/g (Schroeder et al. 2021).
  • Current guideline. EASL-ERN 2025 replaced EASL 2012 (EASL 2025). Its diagnostic criteria, the Leipzig score and copper biochemistry are covered in Toxic Metals and Trace Elements: Lead, Arsenic, Mercury, Implant Metals, Copper and Wilson Disease.

Alpha-1-antitrypsin deficiency

  • Genetics. SERPINA1 variants are inherited as autosomal codominant alleles. The incidence is 1 in 1600 to 1 in 3500 (Menon et al. 2021).
  • Mechanism. Liver injury results from misfolded protein retained in hepatocytes. Lung injury results from unopposed neutrophil elastase (Menon et al. 2021). Of Z-AAT protein, 70% is degraded, 15% secreted and 15% forms insoluble polymers in the endoplasmic reticulum (Fromme et al. 2025).
  • Pi*ZZ. PiZZ is the leading genotype of liver disease, with a biphasic pattern peaking in early childhood and around age 40 (Fromme et al. 2025). In Swedish newborn screening, 12% of PiZZ infants had prolonged neonatal jaundice and 2%–3% needed transplantation (Fromme et al. 2025).
  • Neonatal cholestasis. The commonest presentation is infantile cholestasis that can mimic biliary atresia (Menon et al. 2021). Pediatric disease shows prolonged jaundice, ductular proliferation and sometimes ductopenia (Fromme et al. 2025).
  • Adult risk. Pi*ZZ carried an adjusted odds ratio of 21.7 for fibrosis or cirrhosis and 44.5 for primary liver cancer in the UK Biobank (Fromme et al. 2025).
  • Pi*MZ. Pi*MZ is a disease modifier, with a 1.7-fold risk of fibrosis or cirrhosis that rises with steatotic or alcohol-related liver disease (Fromme et al. 2025).
  • Histology. Hepatocytes contain eosinophilic globules that are PAS positive and diastase resistant (Menon et al. 2021). They localize to zone 1 and also stain with alpha-1-antitrypsin immunohistochemistry (Choi 2025).
  • Transplant. Hepatic artery thrombosis after transplantation for alpha-1-antitrypsin deficiency is covered in Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy.

Glycogenic hepatopathy and erythropoietic protoporphyria

  • Glycogenic hepatopathy. Glycogenic hepatopathy is glycogen overload of hepatocytes in poorly controlled type 1 diabetes (Jarasvaraparn et al. 2024). Hepatocytes are diffusely swollen and pale, and PAS highlights the glycogen (Choi 2025).
  • Pediatric series. In 9 children (median age 16 years), aminotransferases were high with AST above ALT. Biopsies showed diffuse hepatocyte swelling and steatosis with minimal fibrosis and no ballooning or lobular inflammation. Enzymes normalized with improved glycemic control (Jarasvaraparn et al. 2024).
  • Erythropoietic protoporphyria. The liver is dark grossly. Microscopy shows cholestasis and brown deposits with red birefringence in a Maltese cross pattern under polarized light (Yang et al. 2025). Porphyrin biochemistry is covered in Porphyrias and Vitamin Testing.

Liver disease of pregnancy

  • Frequency. Abnormal liver tests occur in 3%–5% of pregnancies (Panther and Blum 2008). Liver diseases unique to pregnancy occur in 3% of pregnancies worldwide (Horani et al. 2025).
  • Grouping. Preeclampsia, HELLP syndrome and acute fatty liver of pregnancy are preeclampsia-associated. Hyperemesis gravidarum and intrahepatic cholestasis of pregnancy are not (Panther and Blum 2008).
  • Acute fatty liver of pregnancy. It is a mitochondrial disorder associated with fetal long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency and occurs in the third trimester (Horani et al. 2025; Kong et al. 2007). Biopsy shows microvesicular steatosis, which is one of the Swansea criteria (Horani et al. 2025). Oil red O on frozen tissue confirms microvesicular fat (Choi 2025).
  • Swansea criteria. Six or more criteria predict AFLP. In biopsy-proven AFLP they had 100% sensitivity and 57% specificity (Horani et al. 2025).
  • HELLP syndrome. In 11 HELLP biopsies, periportal hemorrhage (8), fibrin deposition (6) and fatty change (4) were found (Horani et al. 2025).
  • Biopsy in pregnancy. Biopsy is rarely performed because the Swansea score usually predicts AFLP and coagulopathy raises risk (Horani et al. 2025).
Disorder Trimester Key findings Source
Hyperemesis gravidarum First Intractable vomiting; liver dysfunction in 50% Panther and Blum 2008
Intrahepatic cholestasis of pregnancy Second half of pregnancy, commonly third trimester Pruritus, elevated bile acids; treated with ursodeoxycholic acid Panther and Blum 2008; Horani et al. 2025
Preeclampsia and HELLP syndrome After 20 weeks Periportal hemorrhage and fibrin deposition; hematoma or rupture Horani et al. 2025; Panther and Blum 2008
Acute fatty liver of pregnancy Third Microvesicular steatosis; fetal LCHAD deficiency Horani et al. 2025; Panther and Blum 2008

The liver in systemic disease

Neoplasm Predominant hepatic infiltration pattern Source
CLL/SLL, follicular, marginal zone and mantle cell lymphoma Dense portal (96%, 79%, 100% and 100% of cases) Loddenkemper et al. 2007
Classic Hodgkin lymphoma Predominantly portal Loddenkemper et al. 2007
B-lymphoblastic leukemia/lymphoma, hepatosplenic T-cell lymphoma, leukemic plasmacytoma and hairy cell leukemia Sinusoidal in most cases Loddenkemper et al. 2007
Other T-cell lymphomas No typical pattern Loddenkemper et al. 2007
Acute myeloid leukemia Portal tracts and sinusoids Walz-Mattmüller et al. 1998
Chronic myeloid leukemia, plasma cell myeloma and myeloproliferative neoplasms Mainly sinusoidal Walz-Mattmüller et al. 1998
Lymphocytic leukemia and non-Hodgkin lymphoma Mainly portal Walz-Mattmüller et al. 1998
  • Lymphoma in liver biopsies. Diffuse large B-cell lymphoma was the most frequent lymphoma in liver biopsies (45%) (Loddenkemper et al. 2007).

Pediatric metabolic liver disease

  • Presentations. Metabolic disorders present in children with acute liver failure, cirrhosis, hepatocellular carcinoma or extrahepatic disease (Menon et al. 2021). Biochemical diagnosis and newborn screening are covered in Newborn Screening and Biochemical Genetics: Amino Acid, Organic Acid, Fatty Acid Oxidation, Urea Cycle, Lysosomal and Peroxisomal Disorders.
  • Tissue handling. Frozen and glutaraldehyde-fixed tissue for inherited metabolic defects is covered in Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections.
  • Glycogen storage diseases. Types I, III, IV, VI and IX are hepatic glycogenoses. Glycogen accumulation in an infant or young child usually indicates glycogen storage disease (Menon et al. 2021; Choi 2025).
  • Lysosomal storage disease. Gaucher disease is the most common genetic lysosomal storage disorder. Non-neuronopathic Gaucher disease, Niemann–Pick disease types B and C and lysosomal acid lipase deficiency can cause cirrhosis and portal hypertension (Menon et al. 2021).
  • Cholesteryl ester storage disease. All 112 biopsied patients with lysosomal acid lipase deficiency showed progressive microvesicular steatosis leading to fibrosis and micronodular cirrhosis. Birefringent cholesteryl ester crystals or their clefts in hepatic cells were pathognomonic (Bernstein et al. 2013).
Storage disease Storing cells Histologic clue Source
Gaucher disease Kupffer cells; hepatocytes not damaged Engorged macrophages with wrinkled tissue-paper cytoplasm (Gaucher cells) Lipiński and Tylki-Szymańska 2024; Kulkarni et al. 2024
Acid sphingomyelinase deficiency (Niemann–Pick types A and B) Macrophages and hepatocytes Clusters of enlarged foamy histiocytes (Niemann–Pick cells) in lobules and portal tracts Lipiński and Tylki-Szymańska 2024; Kavčič et al. 2022
Niemann–Pick disease type C Kupffer cells Vacuolated Kupffer cells in all 7 infants with neonatal cholestasis; foam cells only after 3 months of age Wang et al. 2022
Wolman disease (lysosomal acid lipase deficiency) Hepatocytes and histiocytes Massive steatosis and foamy histiocytes, with adrenal calcification; rapidly progressive Arienzo et al. 2026
  • Lysosomal acid lipase deficiency crystals. Birefringent crystals under polarized light are pathognomonic and occur in hepatocytes and Kupffer cells (Lipiński and Tylki-Szymańska 2024).
  • Electron microscopy in storage disease. Glycogen storage disease type II, Gaucher disease and Niemann–Pick disease have characteristic ultrastructural features (Choi 2025). In Niemann–Pick disease type A, concentric myelin-like inclusions and laminated zebra bodies were present in Kupffer cells, hepatocytes, endothelium, biliary epithelium and fibroblasts (Kavčič et al. 2022). The ground-glass inclusions of glycogen storage disease type IV consisted of non-membrane-bound fibrillar material up to 5 nm in diameter (Chan et al. 1999).
Disorder Defect Liver histology Liver outcome Source
Glycogen storage disease type I Glucose-6-phosphatase; type 1b with neutropenia Glycogen-distended pale hepatocytes Hepatocellular adenomas and carcinoma in a noncirrhotic liver Menon et al. 2021; Choi 2025
Glycogen storage disease type III Debranching enzyme Pale enlarged hepatocytes with thickened borders; portal fibrosis Milder than type IV; muscle involved in 85% Menon et al. 2021
Glycogen storage disease type IV Branching enzyme Eosinophilic ground-glass cytoplasmic inclusions; extensive fibrosis Cirrhosis with decompensation before age 5 Menon et al. 2021
Hereditary tyrosinemia type 1 Fumarylacetoacetate hydrolase Steatosis, ballooning, nodules of varying size, cirrhosis Acute liver failure, cirrhosis, hepatocellular carcinoma, renal tubulopathy Menon et al. 2021
Galactosemia Galactose-1-phosphate uridyltransferase Panlobular steatosis, bilirubinostasis, ductular proliferation, pseudoacinar rosettes, fibrosis Acute liver failure in infancy Menon et al. 2021
Urea cycle disorders Urea cycle enzymes; ornithine transcarbamylase deficiency is X-linked Largely unremarkable or canalicular bilirubinostasis; nodules of pale hepatocytes in arginase-1 deficiency Hyperammonemic crises Menon et al. 2021
Niemann–Pick disease types B and C Lysosomal lipid storage Pale-staining storage cell clusters on PAS; fibrosis Cirrhosis Menon et al. 2021
Lysosomal acid lipase deficiency (cholesteryl ester storage disease) LIPA Microvesicular steatosis; granular portal macrophages; birefringent cholesteryl ester crystals Micronodular cirrhosis Bernstein et al. 2013; Menon et al. 2021
Primary mitochondrial hepatopathy Mitochondrial respiratory chain Mixed steatosis and bilirubinostasis Liver failure; transplant contraindicated with major extrahepatic disease Menon et al. 2021
Crigler–Najjar syndrome UGT1A1 No significant morphologic change Bilirubin-induced brain injury without liver injury Menon et al. 2021

Gestational alloimmune liver disease

  • Terminology. Gestational alloimmune liver disease (GALD) was previously called neonatal hemochromatosis. Neonatal hemochromatosis now names the extrahepatic iron phenotype, which is not specific to GALD (Helali et al. 2025; Conover et al. 2025).
  • Pathogenesis. A maternal antibody against a fetal hepatocyte antigen activates complement from mid-gestation and causes severe hepatocyte injury (Conover et al. 2025).
  • Frequency and outcome. GALD causes 60%–90% of neonatal acute liver failure. Mortality exceeds 80% without treatment and falls to 17%–55% with IVIG and double-volume exchange transfusion (Conover et al. 2025).
  • Recurrence. Recurrence in later pregnancies reaches 90% and is prevented by antenatal IVIG (Helali et al. 2025).
  • Extrahepatic siderosis. MRI and oral mucosal biopsy each detect extrahepatic siderosis with 60% sensitivity, and 80% when combined (Conover et al. 2025).
  • C5b-9 immunostaining. Membrane attack complex (C5b-9) in viable hepatocytes supports the alloimmune mechanism. It is neither sensitive nor specific, partly because few viable hepatocytes remain (Conover et al. 2025).
  • Histology. Distinguishing features are extensive parenchymal fibrosis, multifocal parenchymal neotubules in zones 2 and 3, a lack of mature hepatocytes, and little portal tract injury, inflammation or extramedullary hematopoiesis (Conover et al. 2025).

NAFLD activity score and NASH CRN fibrosis stage calculator

Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts

Related page: Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections (biopsy adequacy, stains, chronic cholestatic drug injury and AIH overlap features) Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (alpha-1-antitrypsin deficiency, metabolic disease and GALD) Related page: Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy (chronic rejection and graft-versus-host disease as causes of ductopenia) Related page: Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (perihilar cholangiocarcinoma and choledochal cyst) Related page: Biliary brushing cytology: technique, normal findings and reactive atypia (IgG4 and PSC strictures in brushings) Related page: ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System (AMA, PBC-specific ANA and p-ANCA) Related page: Liver, Kidney and Gastrointestinal Function Tests (cholestatic liver test pattern and neonatal hyperbilirubinemia) Related page: Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease (ADPKD and ARPKD genetics)

Patterns of cholestatic liver injury

  • Ductular reaction. The ductular reaction consists of portal edema, proliferating ductules at the limiting plate and neutrophils adjacent to the ductules. It occurs in obstruction, PBC, PSC and drug injury (Choi 2025).
  • Large bile duct obstruction. Acute obstruction shows ductular proliferation, portal edema and mixed portal inflammation with neutrophils and eosinophils. Findings depend more on duration and severity than on the cause (Choi 2025).
  • Ascending cholangitis. Dilated portal ducts contain intraluminal neutrophils, usually with obstructive changes (Choi 2025).
  • Chronic cholestasis. Bile salt injury produces feathery degeneration of periportal hepatocytes and deposition of copper and copper-associated protein (Sarcognato et al. 2021). CK7 marks periportal intermediate hepatocytes in chronic cholestasis (Choi 2025).
  • Biliary cirrhosis. Biliary cirrhosis has irregular "jigsaw" nodules with periseptal halos of edema and feathery degeneration (Lo and Kim 2017; Sarcognato et al. 2021).
  • Bland lobular cholestasis. Bile in hepatocytes or canaliculi without significant inflammation or duct injury is most often drug-related, and sepsis is the other main consideration (Choi 2025). The prototype drugs are listed in Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections.
  • Cholangitis lenta. In patients with COVID-19 treated with extracorporeal membrane oxygenation, dilated bile ductules with bile plugs at the periphery of portal tracts indicated cholangitis lenta (Hatanaka et al. 2023).
  • Biliary infarcts. A transjugular biopsy in post-COVID-19 secondary sclerosing cholangitis showed ductular reaction, cholangiocyte injury, neutrophils, biliary infarctions, marked cholestasis and portal fibrosis (Cesar Machado et al. 2022).
  • Bile infarcts and bile lakes. A bile infarct (Charcot–Gombault necrosis) is a field of hepatocyte necrosis in cholestasis and a characteristic feature of obstructive biliary disease, including biliary atresia, choledocholithiasis and malignant obstruction (Xin et al. 2024). Bile lakes with a bile pigment-laden xanthogranulomatous response were described in a biliary atresia explant with secondary biliary cirrhosis (Misra et al. 2024).
  • Parenteral nutrition. About two-thirds of neonates receiving prolonged parenteral nutrition develop cholestasis. Active intestinal failure-associated liver disease shows cellular and canalicular cholestasis, ductular reaction and portal bile plugs. Steatosis predominates in older children and adults, and fibrosis persists after nutrition is withdrawn (Karakoyun et al. 2026). Parenteral nutrition can progress to sclerosing cholangiopathy in premature infants (Arienzo et al. 2026).

Ductopenia and vanishing bile duct syndromes

  • Definition. Ductopenia is loss of bile ducts in ≥50% of portal tracts. Assessment requires at least 10 well-preserved portal tracts (Choi 2025).
  • Histologic clues to duct loss. Unpaired hepatic arteries and absent ducts in medium and large portal tracts indicate duct loss. CK7 shows the loss and highlights zone 1 intermediate hepatocytes (Choi 2025; Sarcognato et al. 2021).
  • Idiopathic form. Duct loss without a cause is idiopathic ductopenia or vanishing bile duct syndrome. Lobular cholestasis may be absent (Choi 2025).
  • Drug-induced form. Drug-induced vanishing bile duct syndrome is covered in Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections.
Cause of ductopenia Distinguishing findings Source
Primary biliary cholangitis Florid duct lesion, granulomas, smallest ducts lost first, AMA Sarcognato et al. 2021
Primary sclerosing cholangitis Concentric periductal fibrosis and duct scars; cholangiographic strictures Sarcognato et al. 2021
Drug-induced vanishing bile duct syndrome Chronic cholestatic drug injury, covered in Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections Fontana et al. 2023
Chronic allograft rejection Duct loss in the allograft, covered in Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy Choi 2025
Graft-versus-host disease Duct loss after hematopoietic cell transplantation, covered in Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy Choi 2025
Paraneoplastic, including classic Hodgkin lymphoma Cholestatic liver injury with duct loss Choi 2025; Bugayong and Koo 2026
Alagille syndrome Paucity of interlobular ducts in infancy with JAG1 or NOTCH2 variants Arienzo et al. 2026
  • Sarcoidosis. In hepatic sarcoidosis, ductopenia was present in 15% of patients, bile duct proliferation in 28% and advanced bile duct damage resembling sclerosing cholangitis in 14%. Cholestasis is mainly intrahepatic and results from progressive compression of bile ducts by portal and periportal granulomas (Horst et al. 2025).

Primary biliary cholangitis

  • Clinical profile. AMA in a patient with raised ALP is diagnostic of PBC after other causes of cholestasis are excluded. AMA is present in about 95% of patients (Sarcognato et al. 2021). Antibody testing is covered in ANCA, Anti-GBM and Organ-Specific Autoantibodies: Kidney, Liver, Thyroid, Pancreas and Nervous System.
  • Treatment response. About 40% of patients do not respond biochemically to ursodeoxycholic acid (Sarcognato et al. 2021).
  • Role of biopsy. Biopsy is not required when a cholestatic profile accompanies AMA. It is required for AMA-negative PBC (about 5% of patients) and suspected PBC-AIH variant (Sarcognato et al. 2021; Boyd et al. 2020).
  • Florid duct lesion. The florid duct lesion (nonsuppurative destructive cholangitis) is an intense lymphoplasmacytic infiltrate that surrounds and destroys the duct, with lymphocytes between cholangiocytes and disruption of the basement membrane. It involves small interlobular and septal ducts, spares large and extrahepatic ducts, and is seen in only about 10% of biopsies (Sarcognato et al. 2021).
  • Granulomas. Portal epithelioid noncaseating granulomas abut damaged ducts (Sarcognato et al. 2021).
  • Portal inflammation. Plasma cells are often numerous and do not by themselves indicate AIH. A coronal arrangement of plasma cells around the duct and lymphoid follicles are characteristic. Eosinophils may be numerous early (Sarcognato et al. 2021).
  • Minimal change PBC. Loss of CK19-positive canals of Hering can precede duct loss in otherwise near-normal biopsies (Sarcognato et al. 2021).
  • Nodular regenerative hyperplasia and small-cell change. Nodular regenerative hyperplasia complicates noncirrhotic PBC with portal hypertension. Small-cell change of periportal hepatocytes is regenerative (Sarcognato et al. 2021).
  • PBC versus AIH. Duct loss, CK7-positive metaplastic hepatocytes and periportal orcein deposits indicate chronic cholestasis and are not features of AIH. Interface hepatitis is minimal to mild in PBC (Sarcognato et al. 2021).

Staging and grading of primary biliary cholangitis

  • Current system. The Nakanuma system scores fibrosis, bile duct loss and orcein-positive granule deposition for stage, and chronic cholangitis activity and hepatitis activity for grade (Hiramatsu et al. 2006; Sarcognato et al. 2021).
  • Prognostic value. Nakanuma staging predicted 10-year outcome better than earlier systems and was proposed to replace them. It also showed the strongest prognostic value in PSC (Sarcognato et al. 2021).
  • Basis. Factor analysis of 17 lesions in 188 biopsies showed that fibrosis, bile duct loss and orcein-positive granules correlated with laboratory data and the Mayo prognostic score (Hiramatsu et al. 2006).
Nakanuma parameter Score 0 Score 1 Score 2 Score 3 Source
Fibrosis None, or limited to portal tracts Portal and periportal fibrosis with or without septa Bridging fibrosis with lobular disarray Cirrhosis Sarcognato et al. 2021
Bile duct loss None <1/3 of portal tracts 1/3 to 2/3 of portal tracts >2/3 of portal tracts Sarcognato et al. 2021
Orcein-positive granules None Few periportal hepatocytes in <1/3 of portal tracts Several hepatocytes in 1/3 to 2/3 of portal tracts Many hepatocytes in >2/3 of portal tracts Sarcognato et al. 2021
Cholangitis activity (grade) No cholangitis 1 duct with chronic cholangitis ≥2 ducts with chronic cholangitis ≥1 florid duct lesion Sarcognato et al. 2021
Hepatitis activity (grade) No interface hepatitis and no or minimal lobular hepatitis Interface hepatitis of ≥10 continuous hepatocytes in 1 portal tract, with mild to moderate lobular hepatitis Interface hepatitis of ≥10 continuous hepatocytes in ≥2 portal tracts, with mild to moderate lobular hepatitis Interface hepatitis of ≥20 continuous hepatocytes in ≥1/2 of portal tracts, with moderate lobular hepatitis or bridging or zonal necrosis Sarcognato et al. 2021
  • Stage from the sum. With all three staging criteria, sums of 0, 1–3, 4–6 and 7–9 give stages 1–4. With fibrosis and bile duct loss only, sums of 0, 1–2, 3–4 and 5–6 give stages 1–4 (Sarcognato et al. 2021).
Stage Ludwig system (previous) Scheuer system (previous) Source
I Portal inflammation with bile duct damage, with or without florid duct lesions Portal inflammation with bile duct damage, with or without florid duct lesions Sarcognato et al. 2021
II Periportal inflammation and interface hepatitis Ductular reaction Sarcognato et al. 2021
III Bridging fibrosis Bridging fibrosis Sarcognato et al. 2021
IV Biliary cirrhosis Biliary cirrhosis Sarcognato et al. 2021

PBC-AIH variant

  • Terminology. The term "overlap" has been replaced by "variant" (Sarcognato et al. 2021).
  • Paris criteria. Diagnosis requires at least 2 of 3 criteria for each disease. PBC criteria are ALP >2 times or GGT >5 times the upper limit of normal, AMA >1:40 and florid duct lesions. AIH criteria are ALT >5 times the upper limit of normal, IgG >2 times the upper limit of normal or ASMA, and moderate or severe interface hepatitis (Sarcognato et al. 2021).

Primary sclerosing cholangitis

  • Epidemiology. Incidence reaches 1.3 per 100,000 per year in Northern Europe. More than 60% of patients are male, the median age at onset is 30–40 years, and about two-thirds have inflammatory bowel disease, 75% of it ulcerative colitis (Sarcognato et al. 2021).
  • Diagnosis. PSC is diagnosed by cholangiographic strictures with persistent ALP elevation for more than 6 months after secondary sclerosing cholangitis is excluded. Secondary causes include stones, cholangiocarcinoma, biliary surgery, Caroli disease, chronic infection, ischemic stricturing and cholestatic drug injury (Sarcognato et al. 2021).
  • Hallmark lesion. Concentric periductal "onion-skin" fibrosis around large intrahepatic and extrahepatic ducts leads to strictures and duct scars (Sarcognato et al. 2021). Fibro-obliterative duct lesions with reduced interlobular ducts are virtually diagnostic but are present in fewer than 20% of biopsies (Sarcognato et al. 2021).
  • Needle biopsy. Needle cores sample only peripheral portal tracts and may be normal or show only signs of downstream large duct obstruction (Sarcognato et al. 2021; Boyd et al. 2020). Bile duct basement membrane thickening is seen on PAS-D (Sarcognato et al. 2021).
  • PSC versus PBC. Cholestatic changes appear earlier and are more frequent in PSC. Periductal fibrosis and duct scars favor PSC, and granulomas favor PBC (Sarcognato et al. 2021).
  • Onion-skin fibrosis in other diseases. Onion-skin fibrosis also occurs in secondary sclerosing cholangitis (Sarcognato et al. 2021).
  • Small-duct PSC. Small-duct PSC is 3%–5% of PSC, has normal cholangiography and a better prognosis (Sarcognato et al. 2021). It carries a very low cholangiocarcinoma risk, and 23% develop classic large-duct PSC (Chapman et al. 2019). Biopsy is required to diagnose small-duct PSC and AIH overlap. AASLD does not recommend biopsy for fibrosis staging in practice (Saffioti and Mavroeidis 2024).
  • PSC-AIH variant. The PSC-AIH variant occurs in 6%–14% of PSC patients (Sarcognato et al. 2021).
  • Malignancy risk. Cholangiocarcinoma is about 400 times more frequent than in the general population, with an annual risk of 2% (Sarcognato et al. 2021). Lifetime risk in PSC is covered in Biliary brushing cytology: technique, normal findings and reactive atypia. Colorectal cancer risk with PSC and IBD is 4 times that of IBD alone, and the risk of dysplasia and malignancy appears unrelated to disease duration or fibrosis severity (Sarcognato et al. 2021).

AASLD 2022 practice guidance on PSC and cholangiocarcinoma

  • Colorectal surveillance. Colonoscopic surveillance in PSC with IBD begins at age 15 years (Saffioti and Mavroeidis 2024).
  • Gallbladder polyps. Cholecystectomy is considered for gallbladder polyps >8 mm. The 2017 European guideline used >6 mm (Saffioti and Mavroeidis 2024).
  • Suspicious strictures. Suspicious initial cytology leads to repeat ERCP in 3 months regardless of FISH results (Saffioti and Mavroeidis 2024). Brushing cytology and FISH are covered in Biliary brushing cytology: technique, normal findings and reactive atypia.
  • Clinical profile. IgG4-related sclerosing cholangitis affects middle-aged to elderly men and presents with painless obstructive jaundice. Most patients have or develop other organ involvement, most often type 1 autoimmune pancreatitis (Ren et al. 2026).
  • Serum IgG4. Serum IgG4 is elevated in about 80%. Modest elevation occurs in 10%–15% of PSC and cholangiocarcinoma, and a level above 4 times the upper limit of normal is highly specific (Ren et al. 2026). Subclass assay caveats are covered in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
  • Japanese criteria 2020. Diagnosis combines bile duct narrowing, bile duct wall thickening, serology, pathology, other organ involvement and steroid response (Nakazawa et al. 2021).
  • Histology. The Japanese clinical criteria require more than 10 IgG4-positive plasma cells per high-power field with marked lymphoplasmacytic infiltration, storiform fibrosis or obliterative phlebitis. The international pathology consensus requires >10 per high-power field in biopsies or >50 in resections plus an IgG4/IgG-positive cell ratio >40%, with two of dense lymphoplasmacytic infiltrate, storiform fibrosis and obliterative phlebitis. Some IgG4-related sclerosing cholangitis fails the 40% ratio (Kamisawa et al. 2019).
  • IgG4-positive cells in PSC. More than 50 IgG4-positive cells per high-power field occurred in 15.6% of PSC explants, but IgG4-positive cells are rare in peripheral portal tracts of PSC (Kamisawa et al. 2019).
  • Stricture types (Nakazawa). Type 1 involves only the lower common bile duct and mimics pancreatic cancer and cholangiocarcinoma. Type 2 has diffuse intrahepatic and extrahepatic strictures and mimics PSC: type 2a with prestenotic dilatation, type 2b without dilatation and with reduced duct branches. Type 3 involves the hilar and lower bile duct, and type 4 the hilar ducts only; hilar involvement mimics hilar cholangiocarcinoma. In a 2015 Japanese survey, frequencies were 64% (type 1), 5% (2a), 8% (2b), 10% (3) and 10% (4) (Kamisawa et al. 2019).
  • Treatment and relapse. IgG4-related sclerosing cholangitis responds to corticosteroids, which are ineffective in PSC. Relapse occurs in 30%–50% of patients (Ren et al. 2026).
Feature Primary biliary cholangitis Primary sclerosing cholangitis IgG4-related sclerosing cholangitis Source
Typical patient Woman with cholestasis and AMA (about 95%) Man aged 30–40 years with ulcerative colitis Older man with painless jaundice and autoimmune pancreatitis Sarcognato et al. 2021; Ren et al. 2026
Ducts involved Small interlobular and septal ducts Large intrahepatic and extrahepatic ducts; small ducts in 3%–5% Large ducts; distal common bile duct, hilar or intrahepatic strictures Sarcognato et al. 2021; Ren et al. 2026
Characteristic lesion Florid duct lesion; duct-centric granulomas Onion-skin periductal fibrosis; duct scars Storiform fibrosis, obliterative phlebitis, IgG4-positive plasma cells Sarcognato et al. 2021; Ren et al. 2026
Serology AMA No specific marker Elevated IgG4 in about 80% Sarcognato et al. 2021; Ren et al. 2026
Steroid response No No Yes Ren et al. 2026
Cancer risk Hepatocellular carcinoma in cirrhosis Cholangiocarcinoma 2% per year; colorectal cancer Mimics cholangiocarcinoma Sarcognato et al. 2021; Ren et al. 2026

Pediatric cholestasis

  • Biopsy adequacy. A pediatric cholestasis biopsy is adequate with at least 7 portal tracts (Arienzo et al. 2026).
  • Panel. Reticulin, PAS, PAS-D, trichrome, Perls, CK7 and CK19 are routine. Loss of canalicular BSEP and MDR3 staining suggests PFIC2 and PFIC3, and loss of TJP2 staining is a sensitive and specific marker of PFIC4 (Arienzo et al. 2026).
  • Timing of ductal maturation. Ductal plate remodeling in peripheral portal tracts may not be complete until 4–6 weeks after birth. In term infants, biopsy for suspected biliary atresia is optimally performed at 40–50 days (Arienzo et al. 2026).

Biliary atresia

  • Definition. Biliary atresia is the most common identifiable cause of obstructive jaundice in the first 3 months of life. It is a progressive fibro-inflammatory obliterative cholangiopathy (Arienzo et al. 2026).
  • Forms. Nonsyndromic biliary atresia is 84%. Syndromic biliary atresia with laterality defects such as situs inversus is 10%, and biliary atresia with another malformation without laterality defects is 6% (Arienzo et al. 2026).
  • Early biopsy (<30 days). Findings are subtle: portal edema with mixed inflammation, ductular reaction and bile plugs in ducts and ductules (Arienzo et al. 2026).
  • Late biopsy (>90 days). Findings are marked portal fibrosis with bridging, nodularity, exuberant ductular proliferation and lobular cholestasis (Arienzo et al. 2026).
  • Kasai portoenterostomy. Portoenterostomy before 60 days restores bile flow in about 80%. The median age at portoenterostomy in the United States is 63 days. The porta hepatis specimen shows residual ductules in fibro-inflammatory stroma with reactive epithelium, periductal fibrosis and myofibroblasts. Most patients eventually need transplantation (Arienzo et al. 2026).
  • CMV. CMV-positive infants with biliary atresia have worse outcomes after portoenterostomy (Arienzo et al. 2026).

Neonatal cholestasis: obstruction versus neonatal hepatitis

  • Giant cell transformation. Multinucleated hepatocytes are a nonspecific response seen in idiopathic neonatal giant cell hepatitis, metabolic, infectious and canalicular transport disorders (Arienzo et al. 2026).
  • Idiopathic neonatal giant cell hepatitis. Lobular lymphohistiocytic inflammation, Kupffer cell hyperplasia and spotty necrosis with small portal tracts and little ductular proliferation separate it from biliary atresia (Arienzo et al. 2026).
  • Infection. CMV is the most common infectious cause of neonatal cholestasis. Toxoplasma, rubella, HSV, enteroviruses, Escherichia coli sepsis and Listeria also cause it (Arienzo et al. 2026).
  • Alpha-1-antitrypsin deficiency. Pi*ZZ infants present with neonatal cholestasis that can mimic biliary atresia; frequency and histology are covered in Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease.
  • Bile acid synthesis defects. These autosomal recessive defects cause normal or low GGT cholestasis with finely granular bile plugs, microvesicular steatosis, giant cells and a limited ductular response. Urinary bile acid analysis and genetic testing confirm them, and primary bile acid therapy can reverse disease (Arienzo et al. 2026).
  • Neonatal sclerosing cholangitis. It presents with high GGT cholestasis and mimics biliary atresia on biopsy. Genetic forms involve DCDC2. It is associated with Kabuki syndrome and neonatal ichthyosis-sclerosing cholangitis (claudin-1 deficiency). Langerhans cell histiocytosis and parenteral nutrition cause secondary forms (Arienzo et al. 2026).
Finding Biliary atresia Neonatal giant cell hepatitis Alagille syndrome PFIC1 or PFIC2 Source
Portal tracts Expanded, edematous, fibrotic Small, minimal inflammation Paucity of interlobular ducts Minimal inflammation Arienzo et al. 2026
Ductular reaction and bile plugs Prominent ductular reaction; bile plugs in ductules Limited Sporadic ductular proliferation Mild Arienzo et al. 2026
Key ancillary test Biliary imaging Exclusion of infection and metabolic disease JAG1 or NOTCH2 testing BSEP immunostaining; genetic testing Arienzo et al. 2026

Alagille syndrome

  • Genetics. Alagille syndrome is autosomal dominant. JAG1 variants account for more than 90% and NOTCH2 for most of the rest (Arienzo et al. 2026).
  • Extrahepatic features. Characteristic facies, butterfly vertebrae, posterior embryotoxon, renal and vascular anomalies and pulmonary stenosis accompany cholestasis (Arienzo et al. 2026).
  • Duct paucity. The ratio of interlobular ducts to portal tracts is normally 0.9–1.8. A ratio below 0.5–0.75 in older infants indicates paucity, and 6–10 portal tracts are usually adequate (Arienzo et al. 2026).
  • Biopsy role. Biopsy is no longer required when molecular testing is available. It still separates Alagille syndrome from biliary atresia (Arienzo et al. 2026).
  • Outcome. Only 20%–30% need liver transplantation. Pruritus is the most disabling symptom, and xanthomas follow hypercholesterolemia (Arienzo et al. 2026).

Progressive familial intrahepatic cholestasis

  • Shared histology. PFIC shows canalicular bile accumulation, ballooning and portal fibrosis with minimal inflammation, progressing to biliary-type cirrhosis (Arienzo et al. 2026).
  • PFIC1. PFIC1 (Byler disease) is caused by ATP8B1 (FIC1), and benign recurrent intrahepatic cholestasis is caused by the same gene. Cirrhosis usually develops by the second decade (Cheng and Rosenthal 2023).
  • PFIC2. PFIC2 is caused by ABCB11 (BSEP) and is the most common form. Recurrence after transplantation is covered in Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy. PFIC2 carries a markedly increased risk of cirrhosis and hepatocellular carcinoma (Arienzo et al. 2026).
  • PFIC3. PFIC3 is caused by ABCB4 (MDR3), is distinguished by high GGT and has onset from infancy to early adulthood (Cheng and Rosenthal 2023). Histology is cholangiopathic, with portal expansion, ductular proliferation and bile plugs in interlobular ducts (Arienzo et al. 2026).
Type Gene (protein) Serum GGT Histology or immunostain clue Source
PFIC1 ATP8B1 (FIC1) Low or normal Canalicular cholestasis, mild ductular reaction, foamy hepatocytes Cheng and Rosenthal 2023; Arienzo et al. 2026
PFIC2 ABCB11 (BSEP) Low or normal; AFP elevated Pronounced canalicular cholestasis; loss of canalicular BSEP; rapid fibrosis Cheng and Rosenthal 2023; Arienzo et al. 2026
PFIC3 ABCB4 (MDR3) Elevated Cholangiopathic pattern with bile plugs in interlobular ducts; loss of canalicular MDR3 Cheng and Rosenthal 2023; Arienzo et al. 2026
PFIC4 TJP2 (tight junction protein 2) Low or normal Loss of TJP2 staining Cheng and Rosenthal 2023; Arienzo et al. 2026
PFIC5 NR1H4 (farnesoid X receptor) Low; AFP elevated Morphology overlaps classical PFIC Cheng and Rosenthal 2023; Arienzo et al. 2026
MYO5B-related MYO5B (myosin 5B) Low Morphology overlaps classical PFIC Cheng and Rosenthal 2023; Arienzo et al. 2026
  • Electron microscopy in PFIC. Coarsely granular canalicular bile (Byler bile) characterizes PFIC1 (Kang et al. 2019; Amer and Hajira 2014). PFIC2 shows amorphous or filamentous bile, and PFIC3 shows cholesterol crystals (Amer and Hajira 2014).

  • Extrahepatic features. PFIC1 is accompanied by diarrhea, growth failure, hearing loss and pancreatitis. PFIC4 is accompanied by respiratory disease, hearing loss and neurologic symptoms (Cheng and Rosenthal 2023).

  • Heterozygotes. Heterozygous carriers of PFIC genes can present with neonatal cholestasis, intrahepatic cholestasis of pregnancy, cholelithiasis or susceptibility to drug injury. ABCB4 variants cause low phospholipid-associated cholelithiasis, typically before age 40 (Cheng and Rosenthal 2023).

Ductal plate malformations and fibropolycystic liver disease

  • Fibropolycystic spectrum. Congenital hepatic fibrosis, Caroli disease, polycystic liver disease and biliary hamartomas form the fibropolycystic spectrum. Each arises from a ductal plate insult at a different developmental stage (Wang A et al. 2026).
  • Congenital hepatic fibrosis. Congenital hepatic fibrosis is an autosomal recessive ciliopathy with periportal fibrosis and persistent, abnormally dilated primitive ductal structures. Biallelic PKHD1 variants (fibrocystin) underlie the form associated with ARPKD (Wang A et al. 2026). Congenital hepatic fibrosis causes portal hypertension (Ceri et al. 2025; Wang A et al. 2026).
  • Syndromic congenital hepatic fibrosis. COACH syndrome (Joubert syndrome with hepatic fibrosis) combines cerebellar vermis hypoplasia with hepatic fibrosis. Meckel-type disease combines occipital encephalocele, polydactyly, large cystic kidneys and ductal plate malformation and is usually perinatally lethal (Wang A et al. 2026).
  • Caroli disease and syndrome. Caroli disease is segmental cystic dilatation of intrahepatic bile ducts in continuity with the biliary tree. Caroli syndrome, the more common form, is associated with congenital hepatic fibrosis. Stones, recurrent cholangitis and abscesses occur, and cholangiocarcinoma risk is about 100-fold (5%–10%) (Ceri et al. 2025).
  • Polycystic liver disease. Polycystic liver disease accompanies ADPKD (PKD1, PKD2) and less often ARPKD. Isolated autosomal dominant polycystic liver disease involves PRKCSH and SEC63. Cysts are uncommon before age 20 and present in more than 80% after age 60 (Ceri et al. 2025). Kidney genetics are covered in Tubulointerstitial, Obstructive, Cystic and Developmental Kidney Disease.
Lesion Gross and microscopic findings Associations Source
Von Meyenburg complex (biliary hamartoma) Non-encapsulated nodule usually <5 mm near portal tracts; remnant of ductal plate remodeling Simple cysts, polycystic kidney disease, congenital hepatic fibrosis, Caroli disease Ceri et al. 2025
Congenital hepatic fibrosis Periportal fibrosis with dilated ductal plate-like ducts ARPKD (PKHD1), COACH syndrome Wang A et al. 2026
Caroli disease Segmental saccular dilatation of large intrahepatic ducts communicating with the biliary tree Congenital hepatic fibrosis (Caroli syndrome); cholangiocarcinoma Ceri et al. 2025
Polycystic liver disease Multiple diffuse cysts ADPKD; isolated forms with PRKCSH or SEC63 Ceri et al. 2025

Von Meyenburg complex and hepatic cysts

  • Von Meyenburg complex. Biliary hamartomas affect 0.6%–2.8% of the population and are the commonest fibropolycystic lesion. They are asymptomatic and need no histologic confirmation when imaging is typical (Ceri et al. 2025).
  • Differential diagnosis of small biliary nodules. Ductular reaction is ill defined and non-nodular (Choi 2026). Bile duct adenoma, small intrahepatic cholangiocarcinoma and metastatic adenocarcinoma are compared with the von Meyenburg complex in Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma.
  • Malignant transformation. Case reports describe transitions from biliary hamartoma to dysplasia and cholangiocarcinoma with shared mutations (Ceri et al. 2025).
  • Simple biliary cyst. Simple cysts are found on 2%–5% of ultrasound studies and up to 18% of CT scans. They do not communicate with the bile ducts, are rare before age 10, peak at 50–60 years and are more common in women (Ceri et al. 2025).
  • Ciliated hepatic foregut cyst. The wall contains pseudostratified ciliated columnar epithelium, connective tissue, a smooth muscle layer and an outer fibrous capsule. It arises from embryonic foregut remnants, and 6 of about 223 reported cases (2.7%) underwent malignant transformation (AlQattan et al. 2025). Most arise in segment 4. Squamous metaplasia and squamous cell carcinoma of the lining occur, and all reported malignant cases showed squamous differentiation (Bishop et al. 2015).

Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy

Related page: Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections (zonal anatomy, stains, viral hepatitis and drug injury patterns) Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (steatosis grading, cirrhosis patterns and iron) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (ductopenia, PBC, PSC and pediatric indications for transplantation) Related page: Thrombophilia Testing and Antiphospholipid Antibody Testing (JAK2 testing in splanchnic vein thrombosis and Budd–Chiari syndrome) Related page: HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing (donor-specific antibody methods)

Patterns of hepatic vascular disease

  • Sites. Vascular disorders arise from reduced inflow, disturbed intrahepatic flow or obstructed outflow. Cirrhosis is the commonest cause of impaired intrahepatic perfusion (Choi 2025).
  • Four histologic patterns. The patterns are portal vein disease, sinusoidal/centrilobular disease, outflow obstruction and peliosis hepatis (Choi 2025).
Site Entity Key histology Source
Portal venous (presinusoidal) Porto-sinusoidal vascular disorder; hepatosplenic schistosomiasis Obliterative portal venopathy, nodular regenerative hyperplasia, incomplete septal fibrosis; egg granulomas Barisic-Jaman et al. 2023; Da Silva and Carrilho 1992
Sinusoidal Sinusoidal obstruction syndrome Patchy sinusoidal dilatation, red cells in the space of Disse, fibrous obliteration of central veins Choi 2025; Fontana et al. 2023
Sinusoidal Peliosis hepatis Blood-filled cavities without zonal predilection, initially without endothelial lining Choi 2025
Hepatic venous outflow Budd–Chiari syndrome; cardiac congestion Zone 3 sinusoidal dilatation, hepatocyte atrophy, red cells in the space of Disse Boyd et al. 2020; Choi 2025
Ischemic Hypoxic (ischemic) hepatitis Predominantly centrilobular necrosis Fernández et al. 2024

Hepatic venous outflow obstruction

  • Histology. Outflow obstruction from central vein, hepatic vein or inferior vena cava occlusion or from right heart failure produces zone 3 sinusoidal dilatation with or without congestion (Choi 2025). Hepatic venules may be occluded, adjacent hepatocytes atrophy and red cells are translocated into the space of Disse (Boyd et al. 2020).
  • Nonspecific zone 3 dilatation. Zone 3 sinusoidal dilatation also occurs in portal vein disease, sickle cell anemia, sarcoidosis, rheumatoid arthritis, paraneoplastic syndromes and oral contraceptive use. Patchy ductular proliferation may mimic biliary obstruction (Choi 2025).
  • Causes of Budd–Chiari syndrome. Thrombotic obstruction (primary Budd–Chiari syndrome) is the most common mechanism, and myeloproliferative neoplasms are its most common cause. About 41% of patients with Budd–Chiari syndrome carry JAK2 changes (Găman et al. 2023). JAK2 testing is covered in Thrombophilia Testing and Antiphospholipid Antibody Testing.
  • Biopsy in Budd–Chiari syndrome. Venography usually confirms Budd–Chiari syndrome, and biopsy is mainly used to stage fibrosis (Boyd et al. 2020). Congestive hepatopathy from heart failure or constrictive pericarditis gives similar appearances (Boyd et al. 2020).
  • Acute Budd–Chiari syndrome. Obstruction of the three major hepatic veins causes severe congestion with replacement of the hepatic plates by blood. Biopsies from 6 of 19 patients presenting with acute liver failure showed centrilobular congestion and hepatocellular necrosis without significant fibrosis (Quaglia 2023).
  • Chronic Budd–Chiari syndrome. The chronic phase shows a triad of hepatic (often also portal) vein changes, fibrosis and parenchymal remodeling. Fresh or organized thrombus is followed by local obliterative and bridging fibrosis. The parenchyma develops veno-centric cirrhosis, veno-portal cirrhosis, total parenchymal extinction or nodular regenerative hyperplasia, and the caudate lobe is often hyperplastic (Quaglia 2023).
  • Congestive (cardiac) cirrhosis. Fibrosis in outflow obstruction links adjacent central veins and portal tracts, producing veno-centric ("reversed lobulation") or veno-portal cirrhosis (Lo and Kim 2017). Central vein fibrosis is most frequent in alcohol-related liver disease and venous outflow disorders (Choi 2025).
  • Sinusoidal obstruction syndrome. Sinusoidal obstruction syndrome (veno-occlusive disease) shows patchy sinusoidal dilatation with or without thrombosis or fibrous obliteration of central veins. It follows allogeneic, less often autologous, hematopoietic stem cell transplantation and specific chemotherapy (Choi 2025). Busulfan, cyclophosphamide and pyrrolizidine alkaloids are prototype causes, and endothelial sloughing and perisinusoidal fibrosis accompany it (Fontana et al. 2023).
  • SOS with GVHD. Sinusoidal obstruction syndrome and hepatic graft-versus-host disease can coexist after hematopoietic stem cell transplantation, with centrilobular vein injury and necrosis beside bile duct injury (Pestana et al. 2024).

Porto-sinusoidal vascular disorder (VALDIG 2019)

  • Current rule (2019). Porto-sinusoidal vascular disorder (PSVD) is defined by the absence of cirrhosis on biopsy with lesions involving portal venules or sinusoids, with or without portal hypertension. Known causes of liver disease do not exclude it, but specific causes of vascular liver disease are excluded (De Gottardi et al. 2019).
  • Previous terms. PSVD replaces the clinical labels idiopathic noncirrhotic portal hypertension (INCPH, introduced in 2011), hepatoportal sclerosis, obliterative portal venopathy and idiopathic portal hypertension. Nodular regenerative hyperplasia, obliterative portal venopathy and incomplete septal fibrosis remain the specific histologic lesions (Barisic-Jaman et al. 2023). INCPH required portal hypertension, and VALDIG proposed the name porto-sinusoidal vascular disease (De Gottardi et al. 2019).
  • Biopsy adequacy. Diagnosis requires a noncirrhotic biopsy longer than 20 mm with at least 10 portal tracts (Barisic-Jaman et al. 2023).
  • Diagnostic combinations. PSVD is diagnosed with 1 specific sign of portal hypertension or 1 specific histologic lesion, or with 1 nonspecific sign of portal hypertension plus 1 nonspecific histologic lesion (Barisic-Jaman et al. 2023).
  • Frequency. PSVD was found in 4% of 3600 liver biopsies in a French study (Barisic-Jaman et al. 2023).
Category Clinical signs of portal hypertension Histologic lesions Source
Specific Gastroesophageal or ectopic varices; portal hypertensive bleeding; portosystemic collaterals on imaging Obliterative portal venopathy (thickened wall, luminal occlusion, vanishing portal veins); nodular regenerative hyperplasia; incomplete septal fibrosis (assessable only on explants) Barisic-Jaman et al. 2023
Nonspecific Ascites; platelets <150,000/µL; spleen ≥13 cm Portal tract abnormalities (multiplication and dilatation of arteries, periportal vascular channels, aberrant vessels); irregular distribution of portal tracts and central veins; nonzonal sinusoidal dilatation; mild perisinusoidal fibrosis Barisic-Jaman et al. 2023
  • Associated conditions. Associations include myeloproliferative disorders, Hodgkin lymphoma, thrombophilias, common variable immunodeficiency, autoimmune disease, HIV, celiac disease, Turner syndrome, TERT mutations and the drugs didanosine, azathioprine, thioguanine and oxaliplatin (Barisic-Jaman et al. 2023).
  • Exclusions. Cirrhosis, prior bone marrow transplantation, Budd–Chiari syndrome, biopsy-proven hepatic schistosomiasis, cardiac failure or Fontan surgery, Abernethy syndrome and hereditary hemorrhagic telangiectasia are excluded (Barisic-Jaman et al. 2023).

Nodular regenerative hyperplasia

  • Histology. Nodular regenerative hyperplasia is diffuse micronodular transformation without fibrosis that distorts the relationship of portal and central areas (Barisic-Jaman et al. 2023). Small hyperplastic nodules about 1 mm across are bordered by atrophic plates and may need a reticulin stain (Fontana et al. 2023; Choi 2025).
  • Drug associations. Azathioprine, 6-mercaptopurine, methotrexate, oxaliplatin, didanosine, stavudine, arsenic and copper sulfate cause nodular regenerative hyperplasia or obliterative portal venopathy (Fontana et al. 2023).
  • Immune associations. About 10% of PSVD patients have an immune disorder, and 6% of patients with inflammatory bowel disease had PSVD in one study, partly attributable to azathioprine (Barisic-Jaman et al. 2023).
  • PBC. Nodular regenerative hyperplasia in noncirrhotic PBC is covered in Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts.

Ischemic hepatitis and peliosis hepatis

  • Hypoxic hepatitis. Hypoxic hepatitis follows congestive heart failure or refractory shock, with a sudden very high rise in aminotransferases and INR, abrupt recovery and predominantly centrilobular necrosis (Fernández et al. 2024).
  • Peliosis hepatis. Peliosis consists of non-communicating blood-filled cavities scattered without zonal predilection, initially lacking an endothelial lining. Rupture can cause intraperitoneal hemorrhage (Choi 2025).
  • Bacillary peliosis. Bacillary peliosis hepatis is a manifestation of disseminated Bartonella henselae infection in immunocompromised patients (Steed et al. 2022). Warthin–Starry staining shows the organisms (Steed et al. 2022).
  • Anabolic steroids. Anabolic androgenic steroids cause peliosis hepatis, bland cholestasis and hepatic tumors (Shastri et al. 2026).
  • Infarct of Zahn. The historical term infarct of Zahn names sharply demarcated dark red areas of dilated, severely congested, often centrilobular sinusoids, with or without hepatic plate atrophy, near a thrombotic portal vein occlusion (Quaglia 2023).

Hepatic graft-versus-host disease

  • Histology. Hepatic GVHD after hematopoietic stem cell transplantation shows canalicular cholestasis, bile duct injury and focal hepatocellular necrosis (Pestana et al. 2024).
  • Duct loss. CK7 and CK19 immunostains highlight bile ducts for counting when ductopenia is suspected in graft-versus-host disease (Choi 2025).
  • Differential diagnosis of hepatic GVHD. After stem cell transplantation, sinusoidal obstruction syndrome, drug injury and viral infection overlap clinically with GVHD (Pestana et al. 2024; Fontana et al. 2023).

Liver allograft rejection: Banff 2016 schema

  • Current framework. The 2016 comprehensive update of the Banff Working Group introduced criteria for antibody-mediated rejection with C4d staining, fibrosis staging and immunosuppression-minimization findings, and restated unchanged earlier criteria (Demetris et al. 2016).
  • Banff 2026 position paper. The Banff liver group stated in 2026 that late rejection is underrepresented in the rejection activity index and set goals for revising the scheme. Late T-cell-mediated rejection shows more interface and perivenular activity and fibrosis, with less duct-centered and subendothelial inflammation (Bellamy et al. 2026).
  • Incidence. Acute cellular rejection occurs in about 20% of liver recipients, and antibody-mediated rejection in about 1%. About 20% of recipients can be weaned from immunosuppression (Badwei 2023).

Acute T-cell-mediated rejection and the rejection activity index

  • Timing. Acute T-cell-mediated rejection occurs mostly in the first 3 months and becomes less common later (Gambella et al. 2022).
  • Triad. Portal inflammation (lymphocytes with eosinophils, neutrophils, macrophages and blasts), bile duct inflammation and damage, and subendothelial venous inflammation define it (Gambella et al. 2022; Badwei 2023).
  • Central perivenulitis. Central vein and perivenular inflammation with hepatocyte or confluent necrosis indicates severe rejection (Badwei 2023). Zone 3 necroinflammation reflects greater severity (Boyd et al. 2020).
  • Total RAI. The three component scores are summed for a total of 0–9 (Gambella et al. 2022).
  • Global grade. Banff assigns a global grade of indeterminate, mild, moderate or severe acute rejection in addition to the RAI (Ourfali et al. 2025).
  • RAI is a grade. The rejection activity index grades rejection after the diagnosis is established. It is not a diagnostic index (Gambella et al. 2022).
RAI component Score 1 (mild) Score 2 (moderate) Score 3 (severe) Source
Portal inflammation Mainly lymphocytic; few portal tracts involved Mixed lymphocytes, neutrophils, eosinophils and few blasts; most or all portal tracts As for 2 with more blasts and eosinophils and periportal spillover Gambella et al. 2022
Bile duct inflammation and damage Few ducts cuffed and infiltrated; mild injury Most or all ducts; moderate injury (pyknosis, basement membrane loss) Severe injury with cell disruption Gambella et al. 2022
Venous endothelial inflammation (portal and central) Subendothelial lymphocytes in few venules Most or all venules; focal confluent centrilobular necrosis Severe venulitis with extension into the parenchyma and perivenular necrosis Gambella et al. 2022

Antibody-mediated rejection

  • Acute AMR histology. Acute AMR shows portal microvascular endothelial hypertrophy, capillaritis with monocytes, eosinophils or neutrophils, portal edema, central vein microvascular injury, sinusoidal fibrin with red cells, ductular reaction and cholestasis (Badwei 2023; Gambella et al. 2022). Its appearance can resemble biliary obstruction (Boyd et al. 2020).
  • Definite diagnosis. Linear or granular vascular C4d deposition and circulating donor-specific antibodies are required for a definitive diagnosis of acute AMR (Gambella et al. 2022). DSA methods are covered in HLA Typing, HLA Antibody Testing, Crossmatch and Platelet and Neutrophil Antibody Testing.
  • Timing. Preformed antibodies, including ABO incompatibility, cause early AMR. De novo DSA can cause late acute AMR 6 months or more after transplantation (Badwei 2023).
  • Chronic active AMR (Banff 2016). All of the following are required: at least mild mononuclear portal and/or perivenular inflammation with interface and/or perivenular necroinflammatory activity; at least moderate portal/periportal, sinusoidal or perivenular fibrosis; C4d staining in at least 10% of portal tracts; circulating DSA in serum collected within 3 months of the biopsy; and reasonable exclusion of other causes (Angelico et al. 2021).

Chronic rejection

  • Duct and arterial lesions. Chronic rejection affects bile ducts and arteries: ductopenia and foam cell obliterative arteriopathy of medium and large arteries (Badwei 2023). The arteriopathy is rarely sampled in needle biopsies (Gambella et al. 2022).
  • Ductopenia threshold. Banff requires at least 10 portal tracts with more than 50% showing duct loss. Up to about 7% of normal portal tracts lack a duct on biopsy (Gambella et al. 2022).
  • Ductular reaction and early duct changes. Chronic rejection shows almost no ductular reaction and only mild portal inflammation and endotheliitis (Gambella et al. 2022). Early lesions show duct cell eosinophilia, atrophy and nuclear loss before duct extinction (Gambella et al. 2022).
  • Setting and timing. Chronic rejection usually follows unresolved or repeated acute rejection or poor compliance and is unlikely before 6 months (Gambella et al. 2022; Boyd et al. 2020).
Structure Early chronic rejection Late chronic rejection Source
Small bile ducts (<60 µm) Degenerative change in most ducts (eosinophilic cytoplasm, raised nuclear-cytoplasmic ratio, uneven nuclear spacing, partial epithelial lining); duct loss in <50% of portal tracts Degenerative change in remaining ducts; loss in >50% of portal tracts Angelico et al. 2021
Terminal hepatic venules and zone 3 Intimal or luminal inflammation, lytic zone 3 necrosis, mild perivenular fibrosis Focal obliteration, variable inflammation, severe (bridging) fibrosis Angelico et al. 2021
Portal tract hepatic arterioles Loss in <25% of portal tracts Loss in >25% of portal tracts Angelico et al. 2021
Large perihilar arteries Intimal inflammation, focal foam cells without luminal compromise Luminal narrowing by subintimal foam cells; fibrointimal proliferation Angelico et al. 2021
  • Reversibility. Early chronic T-cell-mediated rejection can be reversible with prompt treatment. Late chronic rejection carries a much higher chance of progression to graft failure, often within the first year (Angelico et al. 2021).

Plasma cell-rich rejection

  • Terminology. Plasma cell-rich rejection was previously reported as de novo autoimmune hepatitis and is now classified by Banff as rejection (Gambella et al. 2022).
  • Criteria. Diagnosis requires portal or perivenular plasma cell-rich infiltrates (plasma cells >30% of the infiltrate) with interface or perivenular necroinflammatory activity, in a patient whose original disease was not AIH (Ourfali et al. 2025; Badwei 2023). Lymphocytic cholangitis is common but not required (Badwei 2023).
  • Frequency and features. It affects 3%–5% of recipients more than 6 months after transplant, often interferon-treated HCV recipients (Badwei 2023). Severe lymphocytic cholangitis is more frequent than in AIH, and IgG4-positive plasma cells may predominate (Gambella et al. 2022).

Other liver transplant complications

  • Ischemia-reperfusion (preservation) injury. Injury centered on terminal hepatic veins shows sinusoidal endothelial swelling, hepatocyte ballooning and apoptosis, neutrophil aggregates, necrosis and cholestasis (Gambella et al. 2022). Microvesicular steatosis and lobular neutrophils also occur (Boyd et al. 2020).
  • Small-for-size syndrome. Graft size mismatch with high metabolic demand and portal hypertension produces a portal-centered pattern with portal and periportal hemorrhage (Gambella et al. 2022).
  • Subcapsular hemorrhage. Erythrocytes beneath the capsule are prominent in wedge biopsies from poorly perfused peripheral parenchyma (Gambella et al. 2022).
  • Hepatic artery thrombosis. In 94 specimens, hepatic artery thrombosis showed ductular reaction (78%), lobular cholestasis (74%), portal inflammation (72%), lobular necrosis (64%) and ductular cholestasis (32%). Lobular necrosis was more frequent within 30 days, and ductular reaction and bile in veins were more frequent later (Lee et al. 2019).
  • Vascular thrombosis patterns. Hepatic artery thrombosis produces zone 3 or localized coagulative necrosis, which can involve zones 1 and 2, followed by ischemic cholangiopathy. Hepatic vein thrombosis produces zone 3 congestion and/or necrosis. Portal vein thrombosis produces sinusoidal dilatation, dilated, occluded or herniated portal veins and possible zone 3 necrosis (Ourfali et al. 2025).
  • Biliary complications. Anastomotic complications and secondary obstruction show cholangitis with neutrophils, ductular injury and proliferation, and portal edema from bile leakage (Gambella et al. 2022).
  • Alpha-1-antitrypsin deficiency recipients. Hepatic artery thrombosis is more frequent after transplantation for alpha-1-antitrypsin deficiency (Menon et al. 2021).

Recurrent and de novo disease in the allograft

Original disease Behavior in the allograft Source
PBC, AIH, steatohepatitis, hepatotropic viral hepatitis Recur Ourfali et al. 2025
PSC Recurs in 10%–40%; risk factors are male sex, an intact colon and active colitis Chapman et al. 2019
Hepatitis B Recurred in 23 of 27 patients; fibrosing cholestatic hepatitis with rapid graft dysfunction Davies et al. 1991
MASLD Recurrent disease more often fibrotic and steatohepatitic than de novo MASLD Leow et al. 2023
PFIC2 Anti-BSEP antibodies cause recurrent cholestasis Cheng and Rosenthal 2023
Wilson disease, alpha-1-antitrypsin deficiency Do not recur Ourfali et al. 2025
Hemochromatosis Recurrence controversial Ourfali et al. 2025
  • Fibrosing cholestatic hepatitis. Fibrosing cholestatic hepatitis showed thin perisinusoidal fibrous bands surrounding ductular-type epithelium, prominent cholestasis, ground-glass change and ballooning with cell loss and mild inflammation, with rapidly progressive graft dysfunction (Davies et al. 1991).
  • Predictors of fibrosing cholestatic hepatitis. Marked hepatocyte ballooning and ductular reaction were independent predictors of fibrosing cholestatic hepatitis after liver transplantation (Llovet et al. 2020).
  • MASLD. Recurrent MASLD was more often associated with diabetes and showed more severe fibrosis and steatohepatitis than de novo MASLD. Steatosis resolved in 22.5% of de novo cases and none of the recurrent cases (Leow et al. 2023).
  • Viral infection. Adenovirus usually occurs within 6 months, with confluent necrosis, hemorrhage and bile duct necrosis. Herpes simplex shows well-delimited necrosis with rare inclusions. EBV shows B-cell-rich portal and lobular inflammation (Gambella et al. 2022). CMV and other viral hepatitis are covered in Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections.
  • Post-transplant lymphoproliferative disorder. EBV causes most PTLD, a group of B-cell proliferations in transplant recipients. EBV-associated smooth muscle tumor shows bland spindle cells, SMA expression and diffuse EBER positivity (Gambella et al. 2022).
PTLD category, revised 4th edition WHO 5th edition (WHO-HAEM5) category Source
Non-destructive PTLD: plasmacytic hyperplasia, infectious mononucleosis and florid follicular hyperplasia types Hyperplasia arising in immune deficiency or dysregulation Green et al. 2026; Alaggio et al. 2022
Polymorphic PTLD Polymorphic lymphoproliferative disorder Green et al. 2026; Alaggio et al. 2022
Monomorphic PTLD (B-cell and T/NK-cell types) Lymphoma, classified as in immunocompetent patients Green et al. 2026; Alaggio et al. 2022
Classic Hodgkin lymphoma PTLD Lymphoma, classified as in immunocompetent patients Green et al. 2026; Alaggio et al. 2022
  • WHO-HAEM5 nomenclature. WHO-HAEM5 names each lesion by histologic diagnosis (hyperplasia, polymorphic lymphoproliferative disorder, mucocutaneous ulcer or lymphoma), viral association (EBV or KSHV) and immune deficiency setting, which is posttransplant after solid organ or bone marrow transplantation (Alaggio et al. 2022).
  • Non-destructive PTLD. Tissue architecture is preserved. Plasmacytic hyperplasia shows sheets of plasma cells, and infectious mononucleosis-like PTLD shows paracortical expansion with immunoblasts and T-cell predominance (Vargas-Nieto et al. 2026).

Donor liver biopsy at frozen section

  • Handling. The core is sent fresh as soon as possible to avoid drying artifacts. At least 6 portal tracts are a commonly accepted adequacy standard. Malignancy is excluded first (Pahlavan 2025).
  • Steatosis definitions (Banff). Large-droplet macrovesicular steatosis is a single droplet distending the hepatocyte and displacing the nucleus. Small-droplet macrovesicular steatosis has variably sized small droplets with a central nucleus. Microvesicular steatosis is diffuse foamy cytoplasm with droplets usually less than 2 µm² and no nuclear displacement (Pahlavan 2025).
  • Steatosis thresholds. Large-droplet macrovesicular steatosis above 33% increases post-transplant complications and requires a case-by-case decision (Pahlavan 2025). Grafts should have less than 60%, preferably less than 30%, large-droplet steatosis to prevent primary nonfunction, and no consensus cutoff has been published (Gambella et al. 2022).
  • Small-droplet steatosis. Small-droplet macrovesicular steatosis is not a contraindication and indicates acute liver stress (Pahlavan 2025).
  • Lipopeliosis. After reperfusion of a steatotic graft, hepatocyte membrane rupture expels lipid droplets into the extracellular space (lipopeliosis) and obstructs sinusoids (Abbas et al. 2024). Lipopeliosis was present on the time-zero biopsy of a graft with microvesicular steatosis that developed primary nonfunction (Limia et al. 2024).
  • Fibrosis. Ishak stage 2 or higher may make a liver less suitable and requires individual assessment (Pahlavan 2025).
  • Necrosis. Diffuse ischemic necrosis of at least 10% has been considered unsuitable, although grafts with up to 50% necrosis from brain-dead donors have been transplanted (Pahlavan 2025).
  • Pigments. Iron starts in zone 1, and zone 3 extension suggests transfusional overload or hemochromatosis. Lipofuscin and bile accumulate in zone 3 (Pahlavan 2025).
  • Findings that do not preclude use. Ductular proliferation, sinusoidal dilatation, glycogenated nuclei, granulomas, phlebosclerosis, cysts and bile duct hamartomas are not contraindications (Pahlavan 2025).
  • Sources of error in donor biopsy assessment. Interobserver variability in steatosis estimation, misreading small-droplet steatosis as microvesicular steatosis, drying artifact, fragmentation and tissue overlap are the main pitfalls (Pahlavan 2025).
Donor parameter Finding that limits use Source
Malignancy Any malignancy is a contraindication Pahlavan 2025
Large-droplet macrovesicular steatosis >33% increases complications; <60% (preferably <30%) recommended Pahlavan 2025; Gambella et al. 2022
Small-droplet macrovesicular steatosis Not a contraindication Pahlavan 2025
Fibrosis Ishak stage 2 or higher Pahlavan 2025
Ischemic necrosis ≥10% diffuse necrosis in non-brain-death donors Pahlavan 2025
Iron Extension to zone 3 Pahlavan 2025

Hepatocellular Nodules and Tumors: Focal Nodular Hyperplasia, Hepatocellular Adenoma, Dysplastic Nodules, Hepatocellular Carcinoma and Liver Cancer Staging

Definition and classification. Hepatocellular nodules range from hyperplasia (focal nodular hyperplasia) through benign neoplasia (hepatocellular adenoma, HCA) and premalignant dysplastic nodules to hepatocellular carcinoma (HCC). The WHO Classification of Digestive System Tumours, 6th edition (2026), describes HCA as an almost completely morpho-molecularly subtyped neoplasm and adds the sonic hedgehog HCA subtype (Arends et al. 2026). In the 6th edition, HCA comprises four molecular pathways across five subtypes, and fewer than 5% of HCAs remain unclassified when specific immunohistochemical and molecular tests are applied. At least 39% of progressed HCCs belong to one of nine morpho-molecular subtypes, and the remainder are conventional HCC (Sempoux et al. 2026). The CAP Hepatocellular Carcinoma protocol, version 4.3.0.0 (June 2022), applies to hepatic resections containing HCC and fibrolamellar carcinoma. Intrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, well-differentiated neuroendocrine tumor, hepatoblastoma, lymphoma and sarcoma are reported with other protocols (CAP 2022).

Related page: Hepatocellular Carcinoma and Its Variants on FNA, with Immunohistochemistry (WHO HCC classification as taught for cytology, the cell-block panel of glypican-3, HSP70 and glutamine synthetase, fibrolamellar carcinoma on FNA) Related page: Benign Liver Lesions on FNA (Abscess, Hydatid Cyst, Focal Nodular Hyperplasia, Hepatocellular Adenoma and Hemangioma) (FNH and HCA subtypes on FNA, hemangioma) Related page: Normal Liver, FNA Indications and Reactive Changes on Liver FNA (reactive hepatocytes versus well-differentiated HCC on FNA) Related page: Intrahepatic Cholangiocarcinoma on FNA and Its Separation from Metastatic Adenocarcinoma (HCC versus intrahepatic cholangiocarcinoma versus metastasis on FNA and cell block) Related page: Diagnostic Enzymes and Serum Tumor Markers (serum alpha-fetoprotein) Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (cirrhosis, hemochromatosis, alpha-1-antitrypsin deficiency and glycogen storage disease) Related page: Medical Liver Biopsy, Viral and Autoimmune Hepatitis, Drug-Induced Liver Injury and Hepatic Infections (Ishak, Batts–Ludwig and METAVIR fibrosis stages; reticulin and other routine stains) Related page: Hepatic Vascular Disorders and Liver Transplant Pathology: Outflow Obstruction, Porto-Sinusoidal Vascular Disorder, Rejection and Donor Biopsy (explant pathology and post-transplant complications) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (intrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, hepatoblastoma, pediatric HCC, vascular tumors and metastases)

Immunohistochemical approach to a well-differentiated hepatocellular nodule

Glutamine synthetase (GS), glypican-3 (GPC3), heat shock protein 70 (HSP70), CD34 and reticulin separate benign hepatocellular nodules from well-differentiated HCC. In a noncirrhotic liver, GS and subtype-specific stains separate FNH, HCA subtypes and HCC. In a cirrhotic liver, the GS, GPC3 and HSP70 panel, CD34 and stromal invasion separate dysplastic nodules from early HCC.

Lesion (noncirrhotic liver) Diagnostic immunostain result Source
Normal liver GS in a pericentral zonal rim CAP 2025b
Focal nodular hyperplasia GS in large anastomosing "map-like" areas, often around hepatic veins, and absent beside fibrous bands with arteries and ductules; CRP and SAA can be positive with a low H-score Bioulac-Sage et al. 2009; Soon et al. 2023
HNF1A-inactivated HCA Loss of liver fatty acid-binding protein (LFABP), 100% sensitivity and specificity for HNF1A mutation Bioulac-Sage et al. 2007
Inflammatory HCA SAA (91% sensitivity) and CRP (97.7% sensitivity) in hepatocytes Bioulac-Sage et al. 2007; Soon et al. 2023
β-catenin exon 3-activated HCA Strong diffuse GS with nuclear β-catenin (combination 85% sensitive and 100% specific for an activating mutation) Bioulac-Sage et al. 2007; Poetter-Lang et al. 2024
β-catenin exon 7/8-activated HCA Weak GS Poetter-Lang et al. 2024
Sonic hedgehog HCA ASS1 overexpression; prostaglandin D2 synthase is a weaker marker Sala et al. 2020
Well-differentiated HCC with β-catenin mutation Diffuse GS without the map-like pattern Bioulac-Sage et al. 2009
CD34 and GPC3 across lesions Sinusoidal CD34 is limited to zone 1 in normal liver, patchy in FNH and HCA and diffuse in well-differentiated HCC; GPC3 is negative in FNH, negative or rarely focal and weak in inflammatory HCA, and positive in 60% of early HCC Choi and Thung 2025
Feature (cirrhotic liver) Large regenerative and low-grade dysplastic nodule High-grade dysplastic nodule Early and grade 1 HCC Source
GS, GPC3 and HSP70 Negative Negative in most Two or more positive favor HCC Di Tommaso et al. 2007
CD34 sinusoidal capillarization Least common in cirrhotic nodules; more common in dysplastic nodules More common than in cirrhotic nodules Most common Park et al. 1998
Unpaired arteries (arteries without bile ducts) Rare in cirrhotic nodules; more common in low-grade dysplastic nodules More common than in cirrhotic nodules Most common Park et al. 1998
Stromal invasion Absent Absent The most important finding for early HCC Ichikawa et al. 2014
  • Capillarization and solitary arteries. In 97 cirrhotic nodules and HCCs, sinusoidal capillarization had the best single sensitivity (90.0%) and solitary arteries had the best specificity (88.9%) for high-grade dysplastic nodule, early HCC and small HCC (Chen et al. 2019).
  • Expanded panels. Adding clathrin heavy chain and EZH2 to GS, GPC3 and HSP70 raised the sensitivity for early HCC from 52% with three markers to 93% with five (Sciarra et al. 2016).
  • HSP70 in hepatocellular adenoma. GS, GPC3 and HSP70 were all negative in typical HCAs. HSP70 was positive in 10% of atypical hepatocellular neoplasms, 71% of very well-differentiated HCCs and 67% of well-differentiated HCCs (Nguyen et al. 2016).
  • Limits of HSP70. Benign hepatocytes may stain for HSP70, and HSP70 is frequently expressed in intrahepatic cholangiocarcinoma and metastatic liver tumors (Takahashi et al. 2021).

Related page: Hepatocellular Carcinoma and Its Variants on FNA, with Immunohistochemistry (sensitivity and specificity of GS, GPC3 and HSP70 in the Di Tommaso series)

Focal nodular hyperplasia

  • Definition and frequency. Focal nodular hyperplasia (FNH) is a hyperplastic response to a vascular insult and accounts for 8% of liver lesions. It is more common than HCA, may be multiple and can grow or regress independently of oral contraceptive use (Poetter-Lang et al. 2024). FNH presents in adolescence in children (CAP 2025b).
  • Morphology. FNH is well circumscribed and unencapsulated, with a central stellate scar and radiating fibrous septa in a noncirrhotic liver (Choi and Thung 2025). The fibrous bands contain arteries and ductules between nodules of hepatocytes (Bioulac-Sage et al. 2009).
  • Glutamine synthetase. The map-like GS pattern of FNH (Benign Liver Lesions on FNA (Abscess, Hydatid Cyst, Focal Nodular Hyperplasia, Hepatocellular Adenoma and Hemangioma)) was identical regardless of lesion size or steatosis in 79 resected FNHs (Bioulac-Sage et al. 2009).
  • CRP and SAA in FNH. FNH can stain for C-reactive protein (CRP) and serum amyloid A (SAA), with a lower modified H-score than inflammatory HCA (Soon et al. 2023).

Hepatocellular adenoma: risk factors and clinical behavior

  • Hormonal and metabolic risk. HCA occurs mainly in women of reproductive age. Oral contraceptive use for more than 5 years is a major risk factor and raises the annual incidence from about 1 to more than 30 per million. The female-to-male ratio has fallen from about 11:1 to 4:1 with increasing anabolic steroid use. Glycogen storage disease, obesity, metabolic syndrome, alcohol, Klinefelter syndrome, MODY type 3 and polycystic ovary syndrome are additional risk factors (Poetter-Lang et al. 2024).
  • Adenomatosis. Adenomatosis is defined by more than 10 HCAs and is strongly associated with glycogen storage disease type 1 (Poetter-Lang et al. 2024).
  • Complications. In 533 HCAs from 411 patients, symptomatic bleeding occurred in 14% of patients, 7% of nodules were borderline between HCA and HCC and 3% of patients developed HCC from HCA (Nault et al. 2017). Male sex, β-catenin exon 3 mutation and size above 5 cm increase the risk of HCC (Poetter-Lang et al. 2024).
  • HCA in men. In 27 HCAs in men (mean age 37 years), inflammatory HCA was the most common subtype (37%). Of 21 resected HCAs and hepatocellular neoplasms of uncertain malignant potential, 5 (23.8%) contained well-differentiated HCC (González et al. 2023). Resection is recommended in men regardless of size. In women, oral contraceptives are stopped and weight loss is advised, and resection is recommended for lesions larger than 5 cm or lesions that continue to grow (Poetter-Lang et al. 2024).
  • Reporting HCC arising in HCA. The sizes of the HCA and the HCC are both reported, and only the HCC size is used for staging. HCA subtyping is optional in the CAP protocol (CAP 2022).

Hepatocellular adenoma subtypes in the WHO 6th edition

The 6th edition recognizes HNF1A-inactivated HCA (H-HCA), inflammatory HCA (IHCA), β-catenin-activated HCA (B-HCA), β-catenin-activated inflammatory HCA (B-IHCA) and the new sonic hedgehog HCA (SHH-HCA) (Arends et al. 2026). Previous rule (5th edition, 2019): H-HCA, IHCA, B-HCA, B-IHCA and unclassified HCA, with no SHH-HCA category (González et al. 2023). The molecular classification of 533 HCAs that defined the SHH group divided HCA into eight subgroups, separating β-catenin exon 3 from exon 7/8 mutations (Nault et al. 2017).

Subtype Frequency Genetics Morphology and immunostains Risk settings Bleeding and malignant risk Source
H-HCA 30%–35% Inactivating HNF1A mutation; germline in MODY type 3 Diffuse steatosis; LFABP loss; no cytologic atypia Women, oral contraceptives Very low malignant potential Bioulac-Sage et al. 2007; Poetter-Lang et al. 2024
IHCA 30%–35% pure; 40%–50% including mixed β-catenin IHCA Mutations activating STAT3 (IL-6/JAK/STAT signaling) Dilated sinusoids (telangiectatic phenotype); SAA and CRP Obesity, steatosis, metabolic syndrome, alcohol; increasingly men Hemorrhage in up to 30% Bioulac-Sage et al. 2007; Sala et al. 2020; Poetter-Lang et al. 2024
B-HCA, exon 3 7% CTNNB1 exon 3 mutation (strong Wnt activation) Atypia, high nuclear-cytoplasmic ratio, acinar formation; strong diffuse GS and nuclear β-catenin Both sexes; glycogen storage disease, testosterone use, familial adenomatous polyposis Malignant transformation in up to 40% Poetter-Lang et al. 2024
B-HCA, exon 7/8 3% CTNNB1 exon 7 or 8 mutation (weak Wnt activation) Microscopic bleeding; weak GS Glycogen storage disease (most frequent subtype in this setting) Negligible malignant risk Poetter-Lang et al. 2024
B-IHCA 19.5% of inflammatory HCAs CTNNB1 exon 3 or exon 7/8 mutation plus inflammatory activation (βex3-IHCA or βex7,8-IHCA) Inflammatory features with GS overexpression As for IHCA β-catenin activation is associated with malignant transformation Nault et al. 2017; Poetter-Lang et al. 2024; Soon et al. 2023
SHH-HCA (new in 6th edition) 5%–10% (WHO); 4% in the molecular series Small somatic INHBE deletions giving INHBE::GLI1 fusion Bland, mostly small hepatocytes; ASS1 overexpression Obesity, hepatic steatosis High risk of hemorrhage without a significant risk of malignant transformation (WHO); borderline lesion or well-differentiated HCC in 4 of 58 ASS1-positive HCAs Arends et al. 2026; Nault et al. 2017; Sala et al. 2020; Poetter-Lang et al. 2024
  • Unclassified HCA. Fewer than 5% of HCAs remain unclassified after full immunohistochemical and molecular testing, compared with 6%–10% in earlier series. They have no specific genetic alteration or histopathologic abnormality (Sempoux et al. 2026; Poetter-Lang et al. 2024), and most formerly unclassified HCAs are SHH-HCA (Sala et al. 2020).
  • ASS1 as the SHH-HCA marker. ASS1 overexpression and the SHH molecular group were superimposed in 15 tumors studied molecularly. Of 67 formerly unclassified HCAs, 58 (85.3%) overexpressed ASS1. Prostaglandin D2 synthase was positive in only 7 of 22 SHH-HCAs (Sala et al. 2020).
  • CRP versus SAA. In 133 inflammatory HCAs, 90.2% stained for both markers. CRP was more sensitive (97.7%) than SAA (92.5%), and 19.5% of inflammatory HCAs were also β-catenin activated (Soon et al. 2023).
  • Malignant risk by subtype. Malignant transformation occurs in up to 4% of steatotic (H-HCA) and up to 40% of β-catenin exon 3 HCAs (Poetter-Lang et al. 2024). β-catenin-activated HCA was associated with HCC at diagnosis or during follow-up (P < 10⁻⁵) (Bioulac-Sage et al. 2007).

Dysplastic nodules, large regenerative nodules and early hepatocellular carcinoma in cirrhosis

  • Precursor status. High-grade dysplastic nodules are precursors of HCC and are diagnosed with the International Working Party criteria. Low-grade dysplastic nodules are difficult or impossible to distinguish from large regenerative nodules and need not be reported (CAP 2022).
  • Sampling. Cirrhotic nodules appreciably larger than the background nodules are sampled because they may harbor dysplasia (CAP 2022).
  • Stromal invasion. The International Consensus Group for Hepatocellular Neoplasia regards stromal invasion as the most important finding that separates early HCC from dysplastic nodules (Ichikawa et al. 2014). In 100 resected nodules, 16 of 42 early HCCs lacked stromal invasion, suggesting a preinvasive stage. Biomarker overexpression increased and ductular reaction decreased along the sequence from low-grade dysplastic nodule to progressed HCC (Sciarra et al. 2016).
  • Small HCC. Small HCCs measure less than 2 cm and are distinctly nodular or vaguely nodular. Vaguely nodular HCCs are thought to arise from dysplastic nodules, often retain portal tracts, occur in advanced fibrosis or cirrhosis in more than 90% and are well differentiated in more than 90% (Torbenson 2021).
  • Early molecular event. TERT promoter mutations were found in 5 of 20 cirrhotic macronodules (25%), with or without dysplasia, and in none of 69 cirrhotic tissues. They are the first recurrent mutation identified in cirrhotic preneoplastic lesions (Nault et al. 2013).

Hepatocellular carcinoma: epidemiology, gross patterns and grade

  • Frequency and setting. HCC accounts for almost 70% of primary malignant liver tumors in the United States (CAP 2022). More than 80% of HCCs develop in a cirrhotic liver (Nault et al. 2013). Risk factors include chronic hepatitis B and C, cirrhosis of any cause, alcohol-related liver disease, hemochromatosis, metabolic syndrome, diabetes mellitus, obesity and MASLD (formerly NAFLD) (Choi and Thung 2024).
  • Aflatoxin. Aflatoxin B1, a Group 1 carcinogen, induces the TP53 R249S hotspot mutation through DNA adducts, and R249S is regarded as a molecular fingerprint of aflatoxin exposure. HBV infection and aflatoxin exposure increase HCC risk synergistically (Moreno-León and Aguayo 2025).
  • Gross patterns. Nodular HCC forms distinct nodules of any size, with or without satellites. Massive HCC replaces almost an entire lobe. Pedunculated HCC protrudes from the capsule. Diffuse HCC is a proliferation of small tumor nodules (Torbenson 2021).
  • Microscopic growth patterns. The predominant pattern is trabecular in about 70%, solid (compact) in 20%, pseudoglandular (pseudoacinar) in 10% and macrotrabecular in 1%. Most HCCs mix several patterns (Torbenson 2021).
  • Cytoplasmic findings. Clear cell change, fatty change, bile, pale bodies, Mallory–Denk bodies and hyaline bodies are the common cytoplasmic findings. Bile production is more common in CTNNB1-mutated HCC, and pale bodies are more common in fibrolamellar carcinoma without being specific for it (Torbenson 2021).
  • Grade. The AJCC 8th edition uses four grades. G1 tumors resemble normal liver with minimal to mild atypia, limited reticulin loss and thin plates. G2 tumors have thick plates, mild to moderate atypia and more prominent reticulin loss. G3 tumors show marked atypia or high mitotic activity, and their hepatocellular nature may not be evident. Tumors without hepatocellular or other differentiation are classified as undifferentiated carcinoma. The Edmondson–Steiner system is based on nuclear features. For multiple tumors, the worst grade is reported (CAP 2022).
  • Undifferentiated carcinoma terminology (6th edition). The 6th-edition undifferentiated carcinoma changes apply to all digestive sites and are given in Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (Arends et al. 2026).

Hepatocellular carcinoma subtypes

The 6th edition groups HCC subtypes by prognosis: poor (macrotrabecular-massive, neutrophil-rich and sarcomatoid), favorable (lymphocyte-rich and clear cell), variable (scirrhous) and similar to conventional HCC (steatohepatitic, chromophobe and fibrolamellar). Two histologic patterns are new: vessels encapsulating tumor clusters (VETC) and the CTNNB1-mutated pattern. Keratin 19 expression remains associated with a poor prognosis (Sempoux et al. 2026). Previous rule (5th edition, 2019): rarer HCC subtypes defined by morphomolecular and clinical features formed 20%–30% of cases, and fibrolamellar carcinoma was defined by the DNAJB1::PRKACA fusion (Nagtegaal et al. 2020). The subtype definitions in the table are from Torbenson 2021, which predates the 6th edition. Prognostic groups are from Sempoux and Park 2026 (abstract).

Subtype Defining morphology Associations Prognostic group (6th edition) Source
Steatohepatitic Macrovesicular steatosis (at least moderate), intratumoral inflammation, ballooning, Mallory–Denk bodies and pericellular fibrosis in at least 50% of the tumor (originally 5%) Metabolic syndrome or alcohol use; fewer CTNNB1, TP53 and TERT promoter mutations; more IL-6/JAK/STAT activation Similar to conventional HCC Torbenson 2021; Sempoux et al. 2026
Clear cell Definite, diffuse clear cell change in at least 50% (90% for a purer group); usually well or moderately differentiated Classified by the predominant pattern when clear cell change and macrovesicular steatosis coexist Favorable Torbenson 2021; Sempoux et al. 2026
Macrotrabecular-massive Macrotrabeculae more than 6 or at least 10 cells thick; CD34 outlines the trabeculae Elevated serum AFP; TP53 mutations and 11q13.3 (FGF19/CCND1) amplification; immune-low phenotype Poor Torbenson 2021; Rhee and Park 2026; Sempoux et al. 2026
Scirrhous Abundant intratumoral fibrosis in at least 50% of the tumor CK7, CK19 and MOC31 can be positive Variable Torbenson 2021; CAP 2026a; Sempoux et al. 2026
Chromophobe Amphophilic to eosinophilic cytoplasm, bland nuclei punctuated by small foci of anaplasia, cystic spaces Alternative lengthening of telomeres (ALT) positive Similar to conventional HCC Torbenson 2021; Sempoux et al. 2026
Fibrolamellar carcinoma Large eosinophilic cells, prominent nucleoli, lamellar intratumoral fibrosis DNAJB1::PRKACA Similar to conventional HCC Torbenson 2021; Sempoux et al. 2026
Lymphocyte-rich Lymphocytes in more than 50% of the tumor and outnumbering tumor cells Epstein–Barr virus negative; no microsatellite instability Favorable Torbenson 2021; Sempoux et al. 2026
Neutrophil-rich Abundant intratumoral neutrophils; usually poorly differentiated, often with sarcomatoid areas Granulocyte colony-stimulating factor production; hepatic differentiation confirmed by immunohistochemistry Poor Torbenson 2021; Sempoux et al. 2026
Sarcomatoid Poorly differentiated spindle cell areas that are keratin positive, sometimes only focally Separate from carcinosarcoma, whose sarcoma is keratin negative with mesenchymal differentiation Poor Torbenson 2021; Sempoux et al. 2026
  • CAP histologic types. CAP 4.3.0.0 lists hepatocellular carcinoma, fibrolamellar, scirrhous and clear cell types. Scirrhous and sarcomatoid HCC are listed separately in the AJCC 8th edition (CAP 2022).
  • Lymphoepithelioma-like HCC. Lymphoepithelioma-like HCC is a poorly differentiated carcinoma in ill-defined sheets and is classified separately from lymphocyte-rich HCC (Torbenson 2021).

Immunohistochemistry and molecular pathology of hepatocellular carcinoma

  • Arginase-1. In 151 HCCs, arginase-1 was 96.0% sensitive (100%, 96.2% and 85.7% in well, moderately and poorly differentiated HCC). HepPar-1 was 84.1% sensitive (100%, 83.0% and 46.4%). Specificity across nonhepatic tumors was 99.6% for arginase-1 and 96.3% for HepPar-1, and no HCC was HepPar-1 positive and arginase-1 negative (Yan et al. 2010).
  • Albumin in situ hybridization. Albumin mRNA was detected in all HCCs, in 81% of intrahepatic cholangiocarcinomas and in gallbladder (39%), lung (20%) and breast (18%) adenocarcinomas (Nasir et al. 2019).
  • Hepatocytic versus biliary markers. Polyclonal CEA and CD10 in a canalicular pattern, HepPar-1, AFP, arginase-1 and GPC3 are hepatocytic markers; cytoplasmic or membranous polyclonal CEA, cytoplasmic CD10, CK7 and CK19 are biliary markers (Brunt et al. 2018).
  • TERT promoter mutation. TERT promoter mutations were present in 179 of 305 HCCs (59%), most often −124G>A (93%). They were more frequent in men, in tumors smaller than 5 cm, in non-HBV tumors, with low serum AFP and with CTNNB1 mutation (Nault et al. 2013).
Marker Hepatocellular carcinoma Intrahepatic cholangiocarcinoma Metastatic adenocarcinoma Source
Arginase-1 96.0% sensitive Used to exclude a hepatocellular component Specificity 99.6% across nonhepatic tumors Yan et al. 2010; CAP 2026a
HepPar-1 84.1% sensitive; 46.4% in poorly differentiated HCC Aberrant expression causes misclassification as combined tumors Specificity 96.3% Yan et al. 2010; Torbenson 2021
Albumin in situ hybridization 100% 81% Gallbladder 39%, lung 20%, breast 18% Nasir et al. 2019
CK7 and CK19 Positive in a subset, especially scirrhous HCC Positive Pattern indicates the likely primary site CAP 2026a; Selves et al. 2018

Fibrolamellar carcinoma

  • Clinical profile. Fibrolamellar carcinoma represents less than 1% of liver cancers (Honeyman et al. 2014). Patients are young (average age 26 years) without underlying liver disease and have hilar lymph node metastases more often than patients with conventional HCC (Torbenson 2021). Outcome is similar to conventional HCC in a noncirrhotic liver (CAP 2022).
  • Morphology. Tumor cells have abundant eosinophilic cytoplasm and prominent nucleoli within striking intratumoral fibrosis, often with pseudoglands, pale bodies and hyaline bodies (Torbenson 2021).
  • Immunohistochemistry. CK7 and CD68 are positive in nearly all fibrolamellar carcinomas and are nonspecific because a subset of conventional HCC expresses them (CAP 2022; Ross et al. 2011).
  • Genetics. A ~400-kb deletion on chromosome 19 fuses DNAJB1 and PRKACA. The chimeric transcript was present in 15 of 15 patients (Honeyman et al. 2014). Protein kinase A is activated by the fusion in more than 99% of cases and rarely by biallelic PRKAR1A mutation (Torbenson 2021).
  • Molecular testing. RT-PCR detected the fusion in all fibrolamellar carcinomas and in none of 25 HCCs, 25 cholangiocarcinomas, 25 HCAs or 5 hepatoblastomas. PRKACA FISH was rearranged in 19 of 19 fibrolamellar carcinomas and 0 of 6 scirrhous HCCs (Graham et al. 2015). The same fusion occurs in other tumors, so the diagnosis requires compatible morphology (Torbenson 2021), and DNAJB1::PRKACA is one of the fusions of intraductal oncocytic papillary neoplasm of the bile ducts (Choi 2026).
  • Fibrolamellar-like HCC with BAP1 loss. HCCs in older patients, often women without liver disease, can focally resemble fibrolamellar carcinoma. They show BAP1 loss and protein kinase A activation by PRKACA gain and PRKAR2A loss (Torbenson 2021).

Hepatic hemangioma and hepatic angiomyolipoma

  • Hemangioma. Cavernous hemangioma accounts for 73% of benign liver tumors, is found in 0.4%–7.3% of autopsies and is the second most common liver tumor after metastases. Malignant transformation is practically nonexistent. Rupture, intratumoral bleeding, Kasabach–Merritt syndrome and compression of organs or vessels are the indications for surgery; size alone is not an indication (Toro et al. 2014).
  • Sclerosing and sclerosed hemangioma. Sclerosing cavernous hemangioma shows increasing fibrosis and hyalinization of a cavernous hemangioma. Sclerosed hemangioma shows extensive fibrosis with almost completely obliterated vessels, represents the end stage of involution and can be difficult to separate from hepatic malignancy (Jia et al. 2021).
  • Angiomyolipoma (perivascular epithelioid cell tumor). Hepatic epithelioid angiomyolipoma is composed mainly of epithelioid cells with eosinophilic cytoplasm, with small amounts of fat and thick-walled vessels. In 27 tumors, HMB45 and melan-A were positive in all and smooth muscle actin in 24 of 26 (92.3%). Patients were women in 88.9% (mean age 44.2 years), 81.5% were asymptomatic and only 3.7% were diagnosed correctly before surgery. About 10% of patients have concurrent tuberous sclerosis complex, and resection is the primary treatment because of malignant potential (Cai et al. 2026). In children, perivascular epithelioid cell tumors including hepatic angiomyolipoma present in later childhood (3–10 years) (CAP 2025b).

Hepatocellular carcinoma staging (AJCC 8th edition)

The AJCC 8th edition liver chapter applies to HCC and fibrolamellar carcinoma. It does not apply to intrahepatic cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma, sarcomas or metastases (CAP 2022). T categories are based on tumor number, size of the largest nodule and vascular invasion. For treated tumors, only the size of viable tumor is used (CAP 2022).

pT Definition (AJCC 8th edition) Source
pT1a Solitary tumor ≤2 cm, with or without vascular invasion CAP 2022
pT1b Solitary tumor >2 cm without vascular invasion CAP 2022
pT2 Solitary tumor >2 cm with vascular invasion, or multiple tumors, none >5 cm CAP 2022
pT3 Multiple tumors, at least one >5 cm CAP 2022
pT4 Single or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or direct invasion of adjacent organs other than the gallbladder, or perforation of visceral peritoneum CAP 2022
pN1 Regional lymph node metastasis (hilar, hepatoduodenal ligament, inferior phrenic, caval, common hepatic artery and portal vein nodes) CAP 2022
  • Small tumors. Tumors up to 2 cm are pT1 regardless of vascular invasion because vascular invasion lacked adverse prognostic impact at that size (CAP 2022).
  • Major vascular invasion. Major vascular invasion means involvement of the right or left portal vein branches (excluding sectoral and segmental branches), the right, middle or left hepatic vein, or the right or left hepatic artery. These tumors are pT4 because their outcome matches that of extrahepatic or peritoneal T4 disease (CAP 2022).
  • Ligaments and diaphragm. Involvement of the falciform or other ligaments is staged pT1–pT3 by the other parameters. Direct invasion of the diaphragm is pT4 (CAP 2022).
  • Multiple tumors. Satellite nodules, multifocal primary HCCs and intrahepatic metastases are all counted as multiple tumors, and TNM does not distinguish among them (CAP 2022).

Pathology reporting of hepatocellular carcinoma resections and explants

  • Microvascular invasion. Microscopic vascular invasion is tumor within an endothelium-lined space, seen only microscopically, in the capsule, noncapsular fibrous septa or surrounding liver. Attachment to the vessel wall or smooth muscle or elastic lamina confirms it. Elastic and smooth muscle stains are used in difficult cases only (CAP 2022).
  • Portal vein tumor thrombus. Portal vein tumor thrombus is reported because of its adverse impact on outcome. Tumors larger than 5 cm or multiple tumors are more likely to show vascular invasion (CAP 2022).
  • Satellitosis. UNOS requires reporting of satellite nodules in explanted livers. The ICCR definition is an HCC nodule smaller than the primary tumor, within 2 cm of it and separated by nontumor tissue. Tumor inside a vessel is reported as vascular invasion (CAP 2022).
  • Treated tumors. After radiofrequency ablation or transarterial chemoembolization, tumors up to 2 cm are examined entirely and larger tumors receive one additional section per centimeter. Necrosis is estimated by combined gross and microscopic findings in up to five of the largest nodules (CAP 2022).
  • Margins. Grossly positive margins are confirmed microscopically, and the distance to the closest margin is reported. Tumor within 1 mm of the margin may carry a higher recurrence risk (CAP 2022).
  • Background liver. Fibrosis is reported with the name and scale of the scheme. The AJCC 8th edition recommends the Ishak system, and Batts–Ludwig or METAVIR may be used. High-grade dysplastic nodules, steatosis, steatohepatitis, iron overload and chronic hepatitis are reported as additional findings (CAP 2022).
  • Milan criteria. Transplant eligibility in the original Milan series was a single HCC ≤5 cm or up to three nodules each ≤3 cm. In 35 patients within these limits on explant review, 4-year overall and recurrence-free survival were 85% and 92%. In 13 patients whose tumors exceeded the limits, they were 50% and 59% (Mazzaferro et al. 1996).
CAP 4.3.0.0 element Responses and rules Source
Procedure Wedge resection; major partial hepatectomy (3 segments or more); minor partial hepatectomy; total hepatectomy CAP 2022
Histologic type HCC; fibrolamellar; scirrhous; clear cell; other type CAP 2022
Histologic grade G1–G4; worst grade for multiple tumors CAP 2022
Tumor focality and characteristics Solitary or multiple; site, viable tumor size and treatment effect for up to 5 largest nodules; satellitosis optional CAP 2022
Tumor extent Confined to liver; major portal vein branch; hepatic veins; visceral peritoneum; gallbladder; diaphragm; other organs CAP 2022
Vascular invasion Small vessel; large vessel (major branch of hepatic or portal vein) CAP 2022
Margins Parenchymal and other margins; distance to closest margin CAP 2022
Regional lymph nodes and pTNM Number examined and involved; AJCC 8th edition pT, pN and pM with m, r and y descriptors CAP 2022
Additional findings (optional) Fibrosis with scheme named, cirrhosis, low-grade or high-grade dysplastic nodule, steatosis, steatohepatitis, iron overload, chronic hepatitis CAP 2022
Version change Hepatoblastoma was removed from the histologic type list in version 4.3.0.0 CAP 2022

Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (AJCC 8th edition intrahepatic bile duct pT categories, which differ from the liver chapter)

Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma

Definition and classification. Intrahepatic cholangiocarcinoma (iCCA) is a malignant epithelial neoplasm with biliary differentiation arising in the intrahepatic bile ducts, which extend from the periphery of the liver to the second-order bile ducts (CAP 2026a; Choi and Thung 2024). The WHO Classification of Digestive System Tumours, 6th edition (2026), divides iCCA into two separate entities: small duct iCCA (SD-iCCA) and large duct iCCA (LD-iCCA), because they differ in etiology, pathogenesis, epidemiology, gross appearance, histology, molecular alterations and clinical and therapeutic profile (Arends et al. 2026). Previous rule (5th edition, 2019): iCCA was one anatomically defined entity with two major subtypes, large duct and small duct (Nagtegaal et al. 2020). The CAP Intrahepatic Bile Ducts protocol, version 4.4.0.0 (September 2026), applies to resected iCCA, combined hepatocellular-cholangiocarcinoma and high-grade neuroendocrine carcinoma of the liver. HCC, fibrolamellar carcinoma, well-differentiated neuroendocrine tumor, lymphoma and sarcoma are reported with other protocols (CAP 2026a). Pediatric liver tumors are classified with the international pediatric liver tumor consensus classification (López-Terrada et al. 2014), which has been incorporated into the WHO classification (López-Terrada et al. 2025).

Related page: Intrahepatic Cholangiocarcinoma on FNA and Its Separation from Metastatic Adenocarcinoma (iCCA in the WHO 5th and 6th editions on FNA, albumin ISH, iCCA versus metastasis, FGFR2 and IDH1 testing on FNA, combined HCC-cholangiocarcinoma on FNA) Related page: Metastases, Lymphoma and Angiosarcoma in Liver FNA (metastases and lymphoma on liver FNA) Related page: Hepatocellular Carcinoma and Its Variants on FNA, with Immunohistochemistry (fibrolamellar carcinoma and hepatoblastoma on FNA) Related page: Hepatocellular Nodules and Tumors: Focal Nodular Hyperplasia, Hepatocellular Adenoma, Dysplastic Nodules, Hepatocellular Carcinoma and Liver Cancer Staging (HCC, its immunohistochemical panel and the AJCC liver chapter) Related page: Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma (intraductal papillary, tubulopapillary and oncocytic papillary neoplasms of the bile ducts; perihilar cholangiocarcinoma) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (von Meyenburg complex and its frozen-section mimicry of metastatic adenocarcinoma, ductal plate malformations, primary sclerosing cholangitis and hepatic cysts) Related page: Colorectal Adenocarcinoma: Histologic Subtypes, Grade, Tumor Budding and the Malignant Polyp (primary colorectal adenocarcinoma, the most common source of liver metastases) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (familial adenomatous polyposis) Related page: Neuroendocrine, Mesenchymal and Lymphoid Tumors of the Esophagus, Stomach and Small Intestine (neuroendocrine neoplasm grading and GI lymphoma) Related page: Diagnostic Enzymes and Serum Tumor Markers (alpha-fetoprotein and CA19-9)

WHO 6th edition changes for intrahepatic biliary, cystic and other liver tumors

Topic WHO 6th edition (2026) Previous rule Source
Intrahepatic cholangiocarcinoma SD-iCCA and LD-iCCA are separate entities One entity with large duct and small duct subtypes (5th edition) Arends et al. 2026; Nagtegaal et al. 2020
iCCA histologic variants Adenosquamous, mucinous/colloid, mucoepidermoid and enteroblastic are variants of LD-iCCA; cholangiolocellular, ductal plate malformation-type, lymphoepithelioma-like and solid-tubulocystic are variants of SD-iCCA CAP 4.3.0.0 (June 2025) listed large duct and small duct iCCA without variants CAP 2026a; CAP 2025c
Mass-forming bile duct precursors IPNB, intraductal tubulopapillary neoplasm (ITPN) and intraductal oncocytic papillary neoplasm (IOPN) are described in the extrahepatic bile duct chapter (Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma); the liver chapter refers to them and keeps mucinous cystic neoplasm No separate ITPN or IOPN entries Arends et al. 2026; Choi 2026
Bile duct adenoma "Peribiliary gland hamartoma" is no longer recommended; a subset is neoplastic (BRAF V600E) "Bile duct adenoma" in the 5th edition; "bile duct adenoma (peribiliary gland hamartoma and others)" in the 4th edition Choi 2026
Precursor grading Two tiers (low grade and high grade) for biliary precursors, including mucinous cystic neoplasm Two tiers in the 5th edition; three tiers (low, intermediate, high; BilIN-1 to BilIN-3) in the 4th edition (2010) Arends et al. 2026; Nagtegaal et al. 2020; Choi 2026
Undifferentiated carcinoma "Carcinoma with mesenchymal differentiation"; SWI/SNF-deficient undifferentiated carcinoma included "Carcinoma with sarcomatoid components" (5th edition) Arends et al. 2026
Metastases Liver metastases and carcinoma of unknown primary have their own sections No separate liver metastasis section Arends et al. 2026
GLI1-altered neoplasms Gastroblastoma-like biphasic tumors with GLI1 fusions, reported in the liver, are grouped as GLI1-altered neoplasms Gastroblastoma classified in the stomach chapter (5th edition) Arends et al. 2026
Neuroendocrine neoplasms At least two neuroendocrine markers, preferably including chromogranin A, synaptophysin or INSM1; CD56 is insufficiently specific Neuroendocrine neoplasms described within each organ chapter (5th edition) Arends et al. 2026

Small duct versus large duct intrahepatic cholangiocarcinoma

Feature SD-iCCA LD-iCCA Source
Location Peripheral liver Large intrahepatic ducts near the hilum (right and left hepatic ducts) Choi and Thung 2024; CAP 2026a
Share of iCCA 40%–90%, varying by region Remainder Choi and Thung 2024
Risk factors Same as HCC: chronic hepatitis B and C, cirrhosis, alcohol, hemochromatosis, metabolic syndrome, diabetes, obesity, MASLD (formerly NAFLD) Same as perihilar and extrahepatic cholangiocarcinoma: liver flukes (Clonorchis sinensis, Opisthorchis viverrini), primary sclerosing cholangitis, hepatolithiasis Choi and Thung 2024; CAP 2026a
Precursor None established BilIN, IPNB and ITPN Choi and Thung 2024
Gross pattern Mass-forming Periductal-infiltrating or periductal-infiltrating plus mass-forming Choi and Thung 2024
Histology Small tubules of cuboidal to low columnar cells with scant cytoplasm; replacing growth in lobules Irregular, angulated, intermediate to large glands of tall columnar cells in desmoplastic stroma; perineural invasion Choi and Thung 2024
Mucin Absent or scant Abundant cytoplasmic and intraluminal mucin Choi and Thung 2024
CRP 97% 5% Akita et al. 2021
N-cadherin 87% 16% Akita et al. 2021
S100P 29% 95% (diffuse in 90%) Akita et al. 2021
Other characteristic markers CD56 (NCAM) MUC5AC, MUC6, TFF1 and AGR2 Choi and Thung 2024
Albumin in situ hybridization 71% 18% Choi and Thung 2024
Protein loss BAP1 SMAD4 Choi and Thung 2024
Molecular IDH1/2 and BRAF mutations and FGFR2 fusions, exclusively KRAS, SMAD4 and TP53 mutations and MDM2 amplification, more frequently Choi and Thung 2024
Histologic variants (CAP 4.4.0.0) Cholangiolocellular, ductal plate malformation-type, lymphoepithelioma-like, solid-tubulocystic Adenosquamous, mucinous/colloid, mucoepidermoid, enteroblastic CAP 2026a
  • Immunohistochemical algorithm. All iCCAs with CRP+/S100P− staining were small duct type, and all but one with CRP−/S100P+ staining were large duct type. N-cadherin classified 7 of 10 double-positive or double-negative tumors, and the panel classified 92% of tumors correctly on biopsy-sized cores (Akita et al. 2021).
  • Shared markers. CK7, CK19 and MUC1 are expressed by both types (Choi and Thung 2024).

Related page: Intrahepatic Cholangiocarcinoma on FNA and Its Separation from Metastatic Adenocarcinoma (mucin-based iCCA typing and albumin ISH in FGFR2-fused and IDH-mutated tumors)

  • Cholangiolocarcinoma. Cholangiolocarcinoma (cholangiolocellular carcinoma) has a ductular configuration in more than 80% of the tumor and can mimic ductular proliferation. The 2010 WHO classification (4th edition) placed it among combined HCC-cholangiocarcinomas with stem cell features. The 2019 WHO classification (5th edition) moved it to the small duct type of iCCA (Choi and Thung 2024; Nagtegaal et al. 2020).
  • Growth patterns. Mass-forming iCCA (60%) forms a demarcated nodule with radial growth. Periductal-infiltrating iCCA (20%) spreads longitudinally along the duct, and 20% are mixed (CAP 2026a).

Combined hepatocellular-cholangiocarcinoma and intermediate cell carcinoma

  • Diagnostic requirement. Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) shows both hepatocellular and biliary differentiation by morphology, supported by immunohistochemistry. Arginase-1 is included with HepPar-1 in the hepatocellular panel. A cholangiocarcinoma component is not diagnosed from CK7, CK19 or MOC31 staining alone, because these markers stain a subset of HCC, especially scirrhous HCC. Discrete glands, with or without mucin, that are CK7, CK19 or MOC31 positive and negative for hepatocellular markers are the most reliable evidence of a biliary component (CAP 2026a).
  • Consensus terminology. Diagnosis is based on H&E, and immunostains are supportive. Stem or progenitor cell features occur in many primary liver carcinomas and are no longer diagnostic subtypes; they are recorded in a comment as "stem/progenitor cell features present" (Brunt et al. 2018).
  • Intermediate cell carcinoma. Intermediate cell carcinoma is a monomorphic tumor of cells smaller than hepatocytes with features intermediate between hepatocytes and cholangiocytes, arranged in trabeculae, cords, solid nests or strands. It spreads like HCC (intravascular and intrabiliary) and like iCCA (lymphatic and perineural). Whether it belongs within cHCC-CCA or is a separate entity is undetermined (Brunt et al. 2018).
  • Clinical behavior. Serum AFP and CA19-9 are each elevated in about one third of patients. Hilar lymph node metastasis (13%) is more common than in HCC (2%) and less common than in cholangiocarcinoma (21%), and prognosis is intermediate between HCC and cholangiocarcinoma (Torbenson 2021). cHCC-CCA has a higher recurrence rate after liver transplantation than conventional HCC (CAP 2026a).
  • Reporting. cHCC-CCA is staged with the intrahepatic bile duct protocol, the size of the entire tumor is used for staging, and the proportion of each component can be reported. Each component can be graded separately (CAP 2026a).

Grading, staging and reporting of intrahepatic cholangiocarcinoma

  • Grade. Grade is based on gland formation: G1 more than 95% glands, G2 50%–95% and G3 less than 49% of tumor composed of glands (CAP wording). Tumors without glandular, squamous or neuroendocrine differentiation are undifferentiated carcinomas, and the scheme does not apply to neuroendocrine carcinoma (CAP 2026a).
  • Multiplicity. Satellite nodules, multifocal primary cholangiocarcinomas and intrahepatic metastases are counted as multiple tumors, and multiple tumor deposits are associated with poorer survival (CAP 2026a).
  • Tumors arising in intraductal neoplasms or mucinous cystic neoplasm. The largest invasive focus, the combined size of all invasive foci and the invasive percentage of the gross tumor are reported (CAP 2026a).
  • Treatment effect. Treatment response is scored with the modified Ryan scheme (0, no viable cancer; 1, single cells or rare small groups; 2, residual cancer with evident regression; 3, extensive residual cancer). Acellular mucin pools after therapy are not counted as tumor (CAP 2026a).
  • Ancillary studies. Mismatch repair immunohistochemistry or microsatellite instability testing and HER2 testing are performed for therapy selection, and the HER2 scoring criteria used are stated (CAP 2026a).
pT Definition (AJCC 8th edition, intrahepatic bile ducts) Source
pTis Carcinoma in situ (intraductal tumor): high-grade BilIN, IPN, ITPN or mucinous cystic neoplasm with high-grade dysplasia CAP 2026a
pT1a Solitary tumor ≤5 cm without vascular invasion CAP 2026a
pT1b Solitary tumor >5 cm without vascular invasion CAP 2026a
pT2 Solitary tumor with intrahepatic vascular invasion, or multiple tumors with or without vascular invasion CAP 2026a
pT3 Tumor perforating the visceral peritoneum CAP 2026a
pT4 Direct invasion of local extrahepatic structures (colon, duodenum, stomach, common bile duct, abdominal wall, diaphragm) CAP 2026a
pN1 Regional node metastasis; right lobe: hilar, periduodenal and peripancreatic nodes; left lobe: hilar, inferior phrenic and gastrohepatic nodes CAP 2026a
pM1 Distant metastasis, including celiac, periaortic or pericaval nodes CAP 2026a
  • Periductal growth. The periductal-infiltrating growth pattern is no longer part of the T classification because its criteria were inconsistent and its prognostic value unclear (CAP 2026a).
  • Size threshold. The intrahepatic bile duct chapter uses 5 cm without vascular invasion for pT1a versus pT1b, whereas the liver (HCC) chapter uses 2 cm (CAP 2026a; CAP 2022).
  • Isolated tumor cells. Isolated tumor cells and micrometastases in nodes are interpreted as positive with a comment (CAP 2026a).
CAP 4.4.0.0 element Responses and rules Source
Procedure Wedge resection; partial hepatectomy; total hepatectomy CAP 2026a
Histologic type LD-iCCA (NOS or a named variant); SD-iCCA (NOS or a named variant); cholangiocarcinoma NOS; squamous carcinoma; cHCC-CCA; mucinous cystic neoplasm, IPN (gastric, pancreatobiliary, intestinal or mixed), ITPN or IOPN with associated invasive carcinoma; undifferentiated carcinoma; neuroendocrine carcinomas; MiNEN CAP 2026a
Previous version (4.3.0.0, June 2025) Large duct and small duct iCCA without named variants; IPN and ITPN with invasive carcinoma; no IOPN option CAP 2025c
Grade, focality and size G1–G3; solitary or multiple with locations; size or multifocal invasive measurements CAP 2026a
Tumor extent and growth pattern Confined to ducts or parenchyma; visceral peritoneum; gallbladder; other structures; mass-forming, periductal-infiltrating or mixed (optional) CAP 2026a
Lymphovascular and perineural invasion Required CAP 2026a
Margins Hepatic parenchymal and bile duct margins for invasive carcinoma; separate margin status for high-grade intraepithelial neoplasia or high-grade dysplasia CAP 2026a
Additional findings Fibrosis with scheme named, cirrhosis, primary sclerosing cholangitis, biliary stones, chronic hepatitis, steatosis CAP 2026a

Bile duct adenoma, biliary adenofibroma, von Meyenburg complex and metastatic adenocarcinoma

Feature Bile duct adenoma von Meyenburg complex Small SD-iCCA or metastatic adenocarcinoma Source
Size and site Usually <10 mm; solitary subcapsular nodule in about 90% Usually <5 mm Variable Choi 2026
Architecture Disordered uniform small tubules in fibrous stroma, entrapped portal tracts, no infiltrative border Irregular, angulated ducts in abundant fibrous stroma, often with intraluminal bile Infiltrative glands; immature stroma and neutrophils in SD-iCCA Choi 2026; Sasaki et al. 2023
Cytology Bland cuboidal cells; no atypia or mitoses Bland Atypia Choi 2026
Immunohistochemistry CK7 and CK19; MUC5AC, MUC6 and p16 positive; Ki-67 <10%; CRP and albumin ISH may be positive Diagnosed on H&E by size, angulated ducts and bile IMP3 and EZH2 in 94% of small SD-iCCA; CK7/CK20 and site-specific markers in metastases Choi 2026; Sasaki et al. 2023; Selves et al. 2018
Genetics BRAF V600E in about 53% Separated from bile duct adenoma by its smaller size, cystic change and bile Small SD-iCCA: TP53 47%, ARID1A 41%, PBRM1 12%, MTAP 12% Choi 2026; Sasaki et al. 2023
  • Frequency. Bile duct adenoma is found in about 0.6% of autopsies and 2.4% of liver resections, in adults without sex predilection (Choi 2026).
  • Precursor question. In 33 bile duct adenomas and 17 small SD-iCCAs, none of the examined alterations, including BRAF, were found in the adenomas, and no evidence supported bile duct adenoma as a precursor of SD-iCCA (Sasaki et al. 2023).
  • Biliary adenofibroma. Lesions smaller than 1 cm favor von Meyenburg complex and lesions larger than 2 cm favor biliary adenofibroma, especially with micro- or macrocysts. A conventional SD-iCCA component or shared ARID1A, BAP1, IDH2, PBRM1 or FGFR2::MCU alterations indicate malignant potential (Choi 2026).

Mucinous cystic neoplasm of the liver

  • Definition (6th edition). Mucinous cystic neoplasm (MCN) is a noninvasive cyst-forming epithelial neoplasm with ovarian-type stroma and no communication with the bile ducts. It is graded in two tiers, and KRAS mutations (about 20%) are progression-associated events (Choi 2026).
  • Demographics. MCN occurs almost exclusively in women (mean age 52 years) and forms about 10% of hepatic cysts (Choi 2026). In 36 MCNs with ovarian stroma, all patients were women, mean size was 11 cm, 91% were intrahepatic and 72% were in the left lobe (Quigley et al. 2018). In 29 hepatic MCNs, 13 of the localized tumors (54%) were in segment IV (Zen et al. 2011).
  • Ovarian stroma criterion. Ovarian-type stroma has been required since the 2010 WHO classification. Of 32 cysts originally diagnosed as hepatobiliary cystadenoma or cystadenocarcinoma, 25% lacked ovarian stroma and were reclassified. Only 47% showed diffuse ovarian stroma (more than 75% of the wall) (Quigley et al. 2018).
  • Immunohistochemistry. ER and PR are restricted to the stromal cells in MCN, whereas both epithelium and stroma express them in endometriotic cysts (Choi 2026).
  • Malignant potential. In situ or invasive carcinoma was present in 2 of 36 MCNs (6%), both with invasion of 7–8 mm, compared with 16% in pancreatic MCN. Recurrence followed incomplete excision (Quigley et al. 2018). Of 29 hepatic MCNs, 90% were adenomas (Zen et al. 2011).
  • MCN versus IPNB. IPNB communicates with the bile ducts and lacks ovarian stroma (Choi 2026). Patients with MCN were younger than patients with cyst-forming IPNB, and MCNs were larger (median 110 mm versus 50 mm) (Zen et al. 2011).

Pediatric liver tumors by age

Primary malignant liver neoplasms represent about 1% of pediatric cancers. Hepatoblastoma is the most frequent, followed by HCC. Benign vascular tumors (hemangiomas) are the most common mesenchymal tumors, and malignant mesenchymal neoplasms form about 10%–15%, led by embryonal sarcoma and malignant rhabdoid tumor (López-Terrada et al. 2025). Hepatomegaly from megakaryoblastic leukemia, Langerhans cell histiocytosis and neuroblastoma mimics hepatoblastoma in infancy (CAP 2025b).

Age Benign Malignant Source
Infancy (0–1 year) Infantile hemangioma, mesenchymal hamartoma, teratoma Hepatoblastoma, rhabdoid tumor, yolk sac tumor, Langerhans cell histiocytosis, megakaryoblastic leukemia, disseminated neuroblastoma CAP 2025b
Early childhood (1–3 years) Infantile hemangioma, mesenchymal hamartoma Hepatoblastoma, rhabdomyosarcoma, inflammatory myofibroblastic tumor CAP 2025b
Later childhood (3–10 years) Perivascular epithelioid cell tumors, including angiomyolipoma HCC, embryonal (undifferentiated) sarcoma, angiosarcoma, cholangiocarcinoma CAP 2025b
Adolescence (10–16 years) Hepatocellular adenoma, focal nodular hyperplasia, mucinous cystic neoplasm (biliary cystadenoma in CAP 2025b) Fibrolamellar carcinoma, Hodgkin lymphoma, leiomyosarcoma CAP 2025b

Hepatoblastoma: clinical features, associations and genetics

  • Incidence and age. Hepatoblastoma has an annual incidence of 1.5 per million (Meyers et al. 2017). In the Pediatric Oncology Group series, 66% presented by the second year, 11% before 6 months and 6% after 5 years (CAP 2025b). SEER incidence rose 2.2% per year from 2004 to 2015 (CAP 2025b).
  • Prematurity. In Japan, hepatoblastoma formed 58% of malignancies in children with birth weight below 1000 g (CAP 2025b).
  • Syndromes. Familial adenomatous polyposis (APC, 5q21–22), Beckwith–Wiedemann syndrome (11p15.5; hepatoblastoma and hemangioendothelioma), Li–Fraumeni syndrome (TP53), trisomy 18 and glycogen storage disease types Ia, III and IV are associated with hepatoblastoma (CAP 2025b).
  • Alpha-fetoprotein. Serum AFP is elevated in hepatoblastoma. Tumors with a normal AFP formerly considered hepatoblastoma are now recognized as malignant rhabdoid tumors or other histologic types. AFP is physiologically high in the perinatal period, and pediatric HCC, germ cell tumors and rare pancreatic tumors also secrete it (CAP 2025b).
  • Genetics. Hepatoblastoma is genomically stable with few somatic mutations. Close to 90% carry CTNNB1 mutations. NFE2L2 is mutated in 5%–10% and is associated with poor prognosis. Recurrent trisomies of chromosomes 20, 2 and 8 and 1q gains occur (CAP 2025b).

Hepatoblastoma histologic patterns (international consensus classification)

Pattern Definition Immunohistochemistry Source
Fetal, well differentiated (mitotically inactive) Uniform round to polygonal cells with small central nuclei and clear or pale cytoplasm in a light-and-dark pattern; ≤2 mitoses per 10 high-power fields Fine stippled pericanalicular GPC3 (1–2+); variable nuclear β-catenin; diffuse GS; SALL4 negative CAP 2025b
Fetal, crowded (mitotically active) Fetal cells with more granular cytoplasm and larger nuclei; >2 mitoses per 10 high-power fields; frequent extramedullary hematopoiesis Coarse diffuse GPC3 (2–3+); diffuse strong GS; SALL4 negative CAP 2025b
Embryonal High nuclear-cytoplasmic ratio, angulated hyperchromatic nuclei, rosettes and tubules; frequent mitoses Strong GPC3 (3+); more diffuse nuclear β-catenin; variable GS; SALL4 frequently strong CAP 2025b
Pleomorphic (poorly differentiated) Fetal or embryonal cells with prominent nucleoli and HCC-like atypia; mostly after chemotherapy GPC3 and nuclear β-catenin CAP 2025b
Macrotrabecular Architectural pattern with trabeculae ≥5 cells thick; pleomorphic cells in macrotrabeculae on biopsy raise the possibility of HCN-NOS or HCC Architectural pattern defined on H&E CAP 2025b
Small cell undifferentiated and blastemal Small blue cells with scant cytoplasm in nests, often within embryonal areas Nuclear β-catenin; pankeratin, CK19 and CK7 with vimentin; INI1 loss defines malignant rhabdoid tumor CAP 2025b
Cholangioblastic Biliary-like profiles at the edges of tumor nodules Nuclear β-catenin; CK19 and pankeratin CAP 2025b
Mixed epithelial and mesenchymal, without teratoid features Osteoid, cartilage, muscle or spindle cell mesenchyme with epithelial hepatoblastoma Nuclear β-catenin possible in mesenchyme; GPC3 and SALL4 usually negative in mesenchyme CAP 2025b
Mixed epithelial and mesenchymal, with teratoid features Primitive neuroepithelium, melanin, glial or ganglion cells, or yolk sac-like glands Yolk sac-like glands GPC3 and SALL4 positive CAP 2025b
  • Pure fetal hepatoblastoma. The designation requires a primary resection composed entirely of well-differentiated fetal pattern and cannot be made on biopsy. Stage I pure fetal hepatoblastoma is treated with surgery alone as very low risk in the Children's Oncology Group study (CAP 2025b).
  • Small cell undifferentiated pattern. Earlier "pure small cell undifferentiated hepatoblastomas" with poor prognosis are now recognized as malignant rhabdoid tumors with SMARCB1 alteration and INI1 loss. Small foci of small cell undifferentiated pattern in otherwise conventional hepatoblastoma had no prognostic value in the last Children's Oncology Group trial (CAP 2025b).
  • Background liver mimic. Well-differentiated fetal areas resemble infant liver. Diffuse GS in tumor contrasts with the pericentral zonal GS of background liver (CAP 2025b).
  • Post-chemotherapy changes. Treated tumors show necrosis, fibrosis, macrophages, osteoid, maturation toward hepatocytes and a ductular reaction at the edge of nodules that is separate from cholangioblastic pattern. Histologic components are assigned from the post-therapy specimen (CAP 2025b).
  • Consensus validation. In 599 tumors from eight multicenter trials, 95.2% were classified as hepatoblastoma by all consortia and 4.8% as non-hepatoblastoma, including hepatocellular neoplasm NOS and malignant rhabdoid tumor. Of 570 hepatoblastomas, 453 were epithelial (Cho et al. 2023).
  • Hepatocellular neoplasm NOS (HCN-NOS). HCN-NOS is a provisional category of the pediatric consensus classification, and TERT promoter mutations are characteristic of it (CAP 2025b). Compared with 23 hepatoblastomas, 16 HCN-NOS occurred in older children, were more often high risk and carried TERT promoter mutations (37.5%) and 1q gains (17 of 17), with similar AFP levels, CTNNB1 mutation rates and survival (Zhou et al. 2024).

Hepatoblastoma staging, risk stratification and CAP reporting

  • PRETEXT and POSTTEXT. PRETEXT is an imaging-based system using the four liver sections (right posterior, right anterior, left medial and left lateral). The PRETEXT group (I–IV) depends on the number of contiguous uninvolved sections. No pathologic staging system is clinically applicable, and the earlier Children's Oncology Group surgical-pathologic staging has been replaced (CAP 2025b).
  • Annotation factors. V (hepatic veins or inferior vena cava), P (portal veins), E (extrahepatic spread), F (multifocality), R (tumor rupture), C (caudate involvement), N (lymph nodes) and M (distant metastases) annotate the PRETEXT group (CAP 2025b).
  • CHIC risk stratification. The Children's Hepatic tumors International Collaboration analyzed 1605 children from eight trials. The most prognostic factors were PRETEXT group, age (younger than 3 years, 3–7 years, 8 years or older), AFP ≤100 ng/mL or 101–1000 ng/mL and the annotation factors M, V, P, E, F and R. Backbone groups were AFP ≤100 ng/mL, metastatic disease and PRETEXT I/II, III or IV, leading to very low, low, intermediate and high risk groups. Sex, low birth weight, prematurity and Beckwith–Wiedemann syndrome were not prognostic (Meyers et al. 2017).
  • Sampling. Frozen section is avoided unless it changes the operation. At least one section per centimeter of greatest diameter is taken to find unfavorable components, with sections of margins, background liver and grossly involved veins, and a photographic section map is recommended (CAP 2025b).
CAP Hepatoblastoma 5.0.0.1 element Responses and rules Source
Preoperative treatment None known or given CAP 2025b
Procedure Right, extended right or total left lobectomy; medial or left lateral segmentectomy; explant CAP 2025b
Tumor focality, site and size Unifocal or multifocal; right, left or both lobes; size of each nodule CAP 2025b
Histologic type and post-treatment histologic type Fetal well differentiated, fetal crowded, embryonal, pleomorphic, macrotrabecular, small cell undifferentiated, mixed epithelial and mesenchymal with or without teratoid features, other patterns, HCN-NOS CAP 2025b
Extent, rupture and vascular invasion Confined to liver or adjacent organs; intraoperative spill or preoperative rupture; portal or hepatic vein involvement CAP 2025b
Treatment effect Percentage of necrosis, fibrosis and other treatment effects CAP 2025b
Margins and capsule Margin status and distance; capsular surface status CAP 2025b
Nodes and metastasis Regional nodes (hilar, hepatoduodenal ligament, caval); inferior phrenic and nodes distal to the hilum are distant CAP 2025b
Special studies Serum AFP at diagnosis (<100, 100 to 1.2 million, >1.2 million ng/mL); β-catenin and INI1 immunohistochemistry CAP 2025b

Mesenchymal hamartoma and undifferentiated embryonal sarcoma

Feature Mesenchymal hamartoma Undifferentiated embryonal sarcoma Source
Age 80% in the first 2 years; second most common benign pediatric liver tumor after infantile hemangioma 6–10 years (median 9); third most common pediatric hepatic malignancy after hepatoblastoma and HCC Martins-Filho and Putra 2020
Gross Cystic and solid, up to more than 30 cm; cysts do not communicate with bile ducts Large (≥10 cm), solitary, right lobe; solid and cystic with necrosis, hemorrhage and gelatinous areas; pseudocapsule Martins-Filho and Putra 2020
Histology Lobules of myxoid connective tissue with stellate cells, branching ductal plate-like bile ducts, pseudocysts, entrapped hepatocytes, extramedullary hematopoiesis Sheets of pleomorphic spindle and stellate cells in myxoid stroma, multinucleated giant cells, atypical mitoses, necrosis; eosinophilic hyaline globules that are PAS positive and diastase resistant Martins-Filho and Putra 2020
Immunohistochemistry Cytokeratin in ducts and hepatocytes; vimentin, smooth muscle actin, desmin and alpha-1-antitrypsin in mesenchyme Vimentin, alpha-1-antitrypsin and CD68 in most; BCL2, CD10, CD56, dot-like keratin and GPC3 in some; Ki-67 usually ≥30% Martins-Filho and Putra 2020
Genetics Androgenetic-biparental mosaicism or rearrangement activating the chromosome 19q microRNA cluster (C19MC), often MALAT1 (11q13) with 19q13.4 19q13.4 rearrangements when arising in hamartoma; TP53 mutations in a few cases Martins-Filho and Putra 2020
AFP Serum AFP typically normal, occasionally mildly elevated; elevated AFP can lead to misdiagnosis as hepatoblastoma Tumor cells AFP negative by immunohistochemistry; elevated serum AFP favors hepatoblastoma Martins-Filho and Putra 2020
Associations and behavior Placental mesenchymal dysplasia; surgical resection; recurrence with positive margins May arise in mesenchymal hamartoma; 5-year overall survival above 70% with surgery Martins-Filho and Putra 2020; Putra and Ornvold 2015
  • Malignant transformation. Undifferentiated embryonal sarcoma and angiosarcoma have arisen in mesenchymal hamartoma, sometimes years after incomplete resection, so different portions of a hamartoma are sampled (Martins-Filho and Putra 2020).
  • Differential diagnosis of embryonal sarcoma. Embryonal rhabdomyosarcoma of the biliary tree (children younger than 5 years, cambium layer, desmin, myogenin and MyoD1), hepatoblastoma (younger than 5 years, fetal or embryonal epithelium) and mesenchymal hamartoma are the pediatric mimics. Sarcomatoid HCC, melanoma, GIST and angiomyolipoma are the adult mimics (Martins-Filho and Putra 2020).

Infantile hepatic hemangioma, hepatic vascular malformation and Kasabach–Merritt phenomenon

  • GLUT1. In 19 pediatric hepatic vascular lesions, hepatic infantile hemangioma was consistently GLUT1 positive and hepatic vascular malformation with capillary proliferation was GLUT1 negative. GLUT1 reactivity links hepatic infantile hemangioma to cutaneous infantile hemangioma (Mo et al. 2004).
  • Consumptive hypothyroidism. Infantile hemangiomas express type 3 iodothyronine deiodinase, which causes severe hypothyroidism (Huang et al. 2000).
  • Kasabach–Merritt phenomenon. In 21 children with a large vascular tumor and Kasabach–Merritt coagulopathy, every tumor was kaposiform hemangioendothelioma and none was infantile hemangioma. Kaposiform hemangioendothelioma shows infiltrating lobules of small, poorly formed vascular channels with spindled endothelial cells, microthrombi and hemosiderin (Sarkar et al. 1997).

Epithelioid hemangioendothelioma and angiosarcoma

  • Epithelioid hemangioendothelioma (EHE) morphology. EHE grows infiltratively as epithelioid cells with immature intracytoplasmic lumina, without well-formed vascular channels, in myxoid, myxochondroid or sclerotic stroma. All tumors in the series were CD31 positive (Errani et al. 2011).
  • WWTR1::CAMTA1. The t(1;3)(p36;q25) translocation fuses WWTR1 and CAMTA1. It was present in virtually all EHEs and absent from other vascular neoplasms (Tanas et al. 2011). It was found in all EHEs and in no epithelioid hemangioma or epithelioid angiosarcoma in a second series (Errani et al. 2011).
  • CAMTA1 immunohistochemistry. WWTR1::CAMTA1 occurs in about 90% of EHEs and YAP1::TFE3 in fewer than 5%. Diffuse nuclear CAMTA1 staining was present in 51 of 59 EHEs (86%), 6 of the 8 negative tumors were TFE3 positive, and the other epithelioid tumors tested were negative except one epithelioid angiosarcoma diagnosed on core biopsy (Doyle et al. 2016).
  • YAP1::TFE3 EHE. The YAP1::TFE3 subset has well-formed vasoformative channels lined by epithelioid cells with abundant eosinophilic cytoplasm and strong TFE3 staining (Antonescu et al. 2013).
  • Angiosarcoma etiology. Hepatic angiosarcoma follows exposure to vinyl chloride, Thorotrast or arsenic, and cases of unknown etiology, including children, evolve in the same way. A precursor stage shows hyperplasia of hepatocytes and sinusoidal cells with excess reticulin and sinusoidal dilatation. Tumor cells then grow along sinusoids, producing peliosis, and finally form solid nodules of spindle or polyhedral cells with necrosis and hemorrhage (Popper et al. 1978). Tumor cells express vimentin and the vascular markers ERG, CD31, CD34, FLI-1 and factor VIII-related antigen (Dong et al. 2025). EHE and angiosarcoma also occur in children (López-Terrada et al. 2025).

Metastatic tumors of the liver

  • Frequency. In 23,154 patients with histologically confirmed liver metastases, 92.4% were carcinomas, 2.4% melanomas and 1.0% sarcomas. Adenocarcinoma NOS formed 74.9% of carcinomas, and 46.1% of these were colorectal, followed by pancreatic and breast primaries. Small cell carcinoma metastases were pulmonary in 76.9% (de Ridder et al. 2016).
  • Breast origin by age. In women aged 50 years or younger, metastatic adenocarcinoma was more often of breast origin (de Ridder et al. 2016).
  • Approach. The first step is deciding whether a liver lesion is primary or metastatic. Metastases are then grouped by epithelioid, spindle, undifferentiated or small round blue cell morphology, and lineage (carcinoma, sarcoma, lymphoma or melanoma) is established with tissue-sparing panels (Hu and Allende 2025).
  • WHO 6th edition. Liver metastases and carcinoma of unknown primary have separate sections, and carcinoma of unknown primary is divided into favorable and unfavorable groups (Arends et al. 2026).
Marker or pattern Favored primary Pitfall Source
CK7−/CK20+ Colorectal adenocarcinoma, the first consideration Medullary or undifferentiated colorectal carcinoma can be CK7−/CK20− Selves et al. 2018
CK7+/CK20− with GATA3 Breast carcinoma (GATA3 in 92%–100%) GATA3 also stains 70%–90% of urothelial carcinomas Selves et al. 2018
TTF-1 Lung or thyroid About 50% of poorly differentiated lung adenocarcinomas are positive Selves et al. 2018
PAX8 Müllerian, renal and follicular thyroid carcinomas Negative in GI and breast carcinomas and mesothelioma Selves et al. 2018
Gastric carcinoma Variable: CK7+/CK20+ 32%, CK7−/CK20+ 35%, CK7−/CK20− 14% Overlaps colorectal and pancreatobiliary profiles Selves et al. 2018
Albumin in situ hybridization Hepatocellular carcinoma and iCCA Positive in some gallbladder, lung and breast adenocarcinomas (Hepatocellular Nodules and Tumors: Focal Nodular Hyperplasia, Hepatocellular Adenoma, Dysplastic Nodules, Hepatocellular Carcinoma and Liver Cancer Staging) Nasir et al. 2019

Hepatic lymphoma

  • Primary hepatic lymphoma. Primary hepatic lymphoma is a lymphoproliferative disorder confined to the liver without lymphatic organ involvement and forms 0.16% of newly diagnosed lymphomas. In 116 patients, diffuse large B-cell lymphoma was the most common type (62.1%), followed by MALT lymphoma (12.0%). Elevated LDH predicted shorter progression-free survival (Hai and Zou 2021).
  • Hepatosplenic T-cell lymphoma. Hepatosplenic T-cell lymphoma infiltrates the sinusoids of the splenic red pulp, liver and bone marrow, has a nonactivated cytotoxic T-cell phenotype and frequently carries isochromosome 7q (Vega et al. 2007). About 75% express TCRγδ, 25% TCRαβ and 5% are TCR silent, and only 49% of patients were younger than 60 years in one study (Alaggio et al. 2022).

Related page: Steatotic, Metabolic and Storage Liver Diseases and Cirrhosis: Alcohol-Related Liver Disease, MASLD, Hemochromatosis, Wilson Disease, Alpha-1-Antitrypsin Deficiency and Pediatric Metabolic Disease (leukemic and lymphoma infiltration patterns in the liver)

Gallbladder and Extrahepatic Bile Duct Pathology: Cholecystitis, Gallstones, Precursor Neoplasms, Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma

Definition and classification. Gallbladder cancer is the most common cancer of the biliary tract and is often found incidentally after cholecystectomy for gallstones (Roa et al. 2022). The WHO Classification of Digestive System Tumours, 6th edition (2026), provisionally designates mass-forming intraepithelial neoplasms of the gallbladder as intracholecystic neoplasms (ICN), describes intraductal papillary neoplasm of the bile duct (IPNB), intraductal tubulopapillary neoplasm (ITPN) and intraductal oncocytic papillary neoplasm (IOPN) as separate entities, and grades all biliary precursors in two tiers (Arends et al. 2026). Perihilar tumors involve the hepatic duct bifurcation or the extrahepatic tree proximal to the origin of the cystic duct, distal tumors arise between the cystic duct junction and the ampulla of Vater, and cystic duct carcinomas are staged with gallbladder carcinomas (CAP 2026b; CAP 2026c). The CAP Gallbladder protocol is version 4.3.0.0 (June 2025), and the Perihilar Bile Ducts and Distal Extrahepatic Bile Ducts protocols are version 4.4.0.0 (September 2026), with WHO 6th edition updates (CAP 2025a; CAP 2026b; CAP 2026c). AJCC 8th edition staging applies to all three sites.

Related page: Biliary brushing cytology: technique, normal findings and reactive atypia (benign strictures, IgG4-related and PSC strictures in brushings) Related page: Biliary adenocarcinoma on brushing and ancillary testing (WHO pancreaticobiliary reporting categories, biliary FISH and NGS, CAP bile duct protocols in cytology) Related page: The WHO Reporting System for Pancreaticobiliary Cytopathology (the WHO reporting system for pancreaticobiliary cytopathology) Related page: Cholestatic and Biliary Liver Disease: Primary Biliary Cholangitis, Primary and IgG4-Related Sclerosing Cholangitis, Pediatric Cholestasis, Ductal Plate Malformations and Hepatic Cysts (primary sclerosing cholangitis, IgG4-related sclerosing cholangitis and Caroli disease) Related page: Intrahepatic Cholangiocarcinoma, Biliary Cystic and Benign Tumors, Pediatric and Mesenchymal Liver Tumors, Metastases and Lymphoma (intrahepatic cholangiocarcinoma, mucinous cystic neoplasm and the AJCC intrahepatic bile duct chapter) Related page: Diagnostic Enzymes and Serum Tumor Markers (CA19-9 and CEA)

Normal gallbladder, Rokitansky–Aschoff sinuses, Luschka ducts and congenital anomalies

  • Wall structure. The gallbladder has a discontinuous muscle layer and no muscularis mucosae. About 30% of its surface is attached to the liver, and the rest is covered by peritoneum (Roa et al. 2022).
  • Rokitansky–Aschoff sinuses. Rokitansky–Aschoff sinuses are epithelial invaginations into the wall that can be colonized by dysplasia or carcinoma in situ (CAP 2025a).
  • Luschka ducts. Luschka ducts are bile ducts that connect the hepatic bile duct system directly to the gallbladder. In 55 cholecystectomies they lay in the subserosa, at the resection surface or both, measured up to 36 mm and appeared as duct-like, cystic or nodular bile duct adenoma-like complexes (Handra-Luca et al. 2020).
  • Agenesis. Gallbladder agenesis is present in 0.0027%–0.007% of the population. In 151 reported patients, 66% were women, median age was 45 years and 73% were diagnosed intraoperatively (Young et al. 2026).
  • Duplication. True duplication consists of two separate gallbladders, each with its own cystic duct, and both can develop cholecystitis and stones (La et al. 2025).
  • Heterotopia. Ectopic pancreatic tissue in the gallbladder wall contains acini, ducts and islets of Langerhans without continuity with the pancreas (Kaur et al. 2024).

Gallstones

Up to 20% of adults develop gallstones, and more than 20% of them develop symptoms or complications: acute cholecystitis, acute cholangitis or biliary pancreatitis. Common variants of the hepatic cholesterol transporter gene ABCG8 account for most of the genetic risk, which is about 25% of total risk (Lammert et al. 2016).

Stone type Setting and risk factors Source
Cholesterol The predominant type; female sex, age, pregnancy, physical inactivity, obesity, overnutrition and metabolic syndrome Lammert et al. 2016
Black pigment Chronic hemolysis Lammert et al. 2016
Brown pigment Obstructed and infected bile ducts Lammert et al. 2016
  • Gallstones and cancer. Gallstones are present in up to 90% of patients with gallbladder cancer. Mendelian randomization supports a causal role (odds ratio 2.0 in Chile and 5.0 in Europe), yet fewer than 1% of gallstone carriers develop gallbladder cancer (Roa et al. 2022).

Acute and chronic cholecystitis and their variants

Variant Definition and findings Associations Source
Acute acalculous cholecystitis Acute necroinflammatory disease without stones Fulminant course; gangrene, perforation and empyema; cardiovascular disease Saragò et al. 2022
Emphysematous cholecystitis Severe acute necrotizing cholecystitis with gas in the wall, lumen or pericholecystic tissue; ischemic injury then infection Clostridium perfringens, Escherichia coli, Klebsiella; with or without stones Miao et al. 2026
Chronic cholecystitis with metaplasia Pseudopyloric (up to 60% of chronic cholecystitis), foveolar and intestinal metaplasia Pseudopyloric metaplasia appears inconsequential; metaplasia–dysplasia–carcinoma sequence Roa et al. 2022
Follicular cholecystitis At least 3 lymphoid follicles per cm with little intervening inflammation 1.9% of routinely sampled and 2.4% of entirely submitted cholecystectomies; older patients (mean 68 years); first described with Salmonella; no link to autoimmunity, lymphoma or obstruction Saka et al. 2020
Eosinophilic cholecystitis More than 90% of inflammatory cells are eosinophils (lymphoeosinophilic: 50%–90%) In children, all cases had stones and acute cholecystitis Garzón et al. 2021
Hyalinizing cholecystitis Dense paucicellular hyaline fibrosis converting the wall into a thin uniform band, calcified in two thirds 1.6% of cholecystectomies; carcinoma in 15% (odds ratio 4.6) Patel et al. 2011
Lymphoplasmacytic cholecystitis Dense lymphoplasmacytic inflammation with fewer than 50 IgG4+ cells per HPF and IgG4/IgG ratio below 40% Historically linked to PSC and autoimmune pancreatitis Ahuja et al. 2026
  • Gangrenous cholecystitis. Ischemia leads to transmural necrosis and gangrene of the gallbladder wall, which can progress to perforation and peritonitis (Botezatu et al. 2025). Histology shows diffuse transmural necrosis, hemorrhagic destruction, severe acute inflammation and complete loss of the mucosal architecture (Mikadze et al. 2026).

  • Porcelain gallbladder. In 44 calcified gallbladders, selective mucosal calcification carried a cancer incidence of about 7% (odds ratio 13.89), and diffuse intramural calcification carried none (Stephen and Berger 2001). The CAP protocol reports diffuse calcification as an additional finding and states that selective mucosal calcification is more closely associated with cancer (CAP 2025a).

  • Hyalinizing cholecystitis carcinomas. Carcinomas in hyalinizing cholecystitis formed no mass, measured a mean wall thickness of 2.6 mm and consisted of scattered bland glands parallel to the surface with clear cytoplasm, irregular contours and washed-out chromatin. Only 42% of invasive cases had calcification, none of 10 diffusely calcified gallbladders had carcinoma, and median survival was 7 months (Patel et al. 2011).

  • PSC gallbladders. Gallbladders from patients with primary sclerosing cholangitis show dysplasia in 37% and adenocarcinoma in 14% (transplant series) and are examined for both (CAP 2025a).

  • Xanthogranulomatous cholecystitis (XGC). XGC was found in 45 of 418 gallbladders (10.8%) removed for chronic cholecystitis or carcinoma. The wall was thickened, yellow xanthogranulomatous nodules of 2–15 mm involved the full wall thickness and extended into adjacent fat and organs, and all cases had cholesterol or mixed stones. Its extension mimics carcinoma grossly (Singh et al. 1989). XGC is marked fibrosis with macrophages and foamy histiocytes (Ahuja et al. 2026).
  • Uniform wall thickening. Diffuse, uniform and regular wall thickening on imaging favors a benign cause such as chronic or xanthogranulomatous cholecystitis (Roa et al. 2022).
  • IgG4-related cholecystitis. IgG4-related cholecystitis is gallbladder involvement by IgG4-related disease and accompanies 25%–32% of autoimmune pancreatitis cases (Ahuja et al. 2026).
  • XGC and IgG4 overlap. About 10% of XGCs in extended cholecystectomies had more than 50 IgG4+ plasma cells per HPF, storiform fibrosis, an IgG4/IgG ratio above 0.40 and extracholecystic extension, and half had obliterative phlebitis. These features alone do not establish IgG4-related disease, which requires clinical, serologic and imaging correlation (Goyal et al. 2023; Ahuja et al. 2026).

Cholesterolosis, cholesterol polyps, adenomyomatosis and other non-neoplastic polyps

Polyp or lesion Morphology Clinical features Source
Fibromyoglandular polyp (48% of non-neoplastic polyps) Broad-based lobules of small, often pyloric-type glands in fibroblastic stroma with smooth muscle Mean 0.43 cm; multifocal in 45%; almost always with gallstones; more common in high-risk regions Taskin et al. 2020
Cholesterol polyp (39%) Pedunculated, cauliflower-like polyp lined by a single layer of normal epithelium over edematous cores with cholesterol-laden macrophages; thin stalk that detaches easily Mean 0.45 cm; cholesterolosis in the remaining gallbladder in 59%; gallstones in 55%; little injury or inflammation; relatively common in men Taskin et al. 2020
Polypoid pyloric metaplasia (9%) Polypoid aggregates of pyloric glands in regenerating mucosa, without back-to-back clonal glands All <1 cm; formerly called mucinous pyloric gland adenoma Taskin et al. 2020
Inflammatory polyp (4%) Lymphoid aggregates, granulation tissue or xanthogranulomas All <1 cm Taskin et al. 2020
Adenomyomatosis Rokitansky–Aschoff sinuses; fundal or segmental/diffuse types 2.4% of cholecystectomies; fundal type most common and less often with stones (gallstones in 69.9% overall); no cancer in 113 cases Kim et al. 2010
  • Cholesterolosis. Cholesterolosis is the accumulation of lipid-laden macrophages in the subepithelial lamina propria. It is focal, diffuse or polypoid and is found in about 20% of cholecystectomies, particularly with chronic cholecystitis (Fındık et al. 2025).
  • Size and malignancy in non-neoplastic polyps. Of 447 non-neoplastic polyps larger than 2 mm, only 5% measured 1 cm or more, and none showed in situ or invasive carcinoma arising in the polyp (Taskin et al. 2020).
  • Cholesterolosis mimicking adenomyomatosis. Focal cholesterolosis can reproduce the imaging features of fundal adenomyomatosis, and histology makes the distinction (Al-Olayan 2026).
  • Perineural adenomyomatous ducts. Ducts of adenomyomatous hyperplasia can involve perineural spaces and mimic perineural invasion by carcinoma (CAP 2025a).
  • Neoplasms in adenomyomas. ICNs arising in adenomyomas form well-demarcated mural nodules that often spare the surface mucosa (Choi 2026).

Biliary precursor neoplasms in the WHO 6th edition

Precursor WHO 6th edition (2026) Previous rule Source
Grading of all biliary precursors Two tiers: low grade and high grade Two tiers in the 5th edition (2019); three tiers in the 4th edition (2010): BilIN-1, BilIN-2 and BilIN-3, and low, intermediate and high grade for IPNB and MCN Arends et al. 2026; Nagtegaal et al. 2020; Choi 2026; Zen et al. 2007
Gallbladder mass-forming precursors Intracholecystic neoplasm (ICN), provisionally, subdivided into intracholecystic papillary neoplasm (ICPN) and intracholecystic tubular neoplasm (ICTN) Intracholecystic papillary-tubular neoplasm (also abbreviated ICPN) as one category (5th edition) Arends et al. 2026; Roa et al. 2022
Pyloric gland adenoma Renamed the gastric subtype of ICPN; the term is no longer recommended Pyloric gland adenoma used as a separate term (5th edition) Arends et al. 2026; Choi 2026; Roa et al. 2022
Bile duct mass-forming precursors IPNB, ITPN and IOPN are separate entities in the extrahepatic bile duct chapter ITPN and IOPN were not separate biliary entities Arends et al. 2026; Choi 2026
IPNB subtypes Pancreatobiliary, intestinal and gastric subtypes; type 1 and type 2 framework clarified IPNB graded in two tiers; ITPN and IOPN not listed as separate biliary entities (5th edition) Choi 2026
  • Grading terms. The 4th edition graded BilIN in three categories (BilIN-1, BilIN-2 and BilIN-3) by atypia, with moderate interobserver agreement (kappa 0.45) (Zen et al. 2007). The 5th edition (2019) replaced the three-tier scheme with two tiers (Nagtegaal et al. 2020); the 6th edition keeps two tiers for all biliary precursors, with former low-grade and intermediate-grade dysplasia combined as low grade (Arends et al. 2026). Low-grade BilIN corresponds to former BilIN-1 and BilIN-2, and high-grade BilIN to BilIN-3 (Choi 2026). The CAP bile duct protocols still define pTis to include BilIN-3 (CAP 2026b; CAP 2026c).

Biliary intraepithelial neoplasia

  • Definition. BilIN is a microscopic, noninvasive flat or micropapillary neoplasm of the large bile ducts and gallbladder. It spares the small terminal intrahepatic ducts and is usually an incidental finding (Choi 2026).
  • Frequency. BilIN is present in the mucosa surrounding up to 80% of invasive gallbladder carcinomas (Choi 2026).
  • Low grade. Low-grade BilIN shows mild atypia, mostly flat growth, nuclear pseudostratification, increased nuclear-cytoplasmic ratio and hyperchromasia with preserved polarity (Choi 2026).
  • High grade. High-grade BilIN shows complex micropapillary architecture, irregular nuclei, a high nuclear-cytoplasmic ratio and loss of polarity (Choi 2026).
  • Reactive atypia versus BilIN. Reactive atypia involves surface epithelium and intramural glands and shows attenuated basophilic cells, intercellular clefts, fine chromatin and a gradual transition from normal epithelium. p53 overexpression supports BilIN (Choi 2026).
  • Genetics. Recurrent mutations include CTNNB1, ARID2, TP53, ERBB3, NFE2L2, PIK3CA, SMARCA4, KRAS and SMAD4, and CTNNB1 mutation is implicated in progression to invasion (Choi 2026).

Intracholecystic neoplasms of the gallbladder

  • Definition and frequency. ICNs are grossly visible, noninvasive polypoid or papillary neoplasms of dysplastic epithelium. They are found in about 0.4% of cholecystectomies, and about 6% of gallbladder carcinomas arise in them. Mean age is 61 years with female predominance. ICPN requires a discrete nodule larger than 10 mm or high-grade dysplasia (Choi 2026).
  • ICPN. ICPNs are broad-based, often multifocal (about one third) papillary neoplasms with biliary, gastric or, less often, intestinal differentiation, and they can extend into Rokitansky–Aschoff sinuses and mimic invasion. TP53 alterations occur, and KRAS mutations are uncommon except in pancreatobiliary maljunction (Choi 2026).
  • ICTN. ICTNs are solitary pedunculated polyps of back-to-back, mucin-poor tubules with morules showing nuclear β-catenin. They are diffusely MUC6 positive and often MUC1 positive, lack MUC2, MUC5AC and CDX2, and carry WNT pathway (CTNNB1) alterations (Choi 2026). No invasive carcinoma has been documented within ICTN, and they appear to arise in cholesterol polyps (Pehlivanoglu 2026).
  • Lineage data (5th-edition ICPN series). In 123 neoplasms of at least 1 cm, the predominant lineage was biliary in 50%, gastric foveolar in 16%, gastric pyloric in 20%, intestinal in 8% and oncocytic in 6%. Of former pyloric gland adenomas, 88% had at least focal high-grade dysplasia and 18% had invasive carcinoma. Invasion was associated with 55% of cases, and 3-year survival was 90% without and 60% with invasion (Adsay et al. 2012).
  • Polypoid pyloric metaplasia. Small polypoid pyloric gland metaplasia in an injured gallbladder lacks the complex architecture of ICPN with gastric differentiation (Choi 2026).

Intraductal neoplasms of the bile ducts: IPNB, ITPN and IOPN

Feature IPNB ITPN (separate entity in 6th edition) IOPN (separate entity in 6th edition) Source
Definition Grossly visible intraductal papillary or villous neoplasm of mucin-producing columnar cells with fibrovascular cores Intraluminal neoplasm without significant mucin, mostly high-grade back-to-back tubules and fewer papillae Intraductal exophytic papillary or nodular neoplasm of oncocytic cells with abundant eosinophilic cytoplasm Choi 2026; Arends et al. 2026
Gross Polypoid or papillary masses in dilated ducts, often with mucin hypersecretion Solid whitish-tan nodules in dilated ducts (mean 50 mm), punctate necrosis, little mucin Brown-tan friable papillary or solid mass (mean 53 mm), minimal mucin Choi 2026
Histology Pancreatobiliary, intestinal or gastric subtypes; low or high grade Packed tubules, cribriform glands, papillae <30% Arborizing papillae, intraepithelial lumina, prominent nucleoli Choi 2026
Immunohistochemistry MUC6 in 30%–80% of gastric type; CK20 in intestinal type MUC6 variably Diffuse MUC5AC and MUC6; focal MUC1; HepPar-1 (20%–50%) and KIT (CD117, 20%–60%) frequently positive Choi 2026; Wang et al. 2023
Genetics KRAS, p16 loss, TP53; GNAS and RNF43 in intestinal type No KRAS, GNAS or IDH1/2 hotspots; occasional CDKN2A PRKACA or PRKACB fusions (ATP1B1::PRKACB, ATP1B1::PRKACA, DNAJB1::PRKACA) Choi 2026; Wang et al. 2023
Behavior Type 2 more aggressive High risk of progression to carcinoma with relatively good survival Invasive carcinoma in about 30%–40%; lymphovascular and perineural invasion and nodal metastasis as frequent as in IPNB-associated carcinoma; overall prognosis more favorable than IPNB-associated invasive carcinoma Arends et al. 2026; Choi 2026
  • IPNB epidemiology. IPNB forms 10%–38% of bile duct tumors in East Asia and 7%–11% in Western countries. Patients are 42–80 years old with a slight male predominance (Choi 2026).
  • Type 1 and type 2 IPNB. Type 1 IPNB is mostly intrahepatic, shows cystic or cylindrical dilatation with mucin hypersecretion and regular papillae, resembles pancreatic IPMN and has a favorable prognosis. Type 2 is mostly extrahepatic, has complex cribriform or solid areas with little mucin, is almost always high grade, frequently invades and has a worse prognosis (Choi 2026).
  • Interobserver data. In 227 tumoral intraductal neoplasms, IPNB (183) was most frequent, then IOPN (28) and ITPN (2). Agreement was slight for two-tier grading (kappa 0.201) and moderate for type 1 and type 2 subclassification (kappa 0.515). Stromal invasion accompanied 49.6% of type 2 and 6.7% of type 1 neoplasms (Nakanuma et al. 2024).
  • Molecular heterogeneity. In 41 tumoral intraductal neoplasms, all gastric-type IPNs had WNT pathway alterations, APC and KRAS mutations were common in gastric type, SMAD4 mutation was more frequent in intestinal type, and 3 of 6 IOPNs carried ATP1B1::PRKACB. Disease-related death was more frequent with invasion (56% versus 10%) (Wang et al. 2023).
  • Reporting. A synoptic report is not required for IPNB, ITPN, IOPN or MCN without invasion. With invasion, the deepest invasive focus determines pT, and the largest focus, combined size and invasive percentage are reported (CAP 2026b).

Gallbladder carcinoma: epidemiology, pathways and histologic types

  • Epidemiology. An estimated 115,949 new cases occurred worldwide in 2020. Incidence is about twice as high in women as in men in the Americas and highest in indigenous populations of South America, northern India and East Asia. In the United States, age-adjusted incidence is 1.9 per 100,000 in women and 1.1 in men (Roa et al. 2022).
  • Two pathways. Most gallbladder carcinomas (70%–90%) arise through a gallstone-related metaplasia–dysplasia–carcinoma sequence in flat mucosa. The adenoma–carcinoma sequence through ICPN accounts for 5%–10% and occurs mostly with non-lithiasic inflammation (Roa et al. 2022).
  • Other risk settings. Pancreatobiliary maljunction (anomalous pancreaticobiliary junction) and inflammatory bowel disease are associated with carcinoma in gallbladders without stones (CAP 2025a). Pancreatobiliary maljunction-related carcinomas carry TP53 (50%), EGFR (20.6%), RB1 (17.6%) and ERBB2 (17.6%) mutations (Roa et al. 2022).
  • Molecular profile. TP53 is mutated in about 40% of gallbladder carcinomas. ERBB2, ERBB3, PIK3CA, CDKN2A/B, ARID1A, ARID2, SMAD4, ELF3 and KRAS are each altered in fewer than 25%. ERBB2 overexpression was found in 13% of 187 Chilean tumors, and 98.5% of 551 tumors were microsatellite stable (Roa et al. 2022).
  • Histologic types. About 95% of gallbladder cancers are epithelial and more than 90% are adenocarcinomas, mostly biliary type, with intestinal, squamous, adenosquamous, mucinous, poorly cohesive with or without signet-ring cells, neuroendocrine and undifferentiated carcinomas less often (Roa et al. 2022). In the 6th edition, "carcinoma with mesenchymal differentiation" replaces the 5th-edition term "carcinoma with sarcomatoid components" for some undifferentiated carcinomas at all digestive sites, and the undifferentiated carcinoma category is expanded to include SWI/SNF-deficient carcinoma (ARID1A, SMARCA2, SMARCA4 or SMARCB1) (Arends et al. 2026).
  • CAP histologic types. CAP Gallbladder 4.3.0.0 lists biliary-type, intestinal-type, mucinous, clear cell, poorly cohesive, signet-ring cell, adenosquamous and squamous carcinomas, MCN, ICPN or ICTN with associated invasive carcinoma, undifferentiated carcinoma, neuroendocrine carcinomas and MiNEN (CAP 2025a).
  • Grade. G1 has more than 95% glands, G2 50%–95% and G3 49% or less. Signet-ring cell carcinoma is G3 by convention. Undifferentiated carcinomas were G4 in the WHO 2010 classification, and AJCC 8th edition has no G4 (CAP 2025a).
  • ICPN-associated carcinoma. Invasive carcinomas with an ICPN component are diagnosed at earlier stages. When matched by T stage, 3-year survival was 60% with and 27% without an ICPN component, and 5-year survival did not differ (Roa et al. 2022).

Incidental gallbladder carcinoma, Rokitansky–Aschoff sinus involvement and cholecystectomy sampling

  • Incidental carcinoma. Incidental carcinoma forms 47%–60% of gallbladder cancers in low-incidence countries such as the United States and 35% in northern India. It is more likely with acute cholecystitis or empyema and is usually early stage (Roa et al. 2022). Port-site recurrence is reported in up to 17% (CAP 2025a).
  • Sampling. When dysplasia is found, multiple additional sections are examined to exclude invasion (CAP 2025a). Extensive, preferably total, sampling is needed before a carcinoma is staged pT1b because pT2 is often mis-staged as pT1 (Pehlivanoglu et al. 2023). Gallbladders are submitted entirely as routine practice in Chile and South Korea (DeSimone et al. 2021).
  • Early gallbladder carcinoma. In 190 early carcinomas (Tis, T1a and T1b) from fully sampled gallbladders, 60% were grossly inapparent and 5-year and 10-year survivals were 92.3% and 90.4%. Rokitansky–Aschoff sinus involvement (17.8%) was an independent adverse factor: 39% of patients with it and 4% without it died of disease (Roa et al. 2013).
  • pT1b frequency. Among 349 extensively sampled invasive carcinomas, only 5% were pT1b, most were smaller than 1 mm and 5-year disease-specific survival was 92% (Pehlivanoglu et al. 2023).
  • Rokitansky–Aschoff sinus involvement versus invasion. Connection of the involved invaginations to the luminal surface, admixed normal biliary epithelium, inspissated bile in long dilated spaces and absence of invasion between smooth muscle bundles favor noninvasive carcinoma in Rokitansky–Aschoff sinuses (CAP 2025a). Carcinoma in situ colonizing these sinuses mimics T2 carcinoma (DeSimone et al. 2021).
  • Re-resection. After incidental gallbladder carcinoma, a second operation with partial hepatectomy of segments IVB and V and regional lymphadenectomy is generally recommended for pT1b to pT3 tumors because the risk of residual disease rises with T category (Roa et al. 2022).

Gallbladder carcinoma staging and CAP reporting (AJCC 8th edition)

pT Definition Source
pTis Carcinoma in situ, typically reserved for high-grade dysplasia with complex (papillary or tubulopapillary) architecture, such as ICPN, confined by intact basement membrane; 'high-grade dysplasia' is the preferable term CAP 2025a
pT1a Invades lamina propria CAP 2025a
pT1b Invades the muscular layer CAP 2025a
pT2a Invades perimuscular connective tissue on the peritoneal side without serosal involvement CAP 2025a
pT2b Invades perimuscular connective tissue on the hepatic side without extension into the liver CAP 2025a
pT3 Perforates the serosa, directly invades the liver, or invades one other adjacent organ or structure (stomach, duodenum, colon, pancreas, omentum, extrahepatic bile ducts) CAP 2025a
pT4 Invades the main portal vein or hepatic artery, or two or more extrahepatic organs or structures CAP 2025a
pN1 / pN2 Metastasis in 1–3 / 4 or more regional nodes (common bile duct, hepatic artery, portal vein and cystic duct nodes) CAP 2025a
pM1 Distant metastasis, including celiac, superior mesenteric and peripancreatic nodes and discontinuous liver involvement CAP 2025a
  • T2b. Hepatic-side T2 tumors have a worse outcome than peritoneal-side tumors, and a tumor involving both sides is pT2b (CAP 2025a). In 316 centrally reviewed T2 carcinomas, 5-year overall survival was 45% (35%–55% by country) and 5-year disease-specific survival 50%–60% by country (DeSimone et al. 2021).
  • Nodes. At least 6 lymph nodes are recommended for staging, and immunohistochemistry for micrometastases is not used routinely (CAP 2025a; Roa et al. 2022).
  • Margins. R0 resection carries a 5-year survival advantage of 30% over R1 or R2 resection (CAP 2025a).
CAP Gallbladder 4.3.0.0 element Responses and rules Source
Procedure Simple cholecystectomy; radical cholecystectomy with liver resection and lymphadenectomy CAP 2025a
Tumor site Fundus, body, neck, cystic duct CAP 2025a
Histologic type and grade WHO types including ICPN or ICTN with invasive carcinoma; G1–G3 CAP 2025a
Tumor size Unifocal size; for multifocal invasion in ICN or MCN, largest focus, aggregate size and invasive percentage CAP 2025a
Tumor extent Lamina propria; muscular layer; perimuscular tissue on the peritoneal or hepatic side; serosa; liver; named adjacent organs; main portal vein; hepatic artery CAP 2025a
Lymphatic and vascular invasion, perineural invasion, treatment effect Required since version 4.3.0.0 CAP 2025a
Margins Cystic duct and liver parenchymal margins for invasive carcinoma; cystic duct margin for high-grade dysplasia CAP 2025a
Additional findings Dysplasia or adenoma, cholelithiasis, chronic or acute cholecystitis, intestinal metaplasia, diffuse calcification, primary sclerosing cholangitis CAP 2025a

Perihilar and distal extrahepatic cholangiocarcinoma

  • Terminology. Under WHO convention, as restated in the CAP 4.4.0.0 protocols, "cholangiocarcinoma" is reserved for intrahepatic carcinoma, and extrahepatic tumors are reported as adenocarcinoma, biliary type (extrahepatic cholangiocarcinoma) (CAP 2026b).
  • Risk settings. Primary sclerosing cholangitis, choledochal cyst, biliary stones, pancreatobiliary maljunction and low union of the common hepatic and cystic ducts are recorded as additional findings (CAP 2026b; CAP 2026c).
  • Perineural benign glands in PSC. Benign hyperplastic intramural glands adjacent to nerves occur in ducts affected by PSC, so perineural location is interpreted with caution (CAP 2026b).
  • Grade. Adenocarcinomas are G1 with more than 95% glands (less than 5% solid or cordlike growth), G2 with 50%–95% and G3 with less than 50%. Signet-ring cell carcinoma is G3 by convention (CAP 2026b).
  • Margins. Locoregional recurrence occurs in up to 59% of perihilar carcinomas, often from tumor at the proximal, distal or soft tissue margins and from longitudinal, perineural and lymphovascular spread. Negative margins raised 5-year survival from 10% to 30%. Frozen sections of duct margins are difficult because of reactive surface and intramural gland changes (CAP 2026b).
  • Synchronous gallbladder tumor. The gallbladder in a bile duct resection is examined because bile duct carcinoma can be associated with synchronous gallbladder carcinoma (CAP 2026b).
  • Prognosis by type. Intraductal neoplasms with invasion have a relatively favorable prognosis, and signet-ring cell carcinoma, poorly differentiated neuroendocrine carcinoma and undifferentiated carcinoma have a poorer prognosis (CAP 2026b).
Bismuth–Corlette type Definition Source
I Limited to the common hepatic duct below the confluence CAP 2026b
II Involves the confluence of the right and left hepatic ducts CAP 2026b
IIIa Type II plus extension into right second-order ducts CAP 2026b
IIIb Type II plus extension into left second-order ducts CAP 2026b
IV Extends into both right and left second-order ducts; worst outcome CAP 2026b
  • Bismuth series. Of 122 patients treated surgically for hilar cholangiocarcinoma, 23 underwent resection. Survival and freedom from recurrence were better with histologically free margins, and curative procedures were chosen by Bismuth type (local excision for type I, hepatectomy with segment 1 for types III and IV) (Bismuth et al. 1992).
Category Perihilar bile ducts (AJCC 8th edition) Distal bile duct (AJCC 8th edition) Source
pTis Carcinoma in situ or high-grade dysplasia, including BilIN-3 and intraductal neoplasms or MCN with high-grade dysplasia Carcinoma in situ or high-grade dysplasia, including BilIN-3 and MCN with high-grade dysplasia CAP 2026b; CAP 2026c
pT1 Confined to the bile duct, up to the muscle layer or fibrous tissue Invades the bile duct wall to a depth less than 5 mm CAP 2026b; CAP 2026c
pT2 pT2a beyond the duct wall into surrounding adipose tissue; pT2b into adjacent hepatic parenchyma Depth 5–12 mm CAP 2026b; CAP 2026c
pT3 Unilateral branches of the portal vein or hepatic artery Depth greater than 12 mm CAP 2026b; CAP 2026c
pT4 Main portal vein or its branches bilaterally, or the common hepatic artery, or unilateral second-order radicals with contralateral portal vein or hepatic artery involvement Celiac axis, superior mesenteric artery or common hepatic artery CAP 2026b; CAP 2026c
pN1 / pN2 1–3 / 4 or more positive nodes (hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal and portal vein nodes) 1–3 / 4 or more positive regional nodes (pancreatic head nodes) CAP 2026b; CAP 2026c
  • Depth measurement (distal). Depth is measured from the basement membrane of adjacent normal or dysplastic epithelium to the deepest invasion on oriented longitudinal sections. The 5-mm and 12-mm cutoffs stratify prognosis better than the anatomic level. Invasion of the pancreas, duodenum, gallbladder, colon, stomach or omentum does not change pT and is still reported (CAP 2026c).
  • Distal nodes. Regional nodes of the distal bile duct are those of the pancreatic head, and examination of at least 12 nodes is suggested (CAP 2026c).
  • Perihilar liver involvement. Direct extension into adjacent liver is pT2b, and discontinuous liver involvement is metastasis. Vascular pT3 and pT4 criteria are usually assessed by imaging (CAP 2026b).
  • Distal cholangiocarcinoma versus pancreatic ductal adenocarcinoma. Tumors of the intrapancreatic common bile duct can be hard to separate from pancreatic adenocarcinoma. Symmetric growth around the bile duct and adjacent BilIN favor a bile duct origin. Pancreatic and ampullary tumors are reported with separate protocols (CAP 2026c).
CAP 4.4.0.0 change (perihilar and distal protocols) Version 4.4.0.0 (September 2026) Version 4.3.0.0 (June 2025) Source
Histologic types Adds enteroblastic carcinoma, hepatoid carcinoma, micropapillary cholangiocarcinoma and IOPN with associated invasive carcinoma; optional IPN subtype (gastric, pancreatobiliary, intestinal, mixed) No enteroblastic, hepatoid, micropapillary or IOPN options CAP 2026b; CAP 2026c; CAP 2025d; CAP 2025e
Cover page IOPN without invasive carcinoma added to the lesions that do not require a synoptic report Distal protocol listed IPN and MCN without invasive carcinoma CAP 2026c; CAP 2025e
Tumor extent "No invasion" option names IPN and ITPN with high-grade dysplasia "No invasion (carcinoma in situ/high-grade dysplasia)" CAP 2026b; CAP 2026c; CAP 2025d; CAP 2025e
Additional findings Adds pancreatobiliary maljunction and low union of the common hepatic and cystic ducts Choledochal cyst, dysplasia, PSC and biliary stones CAP 2026b; CAP 2026c; CAP 2025d; CAP 2025e
Margin(s) involved question (perihilar) "High-grade intraepithelial neoplasia and/or high-grade dysplasia" "High-grade intraepithelial neoplasia" CAP 2026b

Choledochal cyst and pancreatobiliary maljunction

Todani type Definition Frequency Source
IA Cystic dilatation of the entire extrahepatic biliary tree Type I overall 50%–80% Miron et al. 2023
IB Segmental extrahepatic dilatation Within type I Miron et al. 2023
IC Fusiform dilatation of the entire extrahepatic tree with intrahepatic dilatation Within type I Miron et al. 2023
II Saccular diverticulum of the common bile duct 2%–3% Miron et al. 2023
III (choledochocele) Intramural dilatation of the distal common bile duct bulging into the duodenal wall 1.4%–4.5% Miron et al. 2023
IVA Intrahepatic and extrahepatic dilatation Type IV overall 12%–35% Miron et al. 2023
IVB Multiple extrahepatic dilatations only Within type IV Miron et al. 2023
V (Caroli disease) Single or multiple dilatations confined to intrahepatic ducts; Caroli syndrome adds congenital hepatic fibrosis About 20% Miron et al. 2023
  • Pancreatobiliary maljunction. Types IA, IC and IVA are usually associated with pancreatobiliary maljunction (Miron et al. 2023). Type III has the lowest malignancy rate and is associated with pancreas divisum, whereas the other types are associated with abnormal pancreatobiliary union (Govindarajan 2024).
  • Carcinoma risk. Choledochal cysts are precancerous, with malignancy rates of 2.5%–28% that rise with age, and 20%–25% are diagnosed in adulthood (Miron et al. 2023).
  • Pathology of resected cysts. Carcinomas in choledochal cysts are classified like gallbladder and bile duct carcinomas and staged with the perihilar or distal protocol. When dysplasia or carcinoma in situ is found, additional sections are examined to exclude invasion (CAP 2026b). BilIN of various grades was found in 15 resected pediatric choledochal cysts, 80% of them Todani type I (Gang et al. 2024).
  • Forme fruste. A "forme fruste" choledochal cyst is pancreatobiliary maljunction with little or no duct dilatation, with the same symptoms and a high risk of gallbladder cancer (Miron et al. 2023).

References

  1. Abbas SH, Ceresa CDL, Pollok JM. Steatotic Donor Transplant Livers: Preservation Strategies to Mitigate against Ischaemia-Reperfusion Injury. Int J Mol Sci. 2024;25(9). doi:10.3390/ijms25094648. PMID 38731866
  2. Adams PC, Bradley C, Henderson AR. Evaluation of the hepatic iron index as a diagnostic criterion for genetic hemochromatosis. J Lab Clin Med. 1997;130(5):509-14. doi:10.1016/s0022-2143(97)90127-x. PMID 9390638
  3. Adsay V, Jang KT, Roa JC, et al. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol. 2012;36(9):1279–1301. doi:10.1097/PAS.0b013e318262787c. PMID 22895264
  4. Ahuja A, Gautam N, Agarwal N. Clinico-pathological and immunohistochemical profile of plasma cell rich variants of chronic cholecystitis. Ann Diagn Pathol. 2026;83:152626. doi:10.1016/j.anndiagpath.2026.152626. PMID 41785606
  5. Akita M, Sawada R, Komatsu M, et al. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping. Hum Pathol. 2021;109:45–52. doi:10.1016/j.humpath.2020.12.005. PMID 33321161
  6. Al-Olayan HA. Cholesterolosis mimicking gallbladder adenomyomatosis on imaging in an asymptomatic patient with concurrent cholelithiasis: a case report. Int J Surg Case Rep. 2026;138(10):4145–4149. doi:10.1097/RC9.0000000000000908. PMID 42857779
  7. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748. doi:10.1038/s41375-022-01620-2. PMID 35732829
  8. Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun. 2023;7(6):e0150. doi:10.1097/HC9.0000000000000150. PMID 37184530
  9. AlQattan AS, AlSharit MA, AlQatari AA, et al. Ciliated hepatic foregut cyst: a case report and review of literature on a rare hepatic cystic lesion. Ann Med Surg (Lond). 2025;87(12):8953-8958. doi:10.1097/MS9.0000000000004098. PMID 41377347
  10. Amer S, Hajira A. A Comprehensive Review of Progressive Familial Intrahepatic Cholestasis (PFIC): Genetic Disorders of Hepatocanalicular Transporters. Gastroenterology Res. 2014;7(2):39-43. doi:10.14740/gr609e. PMID 27785268
  11. Angelico R, Sensi B, Manzia TM, et al. Chronic rejection after liver transplantation: Opening the Pandora's box. World J Gastroenterol. 2021;27(45):7771-7783. doi:10.3748/wjg.v27.i45.7771. PMID 34963740
  12. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775–784. doi:10.1002/gcc.22073. PMID 23737213
  13. Arends MJ, Esposito I, Gill AJ, et al. Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system. Histopathology. 2026;88(7):1295–1314. doi:10.1111/his.70116. PMID 41724188 (summarizes the WHO Classification of Tumours, Digestive System Tumours, 6th edition)
  14. Arienzo F, Vallese S, Giovannoni I, et al. Pediatric Cholestasis: A Practical Approach to Histological Diagnosis. Diagnostics (Basel). 2026;16(6). doi:10.3390/diagnostics16060878. PMID 41897610
  15. Badwei N. Hepatic allograft rejection after liver transplantation: Clinicopathological debates! ILIVER. 2023;2(2):116-121. doi:10.1016/j.iliver.2023.05.003. PMID 40636567
  16. Barisic-Jaman M, Milosevic M, Pastrovic F, et al. Porto-sinusoidal vascular disease: a new definition of an old clinical entity. Clin Exp Hepatol. 2023;9(4):297-306. doi:10.5114/ceh.2023.133107. PMID 38774199
  17. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6(1):24-9. doi:10.1002/hep.1840060106. PMID 3943787
  18. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409-17. doi:10.1097/00000478-199512000-00007. PMID 7503362
  19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93. doi:10.1002/hep.510240201. PMID 8690394
  20. Bellamy C, Mescoli C, Asadi K, et al. Banff liver allograft pathology group: late rejection activity is insufficiently represented in the current diagnostic framework-rationale and goals for reveision [sic]. Am J Transplant. 2026;. doi:10.1016/j.ajt.2026.08.004. PMID 42600694
  21. Bernstein DL, Hülkova H, Bialer MG, et al. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58(6):1230-43. doi:10.1016/j.jhep.2013.02.014. PMID 23485521
  22. Bioulac-Sage P, Laumonier H, Rullier A, et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int. 2009;29(3):459–465. doi:10.1111/j.1478-3231.2008.01849.x. PMID 18803590
  23. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46(3):740–748. doi:10.1002/hep.21743. PMID 17663417
  24. Bishop KC, Perrino CM, Ruzinova MB, et al. Ciliated hepatic foregut cyst: a report of 6 cases and a review of the English literature. Diagn Pathol. 2015;10:81. doi:10.1186/s13000-015-0321-1. PMID 26122082
  25. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31–38. doi:10.1097/00000658-199201000-00005. PMID 1309988
  26. Botezatu C, Chitca DD, Popescu V, et al. Cholecystectomy in the Context of Cirrhosis, Sclero-Atrophic Cholecystitis, and Gangrenous Cholecystitis: A Literature Review. Medicina (Kaunas). 2025;61(8). doi:10.3390/medicina61081314. PMID 40870359
  27. Boyd A, Cain O, Chauhan A, et al. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol. 2020;11(1):40-47. doi:10.1136/flgastro-2018-101139. PMID 31885839
  28. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113–126. doi:10.1002/hep.29789. PMID 29360137
  29. Bugayong ML, Koo C. Vanishing bile duct syndrome in relapsed classic Hodgkin lymphoma: treatment considerations and outcomes. BMJ Case Rep. 2026;19(6). doi:10.1136/bcr-2025-271364. PMID 42336489
  30. Cai E, Wei H, Shi Y, et al. Clinicopathological features and diagnostic challenges of hepatic epithelioid angiomyolipoma: a retrospective analysis of 27 cases. Front Med (Lausanne). 2026;13:1729519. doi:10.3389/fmed.2026.1729519. PMID 41737406
  31. Cataldo I, Sarcognato S, Sacchi D, et al. Pathology of non-alcoholic fatty liver disease. Pathologica. 2021;113(3):194-202. doi:10.32074/1591-951X-242. PMID 34294937
  32. Ceri A, Busse-Coté A, Weil D, et al. Non-infectious Hepatic Cystic Lesions: A Narrative Review. Curr Med Imaging. 2025;21:e15734056358195. doi:10.2174/0115734056358195250714053120. PMID 40968424
  33. Cesar Machado MC, Filho RK, El Bacha IAH, et al. Post-COVID-19 Secondary Sclerosing Cholangitis: A Rare but Severe Condition with no Treatment Besides Liver Transplantation. Am J Case Rep. 2022;23:e936250. doi:10.12659/AJCR.936250. PMID 35978523
  34. Chan YJ, Lin SP, Chen BF. Glycogen storage disease type IV: a case report. Zhonghua Yi Xue Za Zhi (Taipei). 1999;62(10):743-7. PMID 10533307
  35. Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-1378. doi:10.1136/gutjnl-2018-317993. PMID 31154395
  36. Chen D, Li Z, Zhu W, et al. Stromal morphological changes and immunophenotypic features of precancerous lesions and hepatocellular carcinoma. J Clin Pathol. 2019;72(4):295–303. doi:10.1136/jclinpath-2018-205611. PMID 30610005
  37. Cheng K, Rosenthal P. Diagnosis and management of Alagille and progressive familial intrahepatic cholestasis. Hepatol Commun. 2023;7(12). doi:10.1097/HC9.0000000000000314. PMID 38055640
  38. Cho SJ, Ranganathan S, Alaggio R, et al. Consensus classification of pediatric hepatocellular tumors: a report from the Children's Hepatic tumors International Collaboration (CHIC). Pediatr Blood Cancer. 2023:e30505. doi:10.1002/pbc.30505. PMID 37384428
  39. Choi JH, Thung SN. Pathology and diagnostic approaches to well-differentiated hepatocellular lesions: a narrative review. J Yeungnam Med Sci. 2025;42:5. doi:10.12701/jyms.2024.00766. PMID 39442859
  40. Choi JH, Thung SN. Recent advances in pathology of intrahepatic cholangiocarcinoma. Cancers (Basel). 2024;16(8):1537. doi:10.3390/cancers16081537. PMID 38672619
  41. Choi JH. Benign Biliary Tumors and Precursor Neoplasms: An Updated Clinicopathological and Molecular Review Based on the 2026 WHO Classification. Biomedicines. 2026;14(7). doi:10.3390/biomedicines14071548. PMID 42512021
  42. Choi JH. Histological and Molecular Evaluation of Liver Biopsies: A Practical and Updated Review. Int J Mol Sci. 2025;26(16). doi:10.3390/ijms26167729. PMID 40869049
  43. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med. 2023;23(2):273-285. doi:10.1007/s10238-022-00799-z. PMID 35192111
  44. Chua TH, Punjabi LS, Khor LY. Tissue Pathogens and Cancers: A Review of Commonly Seen Manifestations in Histo- and Cytopathology. Pathogens. 2021;10(11). doi:10.3390/pathogens10111410. PMID 34832566
  45. College of American Pathologists. Protocol for the examination of resection specimens from patients with hepatoblastoma, version 5.0.0.1. Posted June 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). Cited as CAP 2025b.
  46. College of American Pathologists. Protocol for the examination of specimens from patients with hepatocellular carcinoma, version 4.3.0.0. Posted June 2022. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (accessed 2026-11-17). Cited as CAP 2022.
  47. Conover KR, Saul S, Chapin CA, et al. Defining a Histologic Scoring System for Gestational Alloimmune Liver Disease. Am J Surg Pathol. 2025;49(12):1326-1333. doi:10.1097/PAS.0000000000002454. PMID 40698832
  48. Cooney J, Siakavellas SI, Chiodini PL, et al. Recent advances in the diagnosis and management of amoebiasis. Frontline Gastroenterol. 2025;16(1):e102554. doi:10.1136/flgastro-2023-102554. PMID 41809248
  49. Corbett CE, Duarte MI, Bustamante SE. Regression of diffuse intralobular liver fibrosis associated with visceral leishmaniasis. Am J Trop Med Hyg. 1993;49(5):616-24. doi:10.4269/ajtmh.1993.49.616. PMID 8250102
  50. Cotler SJ, Bronner MP, Press RD, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol. 1998;29(2):257-62. doi:10.1016/s0168-8278(98)80011-1. PMID 9722207
  51. Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am. 1992;21(1):163-77. PMID 1568771
  52. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150-7. PMID 1988336
  53. De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4(5):399-411. doi:10.1016/S2468-1253(19)30047-0. PMID 30957754
  54. de Ridder J, de Wilt JH, Simmer F, et al. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget. 2016;7(34):55368–55376. doi:10.18632/oncotarget.10552. PMID 27421135
  55. Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016;16(10):2816-2835. doi:10.1111/ajt.13909. PMID 27273869
  56. DeSimone MS, Goodman M, Pehlivanoglu B, et al. T2 gallbladder cancer shows substantial survival variation between continents and this is not due to histopathologic criteria or pathologic sampling differences. Virchows Arch. 2021;478(5):875–884. doi:10.1007/s00428-020-02968-5. PMID 33411027
  57. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45(3):725–734. doi:10.1002/hep.21531. PMID 17326147
  58. Dong L, Xu J, Wang K, et al. The diagnostic dilemma of sinusoidal-type primary hepatic angiosarcoma: a case report and literature review. Front Oncol. 2025;15:1704861. doi:10.3389/fonc.2025.1704861. PMID 41367857
  59. Doyle LA, Fletcher CD, Hornick JL. Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am J Surg Pathol. 2016;40(1):94–102. doi:10.1097/PAS.0000000000000511. PMID 26414223
  60. Dudina M, Olesen SS, Søgaard KK, et al. Pyogenic liver abscess in the North Denmark Region - a population-based cohort study (2010-2022). Eur J Clin Microbiol Infect Dis. 2026;45(1):287-296. doi:10.1007/s10096-025-05307-1. PMID 41105331
  61. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–653. doi:10.1002/gcc.20886. PMID 21584898
  62. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033. PMID 35662478
  63. European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson's disease. J Hepatol. 2025;82(4):690-728. doi:10.1016/j.jhep.2024.11.007. PMID 40089450
  64. Everett J, Srivastava A, Misdraji J. Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis. Am J Surg Pathol. 2017;41(1):134-137. doi:10.1097/PAS.0000000000000759. PMID 27792061
  65. Fernández J, Bassegoda O, Toapanta D, et al. Acute liver failure: A practical update. JHEP Rep. 2024;6(9):101131. doi:10.1016/j.jhepr.2024.101131. PMID 39170946
  66. Fındık DG, Şahin E, Türelik Ö. Clinicopathological evaluation of cholesterolosis in cholecystitis: histopathological patterns and metabolic correlates. J Clin Med. 2025;14(18):6500. doi:10.3390/jcm14186500. PMID 41010704
  67. Fontana RJ, Liou I, Reuben A, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77(3):1036-1065. doi:10.1002/hep.32689. PMID 35899384
  68. Frey H, Barth TFE. Macroscopic and Microscopic Aspects of Echinococcus multilocularis and Echinococcus granulosus in Humans: A Guideline for Pathologists. Visc Med. 2025;42(2):85-91. doi:10.1159/000548706. PMID 41394247
  69. Fromme M, Klebingat F, Ellis P, et al. Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine. Hepatol Commun. 2025;9(5). doi:10.1097/HC9.0000000000000699. PMID 40227077
  70. Găman MA, Cozma MA, Manan MR, et al. Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature. World J Clin Oncol. 2023;14(3):99-116. doi:10.5306/wjco.v14.i3.99. PMID 37009527
  71. Gambella A, Mastracci L, Caporalini C, et al. Not only a small liver - The pathologist's perspective in the pediatric liver transplant setting. Pathologica. 2022;114(1):89-103. doi:10.32074/1591-951X-753. PMID 35212319
  72. Gang S, Kwon H, Song IH, et al. Clinical implications of pediatric biliary intraepithelial neoplasia diagnosed from a choledochal cyst specimen. World J Surg Oncol. 2024;22(1):105. doi:10.1186/s12957-024-03384-8. PMID 38643155
  73. Garzón G LN, Jaramillo B LE, Valero H JJ, et al. Eosinophilic cholecystitis in children: case series. J Pediatr Surg. 2021;56(3):550–552. doi:10.1016/j.jpedsurg.2020.05.039. PMID 32624207
  74. González IA, Torbenson M, Sharifai N, et al. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Hum Pathol. 2023;138:24–33. doi:10.1016/j.humpath.2023.05.010. PMID 37245629
  75. Govindarajan KK. Current status of the biliary tract malformation. World J Clin Pediatr. 2024;13(2):91268. doi:10.5409/wjcp.v13.i2.91268. PMID 38948002
  76. Goyal S, Jain N, Bhatt VR, et al. Xanthogranulomatous cholecystitis with histologic features suggestive of IgG4 related cholecystitis: a morphologic overlap with IgG4 related disease. Ann Diagn Pathol. 2023;66:152177. doi:10.1016/j.anndiagpath.2023.152177. PMID 37423115
  77. Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28(6):822–829. doi:10.1038/modpathol.2015.4. PMID 25698061
  78. Green M, Michaels MG, Gross T, et al. The IPTA Nashville Consensus Conference on Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation in Children: Updates on Classification and Prevention-2026. Pediatr Transplant. 2026;30(9):e70445. doi:10.1111/petr.70445. PMID 42720126
  79. Hai T, Zou LQ. Clinical management and susceptibility of primary hepatic lymphoma: a cases-based retrospective study. World J Clin Cases. 2021;9(31):9417–9430. doi:10.12998/wjcc.v9.i31.9417. PMID 34877277
  80. Handra-Luca A, Ben Romdhane HM, Hong SM. Luschka ducts of the gallbladder in adults: case series report and review of the medical literature. Int J Surg Pathol. 2020;28(5):482–489. doi:10.1177/1066896920901334. PMID 31983263
  81. Hatanaka S, Yamada Y, Kubo T, et al. Ischemia-induced intestinal de-epithelization and consequent cholangitis lenta after usage of extracorporeal membrane oxygenation in COVID-19 patients: an autopsy series. Oxf Med Case Reports. 2023;2023(4):omad031. doi:10.1093/omcr/omad031. PMID 37091687
  82. Helali N, Gagnon H, Álvarez F. Gestational alloimmune liver disease reconsidered: Advocating for a new nomenclature and enhanced diagnosis accuracy. World J Clin Pediatr. 2025;14(4):106219. doi:10.5409/wjcp.v14.i4.106219. PMID 41255696
  83. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169-76. doi:10.1002/hep.22322. PMID 18537184
  84. Hiramatsu K, Aoyama H, Zen Y, et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology. 2006;49(5):466-78. doi:10.1111/j.1365-2559.2006.02537.x. PMID 17064292
  85. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010–1014. doi:10.1126/science.1249484. PMID 24578576
  86. Horani O, Mohiuddin I, Ahmed Z, et al. Liver Biopsy During Pregnancy: A Review. Cureus. 2025;17(12):e98400. doi:10.7759/cureus.98400. PMID 41487749
  87. Horst LJ, Zimmermann K, Lutz J, et al. Insights Into Hepatic Sarcoidosis: Analysis of Histological Patterns, Hepatic Complications and Therapeutic Approaches. Liver Int. 2025;45(3):e70037. doi:10.1111/liv.70037. PMID 39969799
  88. Hu S, Allende DS. A rational approach to the diagnosis of liver metastases. Mod Pathol. 2025;38(12):100903. doi:10.1016/j.modpat.2025.100903. PMID 41046012
  89. Huang J, Lin S, Wan B, et al. A Systematic Literature Review of Syphilitic Hepatitis in Adults. J Clin Transl Hepatol. 2018;6(3):306-309. doi:10.14218/JCTH.2018.00003. PMID 30271743
  90. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med. 2000;343(3):185–189. doi:10.1056/NEJM200007203430305. PMID 10900278
  91. Ichikawa T, Sano K, Morisaka H. Diagnosis of pathologically early HCC with EOB-MRI: experiences and current consensus. Liver Cancer. 2014;3(2):97–107. doi:10.1159/000343865. PMID 24945000
  92. Jarasvaraparn C, González IA, Tolliver KM, et al. Characteristics, clinical laboratory, histopathology, and outcomes of glycogenic hepatopathy in children. JPGN Rep. 2024;5(2):119-125. doi:10.1002/jpr3.12046. PMID 38756113
  93. Jia C, Liu G, Wang X, et al. Hepatic sclerosed hemangioma and sclerosing cavernous hemangioma: a radiological study. Jpn J Radiol. 2021;39(11):1059–1068. doi:10.1007/s11604-021-01139-z. PMID 34041675
  94. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811-7. doi:10.1056/NEJMoa0706992. PMID 18287603
  95. Kamisawa T, Nakazawa T, Tazuma S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2019;26(1):9-42. doi:10.1002/jhbp.596. PMID 30575336
  96. Kang HJ, Hong SA, Oh SH, et al. Progressive Familial Intrahepatic Cholestasis in Korea: A Clinicopathological Study of Five Patients. J Pathol Transl Med. 2019;53(4):253-260. doi:10.4132/jptm.2019.05.03. PMID 31091858
  97. Karakoyun M, Barut D, Kunay B, et al. Biopsy-Proven Intestinal Failure-Associated Liver Disease in Pediatric Short Bowel Syndrome: Histopathological Findings and Clinical Outcomes. Diagnostics (Basel). 2026;16(14). doi:10.3390/diagnostics16142205. PMID 42510069
  98. Kaur M, Garg A, Sharma R. Ectopic pancreatic tissue in the gallbladder. Ochsner J. 2024;24(3):204–206. doi:10.31486/toj.23.0120. PMID 39280868
  99. Kavčič A, Homan M, Živanović M, et al. Compound Heterozygote Mutation in the SMPD1 Gene Leading to Nieman-Pick Disease Type A. Am J Case Rep. 2022;23:e937220. doi:10.12659/AJCR.937220. PMID 36333862
  100. Khalifa A, Andreias L, Velpari S. Adenovirus Hepatitis in Immunocompetent Adults. J Investig Med High Impact Case Rep. 2022;10:23247096221079192. doi:10.1177/23247096221079192. PMID 35225036
  101. Khan S, Saxena R. Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review. Adv Anat Pathol. 2021;28(6):408-414. doi:10.1097/PAP.0000000000000312. PMID 34326286
  102. Kim JH, Jeong IH, Han JH, et al. Clinical/pathological analysis of gallbladder adenomyomatosis; type and pathogenesis. Hepatogastroenterology. 2010;57(99-100):420–425. PMID 20698201
  103. Kim SJ, Kim JH, Han SY, et al. Recurrent hepatic alveolar echinococcosis: report of the first case in Korea with unproven infection route. Korean J Parasitol. 2011;49(4):413-8. doi:10.3347/kjp.2011.49.4.413. PMID 22355210
  104. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi:10.1002/hep.20701. PMID 15915461
  105. Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661-70. doi:10.1002/hep.26709. PMID 24037963
  106. Koga S, Ozcelik Y, Wang L, et al. Histologic Clues Favoring Cytomegalovirus Hepatitis in Liver Allograft Biopsies With Overlapping Rejection-Type Injury. Int J Surg Pathol. 2026;:10668969261476070. doi:10.1177/10668969261476070. PMID 42762191
  107. Kong XF, Zhang XX, Yu YY, et al. No mutation was found in the alpha-subunit of the mitochondrial tri-functional protein in one patient with severe acute fatty liver of pregnancy and her relatives. J Gastroenterol Hepatol. 2007;22(12):2107-11. doi:10.1111/j.1440-1746.2006.04682.x. PMID 18031367
  108. Kowdley KV, Trainer TD, Saltzman JR, et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. Gastroenterology. 1997;113(4):1270-7. doi:10.1053/gast.1997.v113.pm9322522. PMID 9322522
  109. Kulkarni A, Chen T, Sidransky E, et al. Advancements in Viral Gene Therapy for Gaucher Disease. Genes (Basel). 2024;15(3). doi:10.3390/genes15030364. PMID 38540423
  110. Kumar R, Patel R, Priyadarshi RN, et al. Amebic liver abscess: An update. World J Hepatol. 2024;16(3):316-330. doi:10.4254/wjh.v16.i3.316. PMID 38577528
  111. La QD, Baloch A, Ayub M, et al. Symptomatic gallbladder duplication with mucocele and calculi: an anatomic variant diagnosed by CT. Cureus. 2025;17(7):e87782. doi:10.7759/cureus.87782. PMID 40799895
  112. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024. doi:10.1038/nrdp.2016.24. PMID 27121416
  113. Lardière-Deguelte S, Ragot E, Amroun K, et al. Hepatic abscess: Diagnosis and management. J Visc Surg. 2015;152(4):231-43. doi:10.1016/j.jviscsurg.2015.01.013. PMID 25770745
  114. Lee M, Agostini-Vulaj D, Gonzalez RS. Evaluation of histologic changes in the livers of patients with early and late hepatic artery thrombosis. Hum Pathol. 2019;90:8-13. doi:10.1016/j.humpath.2019.04.019. PMID 31075300
  115. Lee M, Jang JJ, Kim YS, et al. Clinicopathologic features of q Fever patients with acute hepatitis. Korean J Pathol. 2012;46(1):10-4. doi:10.4132/KoreanJPathol.2012.46.1.10. PMID 23109972
  116. Leow WQ, Chan AW, Mendoza PGL, et al. Non-alcoholic fatty liver disease: the pathologist's perspective. Clin Mol Hepatol. 2023;29(Suppl):S302-S318. doi:10.3350/cmh.2022.0329. PMID 36384146
  117. Li CX, Zhang L, Wang P, et al. Clinicopathological diagnosis and treatment of juvenile hemochromatosis. Chin Med J (Engl). 2019;132(24):3018-3020. doi:10.1097/CM9.0000000000000547. PMID 31809314
  118. Li P, Zhang D, Zhou J, et al. Hepatic involvement by T-cell neoplasms: a clinicopathologic study of 40 cases. Hum Pathol. 2020;106:1-12. doi:10.1016/j.humpath.2020.09.007. PMID 33010300
  119. Limia ME, Liu XL, Yu J, et al. Primary Non-Function of Hepatic Allograft With Preexisting Microvesicular Steatosis/Foamy Degeneration and Mild Large-Droplet Macrovesicular Steatosis. Gastroenterology Res. 2024;17(1):37-40. doi:10.14740/gr1687. PMID 38463149
  120. Lipiński P, Tylki-Szymańska A. The Liver and Lysosomal Storage Diseases: From Pathophysiology to Clinical Presentation, Diagnostics, and Treatment. Diagnostics (Basel). 2024;14(12). doi:10.3390/diagnostics14121299. PMID 38928715
  121. Llovet LP, Sciarrone S, Rodríguez-Tajes S, et al. Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation. Gastroenterol Hepatol. 2020;43(1):14-21. doi:10.1016/j.gastrohep.2019.07.006. PMID 31495536
  122. Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017;23(4):302-307. doi:10.3350/cmh.2017.0078. PMID 29281870
  123. Loddenkemper C, Longerich T, Hummel M, et al. Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. Virchows Arch. 2007;450(5):493-502. doi:10.1007/s00428-007-0384-9. PMID 17431676
  124. Lohse AW, Sebode M, Bhathal PS, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology. Liver Int. 2022;42(5):1058-1069. doi:10.1111/liv.15217. PMID 35230735
  125. López-Terrada D, Alaggio R, de Dávila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27(3):472–491. doi:10.1038/modpathol.2013.80. PMID 24008558
  126. López-Terrada D, Stahlschmidt J, Pérez-Atayde AR. Update on pediatric primary liver tumors. Virchows Arch. 2025;486(1):23–47. doi:10.1007/s00428-024-03985-4. PMID 39836187
  127. Malcolm P, Dalton H, Hussaini HS, et al. The histology of acute autochthonous hepatitis E virus infection. Histopathology. 2007;51(2):190-4. doi:10.1111/j.1365-2559.2007.02756.x. PMID 17650215
  128. Martins-Filho SN, Putra J. Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review. Hepat Oncol. 2020;7(2):HEP19. doi:10.2217/hep-2020-0002. PMID 32647564
  129. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM199603143341104. PMID 8594428
  130. Menon J, Vij M, Sachan D, et al. Pediatric metabolic liver diseases: Evolving role of liver transplantation. World J Transplant. 2021;11(6):161-179. doi:10.5500/wjt.v11.i6.161. PMID 34164292
  131. Mermutluoğlu Ç, Dayan S, Demir Y, et al. Frequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta. Viruses. 2026;18(10). doi:10.3390/v18101105. PMID 42944025
  132. Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2017;18(1):122–131. doi:10.1016/S1470-2045(16)30598-8. PMID 27884679
  133. Miao KH, Miao JH, Rosberger S, et al. Advances in imaging and diagnosis of emphysematous cholecystitis. Healthcare (Basel). 2026;14(5):617. doi:10.3390/healthcare14050617. PMID 41827571
  134. Mikadze I, Saribekovi E, Pachkoria E, et al. Clinically Silent Presentation of Acalculous Gangrenous Cholecystitis: A Case Report. Cureus. 2026;18(7):e112491. doi:10.7759/cureus.112491. PMID 42582451
  135. Miron A, Popa LG, Toma EA, et al. The curious case of the choledochal cyst: revisiting the Todani classification: case report and review of the literature. Diagnostics (Basel). 2023;13(6):1059. doi:10.3390/diagnostics13061059. PMID 36980367
  136. Misra S, Badwal S, Dhawan S, et al. Explant pathology in Biliary Atresia post Kasai procedure: a tale of two livers. Autops Case Rep. 2024;14:e2024521. doi:10.4322/acr.2024.521. PMID 39494155
  137. Mitra S, Hanumanthappa MK, Sarkar S, et al. Epstein Barr Virus-Related Acute Liver Failure and Hemophagocytosis in an Immunocompetent Individual: An Autopsy Report. Int J Surg Pathol. 2024;32(4):838-844. doi:10.1177/10668969231195068. PMID 37723947
  138. Mo JQ, Dimashkieh HH, Bove KE. GLUT1 endothelial reactivity distinguishes hepatic infantile hemangioma from congenital hepatic vascular malformation with associated capillary proliferation. Hum Pathol. 2004;35(2):200–209. doi:10.1016/j.humpath.2003.09.017. PMID 14991538
  139. Moral K, Simsek B, Tomar VB, et al. Comparison of the recommendation of international autoimmune hepatitis pathology group 2022 and the simplified criteria for autoimmune hepatitis 2008: A preliminary study. Hepatol Forum. 2024;5(3):100-105. doi:10.14744/hf.2023.2023.0061. PMID 39006139
  140. Moreno-León C, Aguayo F. Cooperation Between Aflatoxin-Induced p53 Aberrations and Hepatitis B Virus in Hepatocellular Carcinoma. J Xenobiot. 2025;15(4). doi:10.3390/jox15040096. PMID 40863326
  141. Mukhopadhya A, Ramakrishna B, Richard V, et al. Liver histology and immunohistochemical findings in asymptomatic Indians with incidental detection of hepatitis B virus infection. Indian J Gastroenterol. 2006;25(3):128-31. PMID 16877824
  142. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975. PMID 31433515 (summarizes the WHO Classification of Tumours, Digestive System Tumours, 5th edition)
  143. Nakanuma Y, Sato Y, Kakuda Y, et al. Interobserver agreement of pathologic classification and grading of tumoral intraductal pre-invasive neoplasms of the bile duct. Ann Diagn Pathol. 2024;69:152247. doi:10.1016/j.anndiagpath.2023.152247. PMID 38128439
  144. Nakazawa T, Kamisawa T, Okazaki K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012). J Hepatobiliary Pancreat Sci. 2021;28(3):235-242. doi:10.1002/jhbp.913. PMID 33586343
  145. Nasir A, Lehrke HD, Mounajjed T, et al. Albumin in situ hybridization can be positive in adenocarcinomas and other tumors from diverse sites. Am J Clin Pathol. 2019;152(2):190–199. doi:10.1093/ajcp/aqz032. PMID 31107526
  146. Nault JC, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152(4):880–894.e6. doi:10.1053/j.gastro.2016.11.042. PMID 27939373
  147. Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013;4:2218. doi:10.1038/ncomms3218. PMID 23887712
  148. Nguyen TB, Roncalli M, Di Tommaso L, et al. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Mod Pathol. 2016;29(3):283-92. doi:10.1038/modpathol.2015.162. PMID 26769138
  149. Orosz L, Sárvári KP, Dernovics Á, et al. Pathogenesis and clinical features of severe hepatitis E virus infection. World J Virol. 2024;13(2):91580. doi:10.5501/wjv.v13.i2.91580. PMID 38984076
  150. Ourfali MB, Hirsch D, Scranton M, et al. Post-transplant liver biopsies: a concise and practical approach for beginners. J Pathol Transl Med. 2025;59(1):1-10. doi:10.4132/jptm.2024.11.15. PMID 39815741
  151. Pahlavan PS. Recommended histopathologic features to evaluate on liver core biopsies for donor liver transplantation. Clin Transplant Res. 2025;39(4):269-272. doi:10.4285/ctr.25.0020. PMID 41030140
  152. Panther E, Blum HE. [Liver diseases in pregnancy]. Dtsch Med Wochenschr. 2008;133(44):2283-7. doi:10.1055/s-0028-1091273. PMID 18946855
  153. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol. 1998;22(6):656–662. doi:10.1097/00000478-199806000-00002. PMID 9630172
  154. Patel S, Roa JC, Tapia O, et al. Hyalinizing cholecystitis and associated carcinomas: clinicopathologic analysis of a distinctive variant of cholecystitis with porcelain-like features and accompanying diagnostically challenging carcinomas. Am J Surg Pathol. 2011;35(8):1104–1113. doi:10.1097/PAS.0b013e31822179cc. PMID 21716080
  155. Pehlivanoglu B, Akkas G, Memis B, et al. Reappraisal of T1b gallbladder cancer (GBC): clinicopathologic analysis of 473 in situ and invasive GBCs and critical review of the literature highlights its rarity, and that it has a very good prognosis. Virchows Arch. 2023;482(2):311–323. doi:10.1007/s00428-022-03482-6. PMID 36580138
  156. Pehlivanoglu B. Intracholecystic tubular nonmucinous neoplasm of the gallbladder. Arch Pathol Lab Med. 2026. doi:10.5858/arpa.2025-0522-RA. PMID 42307525
  157. Peron JM, Danjoux M, Kamar N, et al. Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Arch. 2007;450(4):405-10. doi:10.1007/s00428-007-0382-y. PMID 17333266
  158. Pestana I, Pedro J, Simões C, et al. Transjugular Liver Biopsy: The Key to a Rare Etiology of Cholestatic Hepatitis after Bone Marrow Transplantation. GE Port J Gastroenterol. 2024;31(6):437-442. doi:10.1159/000536535. PMID 39633904
  159. Philips CA. A comprehensive review of diagnosis and management of alcohol-associated hepatitis. SAGE Open Med. 2024;12:20503121241297000. doi:10.1177/20503121241297000. PMID 39526098
  160. Poetter-Lang S, Ba-Ssalamah A, Bastati N, et al. Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course. Br J Radiol. 2024;97(1163):1740–1754. doi:10.1093/bjr/tqae180. PMID 39235933
  161. Popper H, Thomas LB, Telles NC, et al. Development of hepatic angiosarcoma in man induced by vinyl chloride, thorotrast, and arsenic. Comparison with cases of unknown etiology. Am J Pathol. 1978;92(2):349–376. PMID 567014
  162. Putra J, Ornvold K. Undifferentiated embryonal sarcoma of the liver: a concise review. Arch Pathol Lab Med. 2015;139(2):269–273. doi:10.5858/arpa.2013-0463-RS. PMID 25611111
  163. Quaglia A. Histopathology of Budd-Chiari Syndrome. Diagnostics (Basel). 2023;13(15). doi:10.3390/diagnostics13152487. PMID 37568849
  164. Quigley B, Reid MD, Pehlivanoglu B, et al. Hepatobiliary mucinous cystic neoplasms with ovarian type stroma (so-called "hepatobiliary cystadenoma/cystadenocarcinoma"): clinicopathologic analysis of 36 cases illustrates rarity of carcinomatous change. Am J Surg Pathol. 2018;42(1):95–102. doi:10.1097/PAS.0000000000000963. PMID 29016404
  165. Ren X, Jin X, Liu L, et al. IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse. Front Med (Lausanne). 2026;13:1732637. doi:10.3389/fmed.2026.1732637. PMID 41728618
  166. Rhee H, Park YN. Comprehensive radiopathological and molecular review of hepatocellular carcinoma: expanding on the World Health Organization, 6th edition. Clin Mol Hepatol. 2026;32(4):e2026.0431. doi:10.3350/cmh.2026.0431. PMID 42576691
  167. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520. PMID 37363821
  168. Roa JC, García P, Kapoor VK, et al. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69. doi:10.1038/s41572-022-00398-y. PMID 36302789
  169. Roa JC, Tapia O, Manterola C, et al. Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor. Virchows Arch. 2013;463(5):651–661. doi:10.1007/s00428-013-1478-1. PMID 24022828
  170. Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol. 2011;24(3):390–395. doi:10.1038/modpathol.2010.207. PMID 21113139
  171. Saeed O, Panarelli N, Umrau K, et al. The Histopathologic Features of Sickle Cell Hepatopathy: A Multi-Institutional Study. Am J Clin Pathol. 2022;157(1):73-81. doi:10.1093/ajcp/aqab096. PMID 34463318
  172. Saffioti F, Mavroeidis VK. Primary sclerosing cholangitis and cholangiocarcinoma: the 2023 practice guidance and future perspectives. Hepatobiliary Surg Nutr. 2024;13(1):172-175. doi:10.21037/hbsn-23-621. PMID 38322224
  173. Saka B, Memis B, Seven IE, et al. Follicular cholecystitis: reappraisal of incidence, definition, and clinicopathologic associations in an analysis of 2550 cholecystectomies. Int J Surg Pathol. 2020;28(8):826–834. doi:10.1177/1066896920924079. PMID 32423360
  174. Sakhuja P, Goyal S. Autoimmune Hepatitis: From Evolution to Current Status-A Pathologist's Perspective. Diagnostics (Basel). 2024;14(2). doi:10.3390/diagnostics14020210. PMID 38248086
  175. Sala M, Gonzales D, Leste-Lasserre T, et al. ASS1 overexpression: a hallmark of sonic hedgehog hepatocellular adenomas; recommendations for clinical practice. Hepatol Commun. 2020;4(6):809–824. doi:10.1002/hep4.1514. PMID 32490318
  176. Saragò M, Fiore D, De Rosa S, et al. Acute acalculous cholecystitis and cardiovascular disease, which came first? After two hundred years still the classic chicken and eggs debate: a review of literature. Ann Med Surg (Lond). 2022;78:103668. doi:10.1016/j.amsu.2022.103668. PMID 35734727
  177. Sarcognato S, Sacchi D, Grillo F, et al. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica. 2021;113(3):170-184. doi:10.32074/1591-951X-245. PMID 34294935
  178. Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100(6):1377–1386. doi:10.1097/00006534-199711000-00001. PMID 9385948
  179. Sasaki M, Sato Y, Nakanuma Y. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components. Histopathology. 2023;83(2):298–309. doi:10.1111/his.14932. PMID 37140546
  180. Schechter S, Lamps L. Epstein-Barr Virus Hepatitis: A Review of Clinicopathologic Features and Differential Diagnosis. Arch Pathol Lab Med. 2018;142(10):1191-1195. doi:10.5858/arpa.2018-0208-RA. PMID 30281361
  181. Schroeder SM, Matsukuma KE, Medici V. Wilson disease and the differential diagnosis of its hepatic manifestations: a narrative review of clinical, laboratory, and liver histological features. Ann Transl Med. 2021;9(17):1394. doi:10.21037/atm-21-2264. PMID 34733946
  182. Sciarra A, Di Tommaso L, Nakano M, et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol. 2016;64(1):87–93. doi:10.1016/j.jhep.2015.08.031. PMID 26343958
  183. Selves J, Kamar N, Mansuy JM, et al. [Hepatitis E virus: A new entity]. Ann Pathol. 2010;30(6):432-8. doi:10.1016/j.annpat.2010.10.003. PMID 21167429
  184. Selves J, Long-Mira E, Mathieu MC, et al. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers (Basel). 2018;10(4):108. doi:10.3390/cancers10040108. PMID 29621151
  185. Sempoux C, Park YN. Integration of histopathology and molecular features for the classification of benign and malignant hepatocellular neoplasms. Virchows Arch. 2026. doi:10.1007/s00428-026-04685-x. PMID 42678415
  186. Sergi CM. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. Int J Mol Sci. 2024;25(15). doi:10.3390/ijms25158462. PMID 39126031
  187. Serinoz E, Varli M, Erden E, et al. Nuclear localization of hepatitis B core antigen and its relations to liver injury, hepatocyte proliferation, and viral load. J Clin Gastroenterol. 2003;36(3):269-72. doi:10.1097/00004836-200303000-00016. PMID 12590241
  188. Shastri A, Paranthamaiah GC, Gandhi A, et al. Refractory pruritus in cholestatic drug-induced liver injury secondary to androgenic anabolic steroids: Plasmapheresis to the rescue. Asian J Transfus Sci. 2026;20(1):236-238. doi:10.4103/ajts.ajts_223_23. PMID 42344653
  189. Singh UR, Agarwal S, Misra K. Histopathological study of xanthogranulomatous cholecystitis. Indian J Med Res. 1989;90:285–288. PMID 2620955
  190. Soon GST, Yasir S, Jain D, et al. CRP versus SAA for identification of inflammatory hepatic adenomas. Appl Immunohistochem Mol Morphol. 2023;31(9):590–595. doi:10.1097/PAI.0000000000001155. PMID 37698958
  191. Srinivasamurthy P, Mehta KJ. Comparing the types of haemochromatosis- from genetics to clinics. Eur J Hum Genet. 2026;34(8):1022-1032. doi:10.1038/s41431-026-02084-z. PMID 41882292
  192. Steed D, Collins J, Farris AB, et al. Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV. Lancet Infect Dis. 2022;22(10):e303-e309. doi:10.1016/S1473-3099(22)00276-6. PMID 35500593
  193. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001;129(6):699–703. doi:10.1067/msy.2001.113888. PMID 11391368
  194. Summers KM, Halliday JW, Powell LW. Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index. Hepatology. 1990;12(1):20-5. doi:10.1002/hep.1840120105. PMID 2373481
  195. Takahashi Y, Dungubat E, Kusano H, et al. Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors. Int J Mol Sci. 2021;22(11). doi:10.3390/ijms22115780. PMID 34071338
  196. Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82. doi:10.1126/scitranslmed.3002409. PMID 21885404
  197. Tashiro T, Shigeno H, Goto J, et al. [A pathological study on herpes simplex virus infections in adults]. Kansenshogaku Zasshi. 1989;63(8):859-66. doi:10.11150/kansenshogakuzasshi1970.63.859. PMID 2507685
  198. Taskin OC, Bellolio E, Dursun N, et al. Non-neoplastic polyps of the gallbladder: a clinicopathologic analysis of 447 cases. Am J Surg Pathol. 2020;44(4):467–476. doi:10.1097/PAS.0000000000001405. PMID 31725469
  199. Teixeira MR, Weller IV, Murray A, et al. The pathology of hepatitis A in man. Liver. 1982;2(1):53-60. doi:10.1111/j.1600-0676.1982.tb00178.x. PMID 7176838
  200. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007;20 Suppl 1:S3-14. doi:10.1038/modpathol.3800693. PMID 17486049
  201. Then EO, Gayam V, Are VS, et al. Herpes Simplex Virus Hepatitis: A Brief Review of an Oft-overlooked Pathology. Cureus. 2019;11(3):e4313. doi:10.7759/cureus.4313. PMID 31183293
  202. Tian D, Li W, Heffron CL, et al. Antiviral resistance and barrier integrity at the maternal-fetal interface restrict hepatitis E virus from crossing the placental barrier. Proc Natl Acad Sci U S A. 2025;122(18):e2501128122. doi:10.1073/pnas.2501128122. PMID 40310464
  203. Torbenson MS. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Hum Pathol. 2021;112:86–101. doi:10.1016/j.humpath.2020.12.009. PMID 33387587
  204. Toro A, Mahfouz AE, Ardiri A, et al. What is changing in indications and treatment of hepatic hemangiomas. A review. Ann Hepatol. 2014;13(4):327–339. PMID 24927603
  205. Vargas-Nieto LP, Santoyo-Sarmiento ND, Ballesteros-García M, et al. Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review. Front Transplant. 2026;5:1869288. doi:10.3389/frtra.2026.1869288. PMID 42483433
  206. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol. 2007;127(6):869–880. doi:10.1309/LRKX8CE7GVPCR1FT. PMID 17509984
  207. Walz-Mattmüller R, Horny HP, Ruck P, et al. Incidence and pattern of liver involvement in haematological malignancies. Pathol Res Pract. 1998;194(11):781-9. doi:10.1016/S0344-0338(98)80068-X. PMID 9842637
  208. Wang A, He J, Liu K, et al. Congenital hepatic fibrosis and related ciliopathies across the life course: current management, disease burden, and unmet needs in the era of genomic diagnosis and translational therapeutics. Front Pediatr. 2026;14:1928268. doi:10.3389/fped.2026.1928268. PMID 42755537
  209. Wang CH, Byrnes K, Hale GL. A 16-year retrospective investigation of granulomatous liver injury in immunocompetent and immunocompromised patients at a tertiary care center. Am J Clin Pathol. 2026;166(5). doi:10.1093/ajcp/aqag114. PMID 42985919
  210. Wang NL, Chen L, Lu Y, et al. The Presence of Vacuolated Kupffer Cells Raises a Clinical Suspicion of Niemann-Pick Disease Type C in Neonatal Cholestasis. Front Genet. 2022;13:867413. doi:10.3389/fgene.2022.867413. PMID 35368683
  211. Wang T, Askan G, Ozcan K, et al. Tumoral intraductal neoplasms of the bile ducts comprise morphologically and genetically distinct entities. Arch Pathol Lab Med. 2023;147(12):1390–1401. doi:10.5858/arpa.2022-0343-OA. PMID 36821179
  212. Xin X, Jian J, Fan X, et al. Multiscale X-ray phase-contrast CT unveils the evolution of bile infarct in obstructive biliary disease. Commun Biol. 2024;7(1):490. doi:10.1038/s42003-024-06185-7. PMID 38654111
  213. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34(8):1147–1154. doi:10.1097/PAS.0b013e3181e5dffa. PMID 20661013
  214. Yang T, Chen C, Li C, et al. Challenges in the pathological diagnosis of erythropoietic protoporphyria: a case report. Front Med (Lausanne). 2025;12:1664961. doi:10.3389/fmed.2025.1664961. PMID 41080930
  215. Young EN, Dongho GBD, Ngo NV, et al. Gallbladder agenesis: a systematic review of presentation, management, and outcomes. Ann Med Surg (Lond). 2026;88(6):3506–3511. doi:10.1097/MS9.0000000000005084. PMID 42254108
  216. Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol. 2007;20(6):701–709. doi:10.1038/modpathol.3800788. PMID 17431410
  217. Zen Y, Pedica F, Patcha VR, et al. Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol. 2011;24(8):1079–1089. doi:10.1038/modpathol.2011.71. PMID 21516077
  218. Zhou S, Sarabia SF, Estrine D, et al. Comparative clinicopathologic and genomic analysis of hepatocellular neoplasm, not otherwise specified, and hepatoblastoma. Mod Pathol. 2024;37(2):100385. doi:10.1016/j.modpat.2023.100385. PMID 37992967